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1 Summary 
 
Chemokines play a key role in the cellular infiltration of inflamed tissue. They are released by 
a wide variety of cell types during the initial phase of host response to injury, allergens, 
antigens, or invading microorganisms, and selectively attract leukocytes to inflammatory foci, 
inducing  both  migration  and  activation.  Monocyte  chemoattractant  protein-1  (MCP-1),  a 
member of the CC chemokine superfamily, functions in attracting monocytes, T lymphocytes, 
and  basophils  to  sites  of  inflammation.  MCP-1  is  produced  by  monocytes,  fibroblasts, 
vascular endothelial cells and smooth muscle cells in response to various stimuli such as 
tumour necrosis factor-a (TNF-a), interferon-g (IFN-g), and interleukin-1b (IL-1b). It also plays 
an important role in the pathogenesis of chronic inflammation, and overexpression of MCP-1 
has been implicated in diseases including glomerulonephritis and rheumatoid arthritis.  
Oligonucleotide-directed triple helix formation offers a means to target specific sequences in 
DNA  and  interfere  with  gene  expression  at  the  transcriptional  level.  Triple  helix-forming 
oligonucleotides (TFOs) bind to homopurine/homopyrimidine sequences, forming a stable, 
sequence-specific complex with the duplex DNA. Purine-rich sequences are frequent in gene 
regulatory regions and TFOs directed to promoter sequences have been shown to prevent 
binding of transcription factors and inhibit transcription initiation and elongation. Exogenous 
TFOs that bind homopurine/ homopyrimidine DNA sequences and form triple-helices can be 
rationally  designed,  while  the  intracellular  delivery  of  single-stranded  RNA  TFOs  has  not 
been  studied  in  detail  before.  In  this  study,  expression  vectors  were  constructed  which 
directed transcription of either a 19 nt triplex-forming pyrimidine CU-TFO sequence targeting 
the human MCP-1 or two different 19 nt GU- or CA-control sequences, respectively, together 
with the vector encoded hygromycin resistance mRNA as one fusion transcript. HEK 293 
cells were stable transfected with these vectors and several TFO and control cell lines were 
generated. Functional relevant triplex formation of a TFO with a corresponding 19 bp GC-rich 
AP-1/SP-1 site of the human MCP-1 promoter was shown. Binding of synthetic 19 nt CU-
TFO to the MCP-1 promoter duplex was verified by triplex blotting at pH 6.7. Underlining 
binding  specificity,  control  sequences,  including  the  GU-  and  CA-sequence,  a  TFO 
containing one single mismatch and a MCP-1 promoter duplex containing two mismatches, 
did  not  participate  in  triplex  formation.  Establishing  a  magnetic  capture  technique  with 
streptavidin microbeads it was verified that at pH 7.0 the 19 nt TFO embedded in a 1.1 kb 
fusion  transcript  binds  to  a  plasmid  encoded  MCP-1  promoter  target  duplex  three  times 
stronger than the controls. 
Finally, cell culture experiments revealed 76 ± 10.2% inhibition of MCP-1 protein secretion in 
TNF-a stimulated CU-TFO harboring cell lines and up to 88% after TNF-a and IFN-g co-
stimulation  in  comparison  to  controls.  Expression  of  interleukin-8  (IL-8)  as  one  TNF-a ￿￿￿ ￿ ￿￿￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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inducible control gene was not affected by CU-TFO, demonstrating both highly specific and 
effective chemokine gene repression.  
Furthermore, another chemokine target, regulated upon activation normal T cell expressed 
and  secreted  (RANTES),  which  plays  an  essential  role  in  inflammation  by  recruiting  T 
lymphocytes, macrophages and eosinophils to inflammatory sites, was analysed using the 
triplex approach. A 28 nt TFO was designed targeting the murine RANTES gene promoter, 
and gel mobility shift assays demonstrated that the phosphodiester TFO formed a sequence-
specific triplex with the double-stranded target DNA with a Kd of 2.5 x 10
-7 M. It was analysed 
whether RANTES expression could be inhibited at the transcriptional level testing the TFO in 
two different cell lines, T helper-1 lymphocytes and brain microvascular endothelial cells (b-
end3 cells). Although there was a sequence-specific binding of the TFO detectable in the gel 
shift assays, there was no inhibitory effect of the exogenously added and phosphorothioate 
stabilised TFO on endogenous RANTES gene expression visible.  
Additionally, the small interfering RNA (siRNA) approach was tested as another strategy to 
inhibit expression of the pro-inflammatory chemokines MCP-1 and RANTES. Two different 
methods  were  pursuit,  describing  transient  transfection  with  vector  derived  and  synthetic 
siRNA. The vector pSUPER containing the siRNA coding sequence was used to suppress 
endogenous MCP-1 in HEK 293 cells. An empty vector without RNA sequence served as a 
control. Inhibition due to the siRNA was measured in stimulated and unstimulated cells. In 
TNF-a stimulated cells MCP-1 protein synthesis was decreased by 35 ± 11% after siRNA 
transfection. Using a synthetic double-stranded siRNA, the TNF-a induced MCP-1 protein 
secretion could be successfully inhibited about 62.3 ± 10.3% in HEK 293 cells, indicating that 
the  siRNA  is  functional  in  these  cells  to  suppress  chemokine  expression.  The  siRNA 
approach targeting murine RANTES in Th1 cells and b-end3 cells revealed no inhibition of 
endogenous gene expression.  
Gene therapy approaches rely on efficient transfer of genes to the desired target cells. A 
wide  variety  of  viral  and  nonviral  vectors  have  been  developed  and  evaluated  for  their 
efficiency of transduction, sustained expression of the transgene, and safety. Among them, 
lentiviruses have been widely used for gene therapy applications. In order to improve the 
delivery of TFOs or siRNAs into the target cells, cloning of the lentiviral transfer vector SEW, 
the production of lentiviral particles by transient transfection were performed with the aim to 
generate  lentiviral  vector-derived  TFOs  in  further  experiments.  Here,  Th1  cells  were 
transduced  with  infectious  lentiviral  particles  and  transduction  efficacy  was  measured. 
Transduction efficacy higher than 82% could be achieved using the lentiviral vector SEW, 
opening optimal possibilities for the TFO or siRNA approach. 
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2 Introduction 
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Chemokines are a family of chemotactic cytokines that were first identified on the basis of 
their ability to induce the migration of different cell types, particularly those of lymphoid origin. 
They can be roughly divided into two main categories based on functional expression, the 
inducible  and  the  constitutive  chemokines.  Most  of  them  are  inducible  chemokines  and 
participate primarily in inflammatory responses. The constitutive chemokines are expressed 
primarily  in  secondary  lymphoid  organs  and  appear  to  play  a  major  role  in  lymphocyte 
homing (Baggiolini and Loetscher 2000; Feng 2000). In the recent years, an expanded role 
of  chemokines  has  been  identified,  and  they  have  been  shown  to  activate  leukocytes, 
influence  hematopoiesis,  and  modulate  angiogenesis.  For  example,  interferon-inducible 
protein-10  (IP-10)  induces  the  proliferation  of  mesangial  cells  (Romagnani  et  al.  1999). 
Interleukin-8  (IL-8)  has  been  shown  to  stimulate  the  proliferation  of  endothelial  cells  and 
promote  vascularisation  (Miller  et  al.  1998;  Simonini  et  al.  2000).  In  addition,  some 
chemokines are involved in hematopoiesis (Juarez et al. 2004). Platelet factor 4 (PF4), IP-10, 
monokine  induced  by  interferon-g  (MIG),  and  interferon-inducible  T  cell  alpha 
chemoattractant  (I-TAC)  can  act  as  angiostatic  factors,  while  the  ELR-chemokines  IL-8, 
growth related oncogene-a, -b, -g (GRO-a, -b, -g), epithelial neutrophil activating peptide-78 
(ENA-78), and stromal cell-derived factor-1 (SDF-1) have been shown to act as angiogenic 
agents (Belperio et al. 2000; Moore et al. 1998), suggesting that chemokines contribute to 
tissue remodelling and wound healing (Gillitzer and Goebeler 2001). Tumours transfected 
with RANTES (regulated upon activation, normal T cell expressed and secreted) and IP-10 
have  been  shown  to  regress  with  the  subsequent  development  of  tumour  immunity 
(Oppenheim et al. 1997). Chemokines are chemotactic for antigen-presenting dendritic cells 
and  increase  their  capacity  to  activate  T  cells  (Cravens  and  Lipsky  2002;  Proietto  et  al. 
2004).  
 
Chemokines play a major role in chemoattraction and activation of blood leukocytes. They 
are involved in multiple disease processes and are of major importance during acute and 
chronic  inflammation.  Chemokines  have  been  associated  with  a  number  of  inflammatory 
diseases  and  conditions,  including  atherosclerosis,  asthma,  sepsis,  inflammatory  bowel 
disease and respiratory distress syndrome (Conti et al. 1999; Ni et al. 2004; Rose, Jr. et al. 
2003). Chemokines are secreted in a stimulus-specific manner from a variety of cell types, 
including  leukocytes,  fibroblasts,  epithelial  cells,  mesangial  cells,  and  endothelial  cells. 
(Coletta et al. 2000; Ebnet et al. 1996; Galindo et al. 2001; Murugesan et al. 2003; Schwarz ￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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et al. 1997; Umekawa et al. 2003). The principle steps of inflammatory chemokine action on 
tethering, rolling, adhesion and transmigration have been described extensively (Johnston 
and Butcher 2002; Murphy 1994). The attraction of leukocytes out of the circulating blood to 
the site of injury is initiated by changes in the expression and activity of adhesion molecules 
on  the  respective  vascular  endothelial  cells  (Johnston  and  Butcher  2002).  These  early 
adhesion  events  are  induced  by  a  number  of  early  response  mediators  and  cytokines, 
including  histamine,  tumour  necrosis  factor-a  (TNF-a),  and  interleukin-1  
(IL-1). The early response cytokines and mediators upregulate E- and P-selectin molecules 
on  the  endothelial  surface  and  slow  the  leukocytes  from  circulatory  flow,  a  phenomenon 
known as tethering and rolling. Once tethered, the leukocytes roll on the endothelial surface 
in the direction of the blood flow, but much slower. This process exposes a greater surface of 
the leukocytes to the endothelial layer, where locally produced inflammatory chemokines are 
displayed  bound  to  apical  glycosaminoglycans  of  the  endothelium.  After  leukocytes  have 
been  sequestered  to  the  inflamed  vascular  wall,  the  cells  may  firmly  adhere  to  the 
endothelium. During this interaction of adhesion molecules on leukocytes (e.g. lymphocyte-
function-associated antigen 1, LFA-1, and very late antigen 4, VLA-4) with members of the 
immunoglobulin  family  of  adhesion  molecules  on  the  endothelial  cells  (e.g.  intercellular 
adhesion molecule 1, ICAM-1, and vascular-cell adhesion molecule 1, VCAM-1) chemokines 
are involved in the activation of these adhesion molecules. Adhesion allows the spreading of 
leukocytes  along  the  endothelial  surface  (Imhof  and  Aurrand-Lions  2004).  Once  firmly 
adhered  to  the  vascular  endothelium,  leukocytes  then  rapidly  (in  minutes)  transmigrate 
through the endothelial layer without affecting its integrity. Having reached the subendothelial 
space,  leukocytes  follow  the  path  to  the  injured  tissue  along  one  or  more  chemotactic 
gradients.  
 
A  large  number  of  chemokines  (~50)  and  their  receptors  (~20)  have  been  identified  in 
humans or mice. In general they represent small (8-14 kDa) heparin-binding proteins that are 
rich  in  basic  amino  acids  and  contain  conserved  N-terminal  cysteines  forming  essential 
disulfide bonds between the first and third and the second and fourth cysteines. Chemokines 
are single polypeptides of 70-130 amino acids in length, which share 20-96% homology in 
amino acid sequence among each other. Based on the presence of the cysteine containing 
signature  motif  at  the  N-terminal,  chemokines  have  been  classified  into  four  subfamilies 
(Table 2-1).  
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Table 2-1. Chemokines and their receptors (Ono et al. 2003) 
 
Systematic name   Human ligand   Chemokine receptor 
CXC family     
CXCL1  Growth related oncogene GROa a a a/  
Melanoma growth stimulatory activity MGSAa a a a 
CXCR1, CXCR2, Duffy 
(no signalling)  
CXCL2  GROb b b b/ MGSAb b b b  CXCR2 
CXCL3  GROg g g g/ MGSAg g g g  CXCR2 
CXCL4  Platelet factor PF4  Unknown  
CXCL5  Epithelial neutrophil activating peptide ENA-78  CXCR2 
CXCL6  Granulocyte chemotactic protein GCP-2  CXCR1, CXCR2 
CXCL7  Neutrophil activating peptide NAP-2  CXCR2, Duffy (no 
signalling) 
CXCL8  Interleukin IL-8  CXCR1, CXCR2, Duffy 
(no signalling) 
CXCL9  Monokine-induced by interferon-g MIG  CXCR3, CCR3 
(antagonist) 
CXCL10  IFN-g inducible protein IP-10  CXCR3, CCR3 
(antagonist) 
CXCL11  IFN-inducible T-cell a chemoattractant I-TAC  CXCR3 
CXCL12  Stromal cell-derived factor SDF-1a a a a/b b b b  CXCR4 
CXCL13  B-cell attracting chemokine BCA-1  CXCR5 
CXCL14  Breast and kidney-expressed chemokine BRAK/ bolekine  Unknown 
(CXCL15)  Unknown   Unknown 
CXCL16    CXCR6 
     
C family     
XCL1  Lymphotactin/ single C motif SCM-1a a a a/ Activation-induced, chemokine-related 
protein ATAC 
XCR1 
XCL2  SCM-1b b b b  XCR1 
     
CX3C family     
CX3CL1  Fractalkine   CXCR1 
     
CC family     
CCL1  I-309  CCR8, Duffy (no 
signalling  
CCL2  Monocyte chemoattractant protein MCP-1/ Monocyte chemotactic and 
activating factor MCAF/ Tumour-derived chemotactic factor TDCF 
CCR2, CCR5, Duffy 
(no signalling) 
CCL3  Macrophage inflammatory protein MIP-1a a a a/ LD78a a a a  CCR1, CCR5 
CCL3L1  LD78b b b b  CCR1, CCR5 
CCL4  MIP-1b b b b  CCR5 
CCL5  RANTES  CCR1, CCR3, CCR5, 
Duffy (no signalling) 
(CCL6)  Unknown  Unknown 
CCL7  MCP-3  CCR1, CCR2, CCR3 
CCL8  MCP-2  CCR2, CCR3, CCR5 
(CCL9/10)  Unknown  CCR1 
CCL11  Eotaxin  CCR2 (partial 
antagonist), CCR3, 
CCR5, CXCR3 
(antagonist) 
(CCL12)  Unknown   CCR2 
CCL13  MCP-4  CCR2, CCR3 
CCL14  Human CC chemokine HCC-1  CCR1, CCR5 
CCL15  HCC-2/ leukotactin Lkn-1/ MIP-1d d d d  CCR1, CCR3 
CCL16  HCC-4/ liver-expressed chemokine LEC  CCR1, CCR2 
CCL17  Thymus- and activation-regulated chemokine TARC  CCR4, CCR8 
CCL18  Dendritic cell-derived CC chemokine DC-CK1/  
Pulmonary and activation regulated chemokine PARC/  
Alternative macrophage activation associated CC chemokine AMAC-1 
Unknown 
CCL19  MIP-3b b b b/ Ebl-1-ligand chemokine ELC/ exodus-3  CCR7 
CCL20  MIP-3a a a a/ liver and activation regulated chemokine LARC/ exodus-1  CCR6 
CCL21  6Ckine/ secondary lymphoid tissue chemokine SLC/ exodus-2  CCR7, CXCR3 
CCL22  Macrophage-derived chemokine MDC/  
Stimulated T-cell chemoattractant protein STCP-1 
CCR4 
CCL23  Myeloid progenitor inhibitory factor MPIF-1/ chemokine CKb b b b8/ CKb b b b8-1  CCR1 
CCL24  Eotaxin-2/ MPIF-2  CCR3  
CCL25  Thymus-expressed chemokine TECK  CCR9 
CCL26  Eotaxin-3  CCR2 (antagonist), 
CCR3, CCR10 
CCL27  Cutaneous T-cell-activating chemokine CTACK/  
IL-11 receptor alpha-locus chemokine ILC 
CCR10 
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Most chemokines have four characteristic cysteines. Lymphotactins-a and b (CL1 and CL2) 
have only two cysteine residues (Kelner et al. 1994). While the CXC subfamily members 
have two cysteines at the N-terminus of the protein separated by one amino acid, the CC 
subfamily has two juxtaposed cysteine residues. Members of the C subfamily have only one 
cysteine at the amino terminal, and the first two cysteine residues are separated by three 
amino  acids  in  the  CX3C  chemokine  subfamily.  In  humans,  the  genes  of  the  CXC 
chemokines  are  clustered  on  chromosome  4,  and  those  of  the  CC  chemokines  on 
chromosome 17.  
 
Chemokines mediate their effects via chemokine receptors that have been also divided into 
four subfamilies depending on the ligands they bind. Most receptors bind more than one 
chemokine ligand, often from different families. On the other hand, one chemokine ligand 
may bind to several receptors. Chemokine receptors may share 25-80% homology in the 
amino acid sequence. They are membrane molecules which belong to the superfamily of G-
protein  coupled  receptors  (GPCR)  with  seven  transmembrane  domains  (Lefkowitz  2000; 
Milligan 2001). Chemokine receptors are approximately 350 amino acids in length and have 
a  short  extracellular  N-terminus  and  a  short  intracellular  C-terminus.  The  cytosolic  tails 
contain conserved serine and threonine residues that become phosphorylated on receptor 
occupancy. The seven transmembrane domains are a-helical, and three intracellular and 
three extracellular loops exist between the transmembrane domains.  
Engagement of chemokine receptors by their appropriate ligands results in the induction of a 
variety of functions including cell migration and proliferation. The biochemical events include 
GPCR-dependent  calcium  influx  as  well  as  changes  in  the  intracellular  cAMP  levels  and 
phosphoinositol lipid metabolism. Phospholipase C activation is triggered through Gbg and 
yields inositol (1, 4, 5) triphosphate and diacylglycerol. Inositol triphosphate in turn mobilises 
the release of calcium from intracellular stores (Maghazachi 2000). Calcium, together with 
diacylglycerol,  then  activates  multiple  protein  kinase  C  isoforms  that  drive  downstream 
events throughout the cell. Eventually receptor desensitisation appears to operate through G-
coupled  kinases  that  associate  with  Gbg  (Okkenhaug  and  Vanhaesebroeck  2003). 
Phospholipase  A2  and  D  can  also  be  activated  on  chemokine  receptor  activation,  and 
arachidonic acid release driven by phospholipase A2 is important for optimal cell movement 
toward a chemokine gradient.  
Activation signals following stimulation by chemokine ligands
 also involve the initiation of a 
protein  tyrosine  kinase  (PTK)-dependent
  pathway  including  activation  of  a  family  of  focal 
adhesion kinase
 (FAK) proteins, which leads to reorganisation
 of various cytoskeletal proteins 
as  well
  as  activation  of  phosphatidylinositol  3-kinase  and  Janus  kinase
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transducer and activator of transcription (STAT)
 cascades (Dairaghi et al. 1998; Wong and 
Fish 1998).  
 
2.1.1 MCP-1 
 
MCP-1,  a  member  of  the  CC  chemokine  superfamily,  functions  in  attracting  monocytes 
(Uguccioni et al. 1995), T lymphocytes (Carr et al. 1994; Loetscher et al. 1994; Roth et al. 
1995), basophils (Weber et al. 1995), and B cells (Frade et al. 1997) to sites of inflammation. 
MCP-1 is expressed by different cell types including monocytes, T lymphocytes, endothelial 
cells,  fibroblasts,  and in  case  of injury  by  a  number  of  organ  tissue  cells, such  as  renal 
mesangial cells (Rollins et al. 1990; Rovin et al. 1992; Schwarz et al. 1997).  
Several studies have shown that MCP-1 plays a major role in the initiation and progression of 
various forms of nephritis (Anders et al. 2001; Brown et al. 1996; Liu et al. 2003; Radeke et 
al. 2002; Tesch et al. 1999). In addition the expression of MCP-1 is associated with the 
pathogenesis of many other chronic inflammatory diseases, e.g. atherosclerosis (Charo and 
Peters 2003; Ni et al. 2004) and multiple sclerosis (Baggiolini and Loetscher 2000).  
The expression of MCP-1 is regulated by cytokines including tumour necrosis factor (TNF) 
(Murao et al. 2000; Ping et al. 1996), platelet-derived growth factor (PDGF) (Bogdanov et al. 
1998; Ping et al. 1999a; Sridhar et al. 1999), interferon-g (IFN-g) (Zhou et al. 2001), and 
interleukin-1b  (IL-1b)  (Harkness  et  al.  2003;  Lucio-Cazana  et  al.  2001),  but  also  stress 
factors and viral infections cause MCP-1 expression (Glabinski et al. 1996; Rott et al. 2003).  
Several  regulatory  promoter  regions  have  been  identified  that  are  important  for  MCP-1 
expression.  Two  nuclear  factor-kB  binding  sites  located  approximately  2.6  kb  from  the 
transcription initiation site appeared to be critical elements for MCP-1 induction in response 
to  IL-1b  and  TNF-a  (Ping  et  al.  1999b;  Ueda  et  al.  1994).  Additionally,  within  a  150-bp 
segment located 5’ to the ATG translation start codon, two consensus elements for the AP-1 
trans-acting factors have been described in the human MCP-1 promoter. The more proximal 
of these consensus AP-1 elements overlaps with a consensus site for SP-1 that appears to 
be important for the basal transcription activity of the gene (Ueda et al. 1994). Mutation of the 
SP-1 binding site proved to be critical for regulation by both TNF and PDGF (Ping et al. 
1999a). Thus, both disease findings and gene regulatory studies at molecular level point to a 
considerable  pro-inflammatory  role  of  MCP-1.  Several  therapeutic  strategies  including 
neutralizing  antibodies  and  protein  antagonists  have  been  employed  to  reduce  MCP-1 
activity in nephritis and other inflammatory diseases (Wenzel et al. 1997). These anti-protein/ 
-receptor strategies as well as inflammatory disease models in MCP-1 gene deficient mice 
yielded variable and mostly limited success, which in part might be due to an incomplete 
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2.1.2 RANTES 
 
The chemokine RANTES (regulated upon activation normal T-cell expressed and secreted; 
CCL5) is a member of the CC-chemokine family and plays an essential role in inflammation 
by recruiting T cells, macrophages and eosinophils to inflammatory sites. RANTES has been 
implicated in a number of diseases characterised by inflammation. These include asthma 
(Powell et al. 1996), transplantation rejection (Pattison et al. 1994), atherosclerosis (Pattison 
et al. 1996), rheumatoid arthritis (Rathanaswami et al. 1993), delayed-type hypersensitivity 
(Devergne  et  al.  1994),  endometriosis  (Hornung  et  al.  1997),  chronic  polypus  sinusitis 
(Maune et al. 1996) and respiratory syncytial virus-related bronchiolitis (Becker et al. 1997; 
Saito et al. 1997). RANTES expression is induced by a variety of cells (Olszewska-Pazdrak 
et  al.  1998;  Radeke  et  al.  2002;  Shukaliak  and  Dorovini-Zis  2000).  Cytokines  produced 
during acute inflammation induce RANTES expression by fibroblasts and endothelial and 
epithelial cells. For example, TNF-a and IL-1b increase the expression of RANTES mRNA by 
fibroblasts  and  endothelial  cells.  Furthermore,  TNF-a  and  IFN-g  were  shown  to  induce 
RANTES production synergistically by epithelial and endothelial cells (Marfaing-Koka et al. 
1995; Stellato et al. 1995).  
At  nanomolar  concentrations,  RANTES  binds  to  and  activates  GPCRs,  namely  the 
chemokine  receptors  CCR1,  CCR3,  and  CCR5.  Ligation  of  these  receptors  activates  a 
heterotrimeric Gai protein-coupled signalling pathway, characterised by a transient calcium 
influx (Bacon et al. 1995; Ward et al. 1998), and triggers activation of cell polarisation and 
chemotaxis (del Pozo et al. 1995). In addition, RANTES also induces several effects that are 
triggered through a GPCR-independent pathway. Induction of this pathway is mediated by 
protein tyrosine kinases (PTKs), occurs at high micromolar concentrations of the chemokine, 
and leads to a sustained influx of calcium (Bacon et al. 1995). This pathway requires an 
interaction of RANTES with cell surface glycosaminoglycans (GAGs) and depends on the 
ability  of  the  chemokine  to  form  oligomers  (Chang  et  al.  2002;  Czaplewski  et  al.  1999). 
Stimulation of the GPCR-independent pathway by RANTES induces hyperpolarisation and 
generalised cell activation (Appay  and Rowland-Jones 2001). A variety of effects is then 
triggered,  such  as  induction  of  proliferation,  apoptosis,  and  release  of  proinflammatory 
cytokines (Appay et al. 2000).  
Studies  have  demonstrated  that  the  CC-chemokines  RANTES,  MIP-1a,  and  MIP-1b 
suppress human immunodeficiency type 1 (HIV-1) replication in vitro. Infection with HIV-1 
requires expression of CD4 antigen and the chemokine receptor CXCR4 (X4) or CCR5 (R5) 
on  the  surface  of  target  cells.  The  engagement  of  these  receptors  with  the  viral  surface 
proteins is essential for the membrane fusion process. RANTES, like MIP-1a and MIP-1b, 
can inhibit the entry of HIV-1 strains that use CCR5 as an entry co-receptor with CD4 (Dragic ￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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et al. 1996). The chemokines inhibit entry of these R5 viruses by down-regulating CCR5 and 
by competing with the virus for binding sites on the same receptor. But, RANTES can also 
enhance HIV-1 replication in a dose dependent manner. These characteristics are critically 
dependent on its ability to self-aggregate and bind to glycosaminoglycans (Roscic-Mrkic et 
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In addition to drug development methods designed to modulate the activity of protein targets, 
the knowledge of disease gene DNA sequences provides an opportunity for a highly rational 
design  of  therapeutic  agents  that  act  at  the  DNA/RNA  level  through  sequence-specific 
interactions.  Specific  interference  with  gene  expression  has  wide  ranging  applications  in 
experimental biology and is an attractive approach for the development of new therapeutics. 
Several gene-specific inhibitory strategies have been established in vitro and in vivo.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. Molecular strategies to interfere at the level of gene expression, mRNA or protein activity with 
a specific factor. Peptide nucleic acid (PNA), triplex helix-forming oligonucleotide (TFO), small interfering RNA 
(siRNA)  
 
Antisense oligonucleotides  
The notion that gene expression could be modified by the use of exogenous nucleic acids 
derives from studies by Paterson (Paterson et al. 1977), who first used single-stranded DNA 
to  inhibit  translation  of  a  complementary  mRNA  in  a  cell-free  system  in  1977.  In  1978, 
Stephenson  (Stephenson  and  Zamecnik  1978)  added  a  synthetic  oligonucleotide 
complementary to the 3’ end of the Rous sarcoma virus to the medium of chicken fibroblasts 
in  tissue  culture,  along  with  the  Rous  sarcoma  virus  itself.  The  short  13-mer  DNA 
oligonucleotide inhibited the formation of new viruses, and also prevented transformation of 
chicken fibroblasts into sarcoma cells. In cell-free systems, translation of the viral mRNA was 
also  greatly  impaired.  The  findings  showed  that  antisense  oligonucleotides  could  inhibit 
mRNA translation in a sequence-specific way.  
In the mid 1980s, the existence of naturally occurring RNAs and their role in regulating gene 
expression was shown (Mizuno et al. 1984; Simons and Kleckner 1983). These observations 
were important because they stimulated the development of technologies that use nucleic ￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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acids to manipulate gene expression. Since then, various antisense targets, for example in 
the field of oncology, have been analysed in vitro and in animals (Table 2-2).  
 
Table 2-2. Antisense oligonucleotide targets in oncology tested in vitro and in animals 
 
Target  Cell type analysed  Biological endpoints  Reference  
BCL2  B-cell-lymphoma, 
melanoma, lung 
tumour 
Apoptosis  (Jansen et al. 1998) 
Survivin  Cervical tumour, lung 
cancer 
Apoptosis  (Li et al. 1999; Olie et 
al. 2000) 
MDM2  Multiple tumours  p53 activation  (Wang et al. 1999) 
BCLXL  Endothelial cells, lung 
cancer cells 
Apoptosis  (Leech et al. 2000) 
RelA  Fibrosarcoma cell line  Cell adhesion, 
tumourigenicity 
(Sharma and 
Narayanan 1996) 
RAS  Endothelial cells, 
bladder cancer 
CAM expression, 
proliferation 
(Chen et al. 1996) 
RAF  Endothelial cells, 
smooth muscle cells 
CAM expression, 
proliferation 
(Cioffi et al. 1997) 
BCR-ABL  Primary progenitor 
bone marrow cells 
Adhesion, proliferation  (Mahon et al. 1995) 
Jun N-terminal kinase 
1 and 2 
Renal epithelial cells  Apoptosis  (Cioffi and Monia 2000) 
Telomerase  Prostate cell lines  Cell death  (Kondo et al. 2000) 
c-MYC  Leukaemia cell lines  Proliferation, apoptosis  (Holt et al. 1988; 
Wickstrom et al. 1988) 
c-MYB  Leukaemia cell lines  Proliferation   (Anfossi et al. 1989) 
Adapted from Tamm (Tamm et al. 2001) 
 
Ribozymes and DNAzymes 
Another  strategy  for  destabilizing  mRNA  uses  ribozymes  or  DNAzymes.  Ribozymes  and 
DNAzymes are molecules that contain one of a variety of catalytic motifs that cleave the 
mRNA  to  which  they  hybridise  and  thereby  prevent  translation.  Two  ribozymes,  the 
hammerhead ribozyme and the hairpin ribozyme, have been extensively studied owing to 
their  small  size  and  rapid  kinetics  (Earnshaw  and  Gait  1997;  Shippy  et  al.  1999).  The 
catalytic  motif  is  surrounded  by  flanking  sequences  that  are  responsible  for  guiding  the 
ribozyme to its mRNA target and giving stability to the structure. If ribozymes are to work 
effectively, they not only need to bind to the substrate RNA but also dissociate from the 
cleavage product to act on further substrates, which might be an important rate limiting step ￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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that controls their usefulness. Ribozymes can be expressed from a vector that offers the 
advantage of continued intracellular production of these molecules (Irie et al. 1997; Irie et al. 
1999).  
 
RNA interference 
Double-stranded RNA (dsRNA) can trigger silencing of homologues gene expression by a 
mechanism termed “RNA interference” (RNAi) (Fire et al. 1998). RNAi is an evolutionary 
conserved phenomenon and a multistep process that involves the generation of active small 
interfering RNA (siRNA) in vivo through the action of an RNase III endonuclease, “Dicer”. 
The resulting 21 to 23 nt siRNA mediates degradation of the complementary homologues 
RNA (Bernstein et al. 2001; Sharp 2001; Zamore 2001). RNAi has been used as a tool to 
study gene function in multiple model organisms, including plants, Caenorhabditis elegans, 
and  Drosophila,  where  dsRNA  efficiently  induced  gene  specific  silencing  (Chuang  and 
Meyerowitz  2000;  Misquitta  and  Paterson  1999;  Tuschl  et  al.  1999).  The  discovery  that 
synthetic  21nt  siRNA  triggers  gene  specific  silencing  in  mammalian  cells  has  further 
expanded the utility of RNAi into mammalian systems.  
 
Peptide nucleic acid 
Peptide  nucleic  acid  (PNA)  is  a  nucleic  acid  analogue  in  which  the  sugar  phosphate 
backbone has been replaced by a synthetic peptide backbone usually formed from N-(2-
amino-ethyl)-glycine units, resulting in an achiral and uncharged molecule. It is chemically 
stable and resistant to hydrolytic cleavage and thus not expected to be degraded inside living 
cells.  PNA  is  capable  of  sequence-specific  recognition  of  DNA  and  RNA  obeying  the 
Watson-Crick  hydrogen  bonding  scheme,  and  the  hybrid  complexes  exhibit  extraordinary 
thermal  stability  and  unique  ionic  strength  effects  (Ray  and  Norden  2000).  It  may  also 
recognise  duplex  homopurine  sequences  of  DNA  to  which  it  binds  by  strand  invasion, 
forming a stable PNA-DNA-PNA triplex with a looped-out DNA strand. But, according to the 
high molecular mass, the delivery of PNA, involving passage through the cell membrane, 
appears to be critical.  
 
Decoy molecules 
Short,  double-stranded  DNA  decoy  molecules  have  also  been  used  to  disrupt  gene 
expression  at  the  level  of  transcription  (Kraus  et  al.  2003;  Sharma  et  al.  1996).  These 
oligonucleotides are designed to compete for transcription factor complexes, with the final 
aim to distract them from the promoter that they would activate otherwise.  
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Triple helix-forming oligonucleotides  
Normally DNA exists in a duplex form, but under certain circumstances, DNA can acquire 
triple-helical  structures,  which  are  either  intra-  or  intermolecular.  Intermolecular  triplexes, 
formed by the addition of a sequence-specific third strand to the duplex DNA, are shown to 
have  an  enormous  potential  as  site  directed  mutagens,  repressors  of  transcription,  and 
inhibitors  of  replication.  These  triple  helix-forming  oligonucleotides  (TFOs)  bind  with  high 
affinity and specificity to homopurine/homopyrimidine sequences in the major groove of the 
DNA and have proved effective in various gene targeting strategies in living cells and in 
animals. There are some intrinsic advantages of the antigene over the antisense principle, 
and interest in oligonucleotides designed to form triple helices with double-stranded DNA is 
steadily  increasing.  First,  there  are  only  two  copies  (two  alleles)  of  the  targeted  gene 
whereas there may be thousands of copies of a messenger RNA. This should dramatically 
reduce the amount of oligonucleotide needed for activity. Blocking mRNA translation even by 
inducing sequence-targeted cleavage of the RNA does not prevent the corresponding gene 
from  being  transcribed,  thereby  repopulating  the  mRNA  pool.  Moreover,  not  only 
transcriptional  activation  and  deactivation  but  also  gene  knockout  as  well  as  targeted 
mutagenesis, targeted recombination and sequence selective manipulation of the genomic 
DNA can be achieved with the antigene strategy.  
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2.3.1 Structure and stability of triple helix-forming oligonucleotides 
 
The  formation  of  a  triple-helical  nucleic  acid  structure  was  first  observed  in  1957  when 
Felsenfeld et al. demonstrated stable and specific binding of a single-stranded polyuridine 
oligonucleotide  to  a  polyuridine/polyadenosine  duplex.  The  mechanisms  underlying  triple 
helix formation are reasonably well understood (Figure 2-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2. Triple-helix formation at the nucleotide level. A: The TFO binds in the major groove of the DNA. 
B: The parallel, pyrimidine binding motif, C: The antiparallel, purine binding motif. Adapted from Chan (Chan and 
Glazer 1997). 
 
TFOs specifically bind to the major groove of DNA, forming Hoogsteen or reverse Hoogsteen 
hydrogen  bonds  with  bases  in  the  purine  rich  strand  of  the  duplex  DNA.  Optimal  target 
sequences must harbour 12–14 consecutive purines on one strand (Cheng and Van Dyke 
1994) since only purine bases are able to establish two Hoogsteen or reverse Hoogsteen 
type hydrogen bonds in the major groove of DNA. Two binding motifs have been described: 
For  the  pyrimidine  motif,  a  TFO  consisting  of  cytosine  (C)  and  thymine  (T)  binds  with  a 
parallel orientation to the purine strand of DNA via Hoogsteen bonds. Sequence-specificity is 
mediated  by  binding  of  third  strand  thymines  (T)  to  adenine  in  A:T  base  pairs  while ￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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protonated cytosines (C
+) bind to guanine in G:C base pairs. Protonation at N
3 of cytosine is 
required for proper Hoogsteen bonding with N
7 of guanine, therefore mildly acidic conditions 
are necessary. For the purine binding motif, the TFO binds antiparallel to the purine-rich 
strand of the DNA via reverse Hoogsteen bonds. In this case triplex formation is mediated by 
binding of adenine or thymine (A or T) to adenine in A:T base pairs, and guanine (G) to 
guanine in G:C base pairs. The purine binding motif is largely pH independent.  
Both pyrimidine and the purine motifs are stabilised by the presence of divalent cations such 
as Mg
2+, Ca
2+, and Zn
2+ (Felsenfeld et al. 1957) as well as naturally occurring polyamines 
such as spermine, spermidine, and putrescine (Hampel et al. 1991; Thomas and Thomas 
1993).  These  agents  presumably  reduce  the  electrostatic  repulsive  forces  between 
negatively charged phosphate backbones of the three strands, allowing triplex DNA to form 
more readily. In general, both polypyrimidine and polypurine TFOs form triplexes efficiently 
under  conditions  of  high  Mg
2+  ions  (10  mM)  whereas  monovalent  cations  (Na
+,  K
+)  at 
physiological  concentrations  (140  mM)  favour  G-quartet  formation  which  competes  with 
triplex  formation  (Cheng  and  Van  Dyke  1994).  Furthermore,  formation  of  both  types  of 
triplexes depends on chain length, base composition and temperature (Frank-Kamenetskii 
and Mirkin 1995).  
 
2.3.2 General modifications which stabilise triplex formation 
 
Various modifications in the sugar-phosphate backbone or the bases, as well as at the 5’ and 
3’ ends of the TFOs, have been introduced to stabilise triplexes and to minimise degradation 
and increase the half life of these TFOs inside cells and tissues. A generalised approach to 
improving triplex stability involves coupling non-specific DNA binding agents to TFOs. These 
agents  may  improve  nuclease  resistance  and  aid  in  TFO  cellular  uptake  or  localisation. 
Oligonucleotides, when end-conjugated with polyamines such as spermine, also form stable 
triplexes  even  in  the  absence  of  free  polyamines  or  Mg
2+  by  presumably  increasing  the 
effective local polyamine concentration.  
Psoralen,  a  photoreactive  intercalating  cross-linker,  also  enhances  triplex  binding  affinity 
when attached to a TFO. When exposed to long wavelength UV light, psoralen covalently 
cross-links  the  triplex  strands  together,  forming  mixtures  of  monoadducts  and  cross-links 
(Gunther et al. 1996; Song et al. 2004; Takasugi et al. 1991).  
The use of 5-methylcytosine partially alleviates the pH restriction of TFOs in the pyrimidine 
motif (Lee et al. 1984; Leitner et al. 2000). Cytosine has also been replaced with analogues 
such as 8-oxoadenine (Jetter and Hobbs 1993; Miller et al. 1996), pseudoisocytidine (Ono et 
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Backbone modifications were performed to optimise triplex stability while keeping sequence-
specificity, to minimise self-associations, and furthermore to design oligonucleotides which 
are resistant towards degradation by cellular nucleases (Figure 2-3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3. Different backbone modifications conferring stability towards intracellular nucleases and used 
in the antigene strategy. PNA: Peptide nucleic acid. Adapted from Praseuth (Praseuth et al. 1999).  
 
Protection of the oligonucleotide against cellular nucleases can be achieved by changing the 
anomeric configuration of the glycosidic bond from b to a without much incidence on triplex 
stability  (Noonberg  et  al.  1995b).  Another  modification  was  obtained  by  substitution  of 
deoxyribose for ribose in the third strand of the triplex and this resulted in stabilisation of 
triple helices for the CU or GU motif with a parallel orientation with respect to the purine 
target sequence (Escude et al. 1993). The replacement in both purine and pyrimidine TFOs 
of  the  phosphate  groups  with  phosphorothioates  greatly  improves  the  resistance  to 
nucleases (Cogoi et al. 2001; Joseph et al. 1997). In the pyrimidine motif, the substitution of 
the phosphodiester linkage with N3’-P5’ phosphoramidate linkage in which the 3’-oxygen is 
substituted  with  3’-nitrogen  (Escude  et  al.  1996;  Sun  et  al.  1996;  Torigoe  2001)  or  the 
substitution of the sugar-phosphate with a morpholino phosphoramidate backbone (Basye et 
al. 2001) increased significantly the binding to DNA at neutral pH. The substitution of the 
phosphodiester backbone with methylphosphonate in the pyrimidine motif also increased the 
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acid analogue in which the entire sugar-phosphate backbone is replaced by a polyamide 
backbone to obtain a neutral molecule which minimises unspecific electrostatic interactions 
with proteins.  
 
2.3.3 Biological activity of TFOs 
 
Accessibility of target sites in the context of chromatin is crucial for the development of the 
antigene strategy. The first report describing the accessibility of nuclear DNA sequences to 
an antigene oligonucleotide dealt with a viral HIV-1 sequence in chronically infected cells 
(Giovannangeli et al. 1997). Triplex formation was detected on one of the two viral polypurine 
tract sequences present in the integrated HIV-1 proviral genome within cells incubated with a 
psoralen-modified TFO. Different possibilities of TFOs to interfere with gene expression are 
shown in Figure 2-4.  
Triplex formation induced site-directed mutagenesis and promoted recombination in a site-
specific manner (Nagatsugi et al. 2003; Rogers et al. 2002). Triplex-based activity in animals 
was demonstrated by successfully introducing site-specific genomic modifications in somatic 
cells  of  adult  mice  (Vasquez  et  al.  2000).  Psoralen  can  form  adducts  and  interstrand 
crosslinks when it is activated by long wave UV light, and psoralen linked TFOs were used to 
stimulate homologues recombination in yeast and in mammalian targets and could increase 
mutation frequencies compared to the control oligonucleotide (Datta et al. 2001; Vasquez et 
al.  2001b).  A  psoralen-conjugated  TFO  designed  to  bind  to  a  transcription  factor  in  the 
upstream sequence of the human gamma-globulin gene, mutation frequencies as high as 
20% were reported by Xu (Xu et al. 2000).  
It has been shown that shorter (10 bp) target sites in a gene can be achieved by using 
cationic  phosphoramidate  linkages.  N,N-diethylethylenediamine  and  N,N-
dimethylaminopropylamine  phosphodiester  TFOs  increase  the  efficiency  of  targeted 
mutagenesis by 6-10 fold (Vasquez et al. 2001a). Double strand breaks in the target gene 
could be induced by TFOs containing radioactive isotopes (Mezhevaya et al. 1999; Panyutin 
et  al.  2001).  TFOs  containing  non-radioactive  chemicals  have  been  successfully  used  to 
cleave target DNA at specific sites (Arimondo et al. 2001; Nunez et al. 2000). Camptothecin, 
an antitumour drug, acts by interfering with DNA topoisomerase I. Camptothecin-conjugated 
TFOs, upon binding to the duplex target DNA, selectively positions the drug at the triplex site 
where it stimulates topoisomerase I mediated DNA cleavage at this site (Arimondo et al. 
2002).  
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Figure  2-4.  Schematic  diagram  of  current  oligonucleotide  based  triplex  applications.  Triplex  DNA  can 
inhibit transcription in two ways. A triplex formed in the regulatory region of a gene can interfere with the formation 
of the initiation complex, while a triplex formed in the coding region of the target gene can block transcription 
elongation. Selective modification of the genome includes homologous recombination through triplex delivered 
donor  DNA  via  DNA  repair  or  site-specific  mutagenesis  via  triplex  delivered  mutagens  like  psoralen.  Further 
applications  arise from triplex targeted chemical modifications  of the gene (e.g. cleavage, site-specific cross-
linking or alkylation). Adapted from Buchini (Buchini and Leumann 2003). 
 
TFOs can be designed as tools to inhibit gene expression by blocking transcription initiation 
or elongation. Modulation of transcription by TFOs was described in vitro and in cell cultures 
for several plasmid targets transiently transfected into living cells (Faria et al. 2000; Intody et 
al. 2000) and for endogenous genes (Carbone et al. 2004). Moreover, it was shown that at a 
given promoter triplex formation blocked the binding of various transcription factors, including 
SP-1, thereby inhibiting transcription initiation (Carbone et al. 2003). The triplex mediated 
antigene approach was used to selectively inhibit a wide array of clinical important genes. 
Examples include transcriptional inhibition of aldehyde dehydrogenase (Tu et al. 1995), IL-2 
receptor (Orson et al. 1991), the human HER2/neu gene (Porumb et al. 1996), c-myc (Postel 
et al. 1991; Thomas et al. 1995), and GM-CSF (Kochetkova and Shannon 1996). In Table  
2-3, some important examples of TFOs are shown which led to successful inhibition of gene 
expression  inside  cells  in  the  range  between  40  and  90%.  In  general,  success  of 
transcriptional inhibition might vary depending on the target sequence itself (accessibility, 
mismatches),  TFO  delivery,  stability  of  TFO  binding,  the  use  of  nuclease  resistant 
oligonucleotides, use of stabilizing agents, the binding motif, and other factors.  
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Table 2-3. Inhibition of transcription in cells using triple helix-forming oligonucleotides 
 
Target  
 
TFO and modification 
 
Control 
 
Biological effect 
Human c-myc gene, 
P2 promoter 
 
Phosphorothioate 
internucleotide linkages; 
fluorescein-labelled TFO 
23 bp, 1 mismatch 
1) scrambled sequence 
 
50 % inhibition of c-myc expression (10 
µM TFO) in Northern and Western blots 
80 % growth inhibition (10 µM TFO)  
(McGuffie et al. 2000) 
 
Human c-myc gene  
 
 
3’-amino-modified  
phosphodiester TFO 
-target 1: 27 bp, 3 mismatches  
-target 2: 23 bp, 1 mismatch 
-target 3: 25 bp, 3 mismatches  
-target 4: 21 bp 3 mismatches  
 
 
2 controls: length and 
base composition similar 
to the TFOs but different 
in nucleotide sequence 
 
Inhibition of c-myc expression and 
proliferation in CEM cells (sequence 
and target specific) 
50 % reduction of mRNA expression 
(20 µM TFO),  
(Catapano et al. 2000) 
Human MCP-1 
promoter 
 
Phosphorothioate 
oligonucleotide 
19 bp GT, 1 mismatch 
 
 
Scrambled 
oligonucleotide 
 
40-45 % inhibition of MCP-1 gene 
expression (5 µM TFO) 
(Marchand et al. 2000) 
alpha 1(I) procollagen 
 
 
 
Phosphodiester and 
phosphorothioate 
oligonucleotides 
Rat C1 region 30 bp 
Human C1 region 30 bp, 1 
mismatch 
Human C2 region 25 bp, 8 
mismatches  
 
Control for human C1 
region was a TFO to 
human C2 region 
TFOs specific for human C1 inhibited 
transcription from human promoter both 
in vitro in HeLa cell nuclear extracts 
and in vivo in cultured chicken embryo 
fibroblasts 
Triplex formation of human C2 TFO: 
very inefficiently and at extremely high 
concentrations 
(Nakanishi et al. 1998) 
Human bcl-2 proto-
oncogene 
Phosphorothioated at its 5’- 
and 3’- ends and amino-linked 
at its 3’- end,  
18 bp GT or GA, 1 mismatch 
 
3 different controls  
1) inverted  
2) scrambled  
3) targeted to another 
sequence (bcl-2 promoter 
P2) 
Downregulation of bcl-2 expression and 
inhibition of transcription elongation 
(Shen et al. 2001) 
Human rhodopsin  2 psoralen-modified TFOs 
TFO2: 18 bp GA, 1 mismatch 
TFO9: 28 bp GA, 2 
mismatches 
 
1) Mutated TFO binding 
site to confirm that the 
effects of TFOs are 
mediated through triplex 
formation 
2) Control oligonucleotide 
which is targeted to 
another sequence 
 
 
 
 
 
 
 
 
Each TFO reduced rhodopsin-GFP 
expression by 70-80 %, treatment with 
both TFOs reduced expression by  
90 % (Intody et al. 2000) 
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HIV-1 polypurine tract 
 
Oligonucleotide analogues 
with N3’-P5’np linkages 
acridine and psoralen-
5’modified oligonucleotides 
15 bp TCG,  
 
2 control oligonucleotides   Sequence-specific inhibition of 
transcription elongation in cell cultures 
50 % inhibition of luciferase activity (0,5 
µM Acr-15 TCG) 
(Faria et al. 2000) 
Insulin-like growth 
factor type 1 receptor 
(IGF-IR) 
 
 
AG-RNA TFO 
IGF-IR: 24 bp, 
stable transfection 
Control vectors: 
1) CT-insert 
2) without insert 
3) untransfected cells 
Suppression of IGF-IR transcription, 
Inhibition of tumour growth in nude 
mice (80 %) 
Downregulation of IGF-I transcription, 
upregulation of nexin-I mRNA 
(Rininsland et al. 1997) 
GM-CSF  Phosphodiester TFO  
15 bp GT, 1 mismatch 
15 bp GT, different base 
composition 
Reduction of endogenous GM-CSF 
level (70 %) 
65 % inhibition of the luciferase 
reporter gene activity  
(Kochetkova and Shannon 1996) 
c-myc P1 promoter 
 
 
 
 
 
Phosphodiester TFO  
27 bp GAT, 3 mismatches 
27 bp CTA, scrambled  -The TFO (without chemical 
modification) can enter the nucleus of 
HeLa cells and remains intact for 4 h 
-TFO treatment: 10-fold reduction of P1 
c-myc steady state mRNA in Hela cells 
(Postel et al. 1991) 
Rat alpha 1(I) collagen 
promoter 
 
 
Phosphodiester and 
phosphorothioate 
oligonucleotides, parallel and 
antiparallel orientation  
C-1 region: 
30 bp GA  
different 18 bp GA 
C-2 region: 
30 bp GA(CT), 8 mismatches 
18 bp GA(T) 
  
18 bp ATGC scrambled  Inhibition of collagen promoter activity 
in HeLa cells: 
18 bp phosphorothioate TFOs resulted 
in a significant decrease in promoter 
activity (up to 80 % reduction in CAT 
activity) 
(Joseph et al. 1997) 
Human bcl-1  Phosphodiester and 
phosphorothioate 
oligonucleotides,  
18 bp GT, 3 mismatches 
 
1) 18 bp GT in parallel 
orientation 
2) Control plasmid with 
different promoter target 
sequence 
Luciferase activity: 60 % inhibition (10 
µM TFO) 
(Kim and Miller 1998) 
IL-2R alpha 
 
Psoralen conjugated 
oligonucleotide  
15 bp TC 
 
Plasmid with mutated 
target sequence  
70% inhibition of transcription in vitro 
and in vivo (20 µM TFO) 
(Grigoriev et al. 1992) 
 
The examples of antigene strategies indicate that TFOs constitute a new class of molecules 
potentially useful in therapy. However, there are some limitations to oligonucleotide based 
technology, and in order to use these compounds in clinical applications their delivery to the 
cells must be improved, as the oligonucleotides have to be delivered to cells in adequate 
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Despite any modifications they must be able to bind to their target DNA with high affinity. For 
some applications high nuclear concentrations must be maintained, and lastly, TFOs must 
not be immunogenic, even when bound to carrier proteins.  
To circumvent the limits on the use of TFOs due to nuclease degradation and delivery to 
target cells, one possible solution is to generate TFOs endogenously in the target cell by 
specific recombinant expression vectors. Different strategies have been followed to generate 
single-stranded DNA (Datta and Glazer 2001) or RNA (Ilves et al. 1996; Noonberg et al. 
1994a)  inside  cells  which  may  bind  to  the  duplex  DNA  in  a  triplex  mediated  way.  RNA 
oligonucleotides can also form triple helices with duplex DNA, and triplexes formed by CU 
motif  TFOs  are  generally  more  stable  than  those  formed  by  their  CT  motif  counterparts 
(Bates  et  al.  2002;  Han  and  Dervan  1994;  Roberts  and  Crothers  1992).  The  data  about 
binding of a purine oligoribonucleotides (GA or GU) to the duplex DNA are controversial. 
There are studies which exclude the possibility that purine oligoribonucleotides form triplex 
structures with duplex DNA as determined by electrophoretic mobility shift assays (Semerad 
and Maher, III 1994). On the other hand, there are positive examples of RNA third stands to 
form  triplexes  in  the  purine  binding  motif  (Cogoi  et  al.  2000;  Ririe  and  Guntaka  1998), 
suggesting that the stability of RNA GA and GU motif triplexes are more dependent on the 
sequence itself.  
 
2.3.4 The intracellular generation of TFOs 
 
Appropriate  DNA  vectors  can  be  constructed  to  generate  RNA  transcripts  inside  the  cell 
nucleus  which  allows  triplex  formation  on  the  targeted  DNA  sequence.  Rininsland 
(Rininsland et al. 1997) described the specific suppression of the insulin like growth factor 
type I receptor (IGF-IR) in rat C6 glioblastoma cells and tumour growth in nude mice by using 
a plasmid-encoded homopurine (AG) RNA effector sequence. Only the RNA containing the 
homopurine  sequence  was  shown  to  suppress  IGF-IR,  whereas  a  homopyrimidine  RNA 
sequence had no effect. 
Noonberg (Noonberg et al. 1994a) constructed a recombinant expression vector containing a 
promoter,  capping,  and  termination  sequences  from  the  human  small  nuclear  U6  gene, 
surrounding  a  synthetic  sequence  incorporating  the  TFO  of  interest.  In  vivo,  these 
oligonucleotides were produced constitutively and without cell type specificity at levels up to 
5 x 10
6 copies per cell. The oligonucleotides had an intracellular half life of approximately one 
hour and were still readily detectable 7 days post-transfection.  
Cogoi (Cogoi et al. 2000) demonstrated triplex formation using CU-, GU- as well as GA-
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-2612/-2603     -152/-144      -96/-90   -88/-79          -69/-63  -64/-59       -38/-33                +1
NFk k k kB GAS            AP-1      NFk k k kB AP-1  SP-1            TATA                 Exon 1
5´CTCCgCCCTCTCTCCCTCT 3´
3´GAGGcGGGAGAGAGGGAGA 5´
MCP-1 promoter target
sequence
oligoribonucleotides  led  to  38,  40  and  47%  inhibition  of  c-Ki-ras  promoter  activity, 
respectively, when generated in HEK 293 cells in comparison to a control sequence. 
As homopurine RNA may not always form sufficiently stable triplexes with duplex DNA, it has 
been proposed to use vectors capable to generate single-stranded DNA (Chen et al. 2000). 
They designed a vector set that directed the in vivo production of single-stranded DNA of a 
desired  target  sequence.  One  plasmid  was  designed  to  express  the  Moloney  murine 
leukemia virus (MoMuLV) reverse transcriptase. Another expression plasmid contained the 
MoMuLV primer binding site at the 3' -end of its RNA transcript so that a single-stranded DNA 
would be synthesised by the reverse transcriptase when both plasmids were co-transfected 
into  cells.  In  principle,  this  single-stranded  DNA  expression  system  can  generate  any 
sequence of interest in vivo for antisense, RNA-cleavage, DNA enzyme, or triplex-forming 
strategies and represents a promising alternative to extracellular added oligonucleotides.  
The synthesis of TFOs in vivo circumvents the problem  of delivery  and could become a 
powerful tool for triplex applications, but for its successful employment in therapy vectors still 
need to be optimised.  
 
2.3.5 A TFO targeting the human MCP-1 promoter 
 
A computer search was conducted to identify potential triple helix-forming target sites within 
the promoter of the human MCP-1- gene. Sequences were scanned for motifs consisting of a 
continuous stretch of at last 15 purine bases in one strand, with no more than one mismatch. 
One possible 19 bp TFO target site was identified in the promoter region at bp -66 to -48. 
The target site in the promoter includes the binding site for SP-1 and partially overlaps a 
putative AP-1 binding site (Figure 2-5).  
 
 
 
 
 
 
Figure 2-5. Structure of the human MCP-1 promoter and TFO target sequence. The proximal promoter region 
of the human MCP-1 gene contains putative binding sites for the transcription factors NF-kB, AP-1, GAS, and  
SP-1 as well as a TATA box. Position +1 corresponds to the major transcriptional start site, as described by Ueda 
(Ueda et al. 1994). The 19 bp target sequence for the TFO is indicated, a point of mismatch is shown by small 
capital letters.  
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Previously it was demonstrated in Prof. Radeke’s lab (Medical School Hannover) that a 19 nt 
purine TFO binding in an antiparallel orientation to the human MCP-1 promoter formed a 
sequence-specific triplex with the target DNA in vitro and blocked in vitro binding of nuclear 
extract proteins and recombinant SP-1 to the promoter DNA. When HEK 293  cells were 
treated  with  the  TFO,  MCP-1  expression  gene  expression  was  inhibited  by  40-45%  in 
comparison  to  a  control  oligonucleotide,  as  analysed  by  Northern  blots  and  ELISA 
(Marchand et al. 2000).  
 
2.3.6 A TFO targeting the murine RANTES 
 
It has been demonstrated that the RANTES promoter contains a large number of potential 
consensus  elements  for  transcription  factors.  The  murine  RANTES  promoter  contains  a 
single interferon regulatory factor (IRF) and three putative NF-kB binding sites, each of which 
is well conserved in the human RANTES promoter. Interactions between NF-kB and IRF are 
crucial for the induction of RANTES promoter activity (Lee et al. 2000). Both NF-kB and IRF 
transcription factors participate in the induction of the RANTES promoter in response to TNF-
a and IFN-g.  
 
In the RANTES promoter a possible 28 bp TFO target site is located from -265  to -238 
relative to the transcriptional start site and about 78 bp downstream to a putative NF-kB1 
binding  site.  This  homopurine/homopyrimidine  target  sequence  of  28  bp  in  length  was 
chosen as a proinflammatory chemokine of interest out of a high number of possible TFO 
targets in the mammalian genome, which have been found with a proprietary gene bank 
search  algorithm  (Radeke  HH  &  Bruno  B,  unpublished  data).  The  sequence  contains  no 
mismatch and a G-content of 78%. In the following study a TFO was designed targeting the 
RANTES promoter sequence, and it was analysed whether RANTES gene expression could 
be inhibited using this TFO.  
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Lentiviral  vectors  derived  from  human  immunodeficiency  virus  (HIV)  are  highly  efficient 
vehicles  for  in  vivo  gene  delivery,  and  they  have  been  strongly  developed  in  design,  in 
biosafety and in their ability of transgene expression inside target cells. 
Lentiviruses are a family of complex retroviruses inducing chronic and progressive disease 
typically associated with infection of macrophages. Gene transfer vectors were derived from 
lentiviruses to complement the successful features of previously developed retroviral vectors 
- efficient integration in the chromatin, absence of viral genes from the genetic information 
transferred to the recipient - with the ability to infect non-dividing cells. 
The design of viral vectors is based on the separation of cis-acting sequences required for 
the transfer of the viral genome to the target cell from trans-acting sequences encoding the 
viral proteins (Mann et al. 1983; Miller et al. 1993). In addition to the structural genes (gag, 
pol, and env) common to all retroviruses, lentiviruses also contain two essential regulatory 
(tat  and  rev)  and  several  accessory  genes  involved  in  the  modulation  of  viral  gene 
expression,  assembly  of  viral  particles,  and  structural  and  functional  alterations  in  the 
infected cells. The lentivirus replication is partially mediated by cis-acting viral sequences, 
which do not encode proteins. The trans-acting sequences encode structural, regulatory, and 
accessory proteins and are included in the packaging construct. Most cis-acting sequences 
are  essential  for  lentivirus  functioning  and  are  usually  included  in  the  transfer  construct, 
which is the part of the lentivirus which integrates in the host cell genome and encodes the 
gene of interest. Both types of constructs are introduced in the same cell to produce vector 
particles.  As  the  particles  can  only  encapsidate  and  transfer  the  vector  construct,  the 
infection process is limited to a single round, the transduction. Since the early steps do not 
depend on viral protein synthesis, all trans-acting genes can be excluded from the transfer 
construct that encodes only the gene of interest. The required trans-acting sequences are 
provided by the packaging construct. The efficiency and biosafety of a vector depends on the 
extent to which segregation of cis- and trans-acting functions of the viral genome is achieved. 
Lentiviral vectors were originally designed as replication-defective, hybrid viral particles made 
from the core proteins and enzymes of HIV-1, and the envelope of a different virus, most 
often the vesicular stomatitis virus (VSV) (Akkina et al. 1996; Naldini et al. 1996; Reiser et al. 
1996). The packaging functions are provided by at least two separate expression plasmids 
that use transcriptional signals unrelated to those of the virus. One or more core packaging 
constructs, derived from the lentiviral genome, express the viral proteins but not the env 
gene that has been deleted. A separate construct expresses a heterologous envelope that is 
incorporated into the vector particles (pseudotyping) and allows entry into a wide spectrum of 
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In order to be considered for clinical applications, lentiviral vectors must comply with the 
strictest safety standards. It is theoretically possible that multiple recombination events join 
the viral cis-acting sequences in the transfer vector to trans-acting viral genes in packaging 
constructs  to  generate  replication  competent  recombinants  (RCR).  While  the  use  of  a 
heterologous  envelope  makes  the  generation  of  a  wild-type  lentivirus  impossible, 
contamination of a vector batch by such an RCR may represent a hazard to the recipient. A 
strategy to improve vector biosafety is to eliminate all the viral genes that are not essential 
for gene transfer from the packaging constructs. In the first generation packaging construct, 
all the genes encoding structural and accessory proteins of HIV-1 except for the envelope 
are maintained. In the second generation packaging construct, all the accessory genes have 
been deleted. In the third generation packaging construct, the sequences encoding the tat 
and rev protein have also been eliminated. Tat acts as a transcriptional activator, and it plays 
an  important  role  in  the  exceedingly  high  replication  rates  that  characterise  HIV-induced 
disease. Rev inhibits formation of early regulatory mRNAs and, conversely, promotes the 
cytoplasmatic export of late viral transcripts expressing the viral structural proteins (gag, pol, 
and env). As rev is required for expression of the gag and pol genes, recombinants between 
the packaging and transfer vectors would be non-functional outside vector producer cells 
(Follenzi and Naldini 2002).  
The biosafety of lentiviral vectors is also improved by generating self-inactivating transfer 
(SIN) vectors (Bukovsky et al. 1999; Iwakuma et al. 1999; Miyoshi et al. 1998; Zufferey et al. 
1998). The SIN transfer vector carries a large deletion in the U3 region of the 3’ long terminal 
repeat  (LTR)  completely  inactivating  its  promoter  and  enhancer  activity.  This  deletion  is 
duplicated upstream of the vector upon transduction into target cells, thus inactivating both 
LTRs. The 5’ LTR was also modified by substituting the U3 region with a strong constitutive 
promoter  derived  from  the  rous  sarcoma  virus  (RSV)  to  abolish  tat  dependence  of 
transcription in vector-producer cells. An improved SIN vector contains the central polypurine 
tract (cPPT) sequence from the HIV-1 pol gene inserted in front of the internal promoter to 
improve gene transfer performance (Follenzi et al. 2000; Zennou et al. 2000), and the post-
transcriptional regulatory element of the woodchuck hepatitis virus (WPRE) positioned after 
the transgene to enhance its expression (Deglon et al. 2000; Farson et al. 2001; Zufferey et 
al. 1999). 
Combining a self-inactivating transfer vector with a packaging system of the third generation, 
it is now possible to achieve a high level of predicted biosafety, theoretically superior to that 
of  retroviral  vectors  currently  in  clinical  use,  and  possible  acceptable  for  clinical 
experimentation.  
In the following work the transfer vector pHR’SIN-cPPT-SEW (“SEW”) is used which was 
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Demaison (Demaison et al. 2002). Here, the internal CMW promoter was replaced by the U3 
part of the spleen focus forming virus (SFFV) strain P long terminal repeat sequence (3’LTR 
SFFV). The incorporation of the HIV cPPT and termination sequence in the lentiviral vector 
facilitates reverse transcription, nuclear entry, and transduction. It had also been suggested 
that the cPPT element could enhance gene expression (Figure 2-6).  
 
 
 
Figure 2-6. Schematic representation of the lentiviral transfer vector pHR’SIN-cPPT-SEW. Abbreviations: 
Long terminal repeats (LTR), central polypurine tract (cPPT), spleen focus forming virus (SFFV), enhanced green 
fluorescent protein (eGFP), post-transcriptional regulatory element of the woodchuck hepatitis virus (WPRE). ￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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The  chemokine  system  has  emerged  as  a  central  player  in  human  health  and  disease. 
Whereas  normal  chemokine  expression  is  necessary  for  host  defence,  inappropriate  or 
exaggerated activation of these genes are a threat to health. One of the major chemokines 
produced during glomerulonephritis and several other inflammatory diseases is MCP-1, and 
the modulation of MCP-1 activity and/or expression may be a promising therapeutic strategy 
for nephritis and possible other inflammatory diseases.  
The potential of triple helix-forming oligonucleotides (TFOs) to selectively inhibit expression 
of target genes is of great interest for gene therapeutic strategies. RNA oligonucleotides that 
bind homopurine/homopyrimidine DNA sequences by forming triple-helices can be rationally 
designed, but intracellular delivery of TFOs needs improvement.  
The  central  goal  of  this  study  was  the  establishment  of  on  optimised  method  for  TFO 
delivery, using expression vectors which generate RNA transcripts that are capable of triplex 
formation.  
The study is divided into four parts: 
 
1. Validation of triplex formation in vitro  
Two  TFO  target  sequences  were  found  in  the  human  MCP-1  promoter  and  the  mouse 
RANTES promoter. Triplex formation should be examined in vitro via gel mobility shift assays 
and  following,  the  capacity  of  extracellular  added  TFOs  to  inhibit  gene  expression  was 
analysed in different cell systems.  
 
2. In vivo synthesis of TFOs 
To improve TFO delivery and to make the TFO application a powerful gene-therapeutic tool, 
a system for the in vivo synthesis of TFOs should be established. First, specific binding of the 
RNA CU-TFO to the MCP-1 promoter fragment had to be verified in vitro in comparison to 
unrelated control oligoribonucleotides. To generate RNA-TFOs targeting the human MCP-1 
in vivo, an expression vector was cloned which directed transcription of either a 19 nt triplex-
forming  CU-TFO  sequence  or  two  different  19  nt  GU-  or  CA-control  sequences.  These 
sequences were transcribed together with the RNA of a hygromycin resistance gene as one 
fusion transcript. The inhibitory effects of the vector-derived CU-TFO on endogenous MCP-1 
gene expression should be analysed in stable transfected HEK 293 cells. A set of control 
experiments had to be established to rule out unspecific binding of the TFO to the target 
sequence, including control and target sequences with single mismatches, RT-PCR using 
nuclear  and  total  RNA  containing  the  cytosolic  fraction,  and  a  novel  magnetic  capture 
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3. siRNA technique 
In  addition  to  the  TFOs  the  siRNA  technique  was  tested  to  inhibit  the  expression  of 
proinflammatory  chemokines  MCP-1  and  RANTES,  as  there  is  no  siRNA  sequence 
described in the literature for these two chemokines till now. Here, different strategies were 
followed.  Experiments  were  performed  using  vector-derived  siRNAs;  therefore  several 
expression vectors (pSUPER) had to be cloned. On the other hand, transient transfections 
were performed using synthetic siRNAs to suppress translation of the gene of interest.  
 
4. Production of lentiviral vectors 
Gene therapy approaches rely on efficient transfer of genes to the desired target cells. A 
wide  variety  of  viral  and  nonviral  vectors  have  been  developed  and  evaluated  for  their 
efficiency of transduction, sustained expression of the transgene, and safety. Among them, 
lentiviruses have been widely used for gene therapy applications.  
Here, the cloning of the lentiviral transfer vector SEW, the production of lentiviral particles by 
transient transfection, determination of the viral titre, and the transduction of T helper 1 cells 
were performed.  
In the future it should be possible to generate lentiviral vector-derived TFOs, which then 
could be easily tested in variety of cell lines or animal models.  
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3 Materials and Methods 
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3.1.1 Isolation of nucleic acids 
 
Table 3-1. Materials nucleic acids 
Gibco RBL, Life Technologies, Eggenstein  Phosphate buffered saline (PBS) 
Invitrogen GmbH, Karlsruhe  Trizol reagent 
Qiagen GmbH, Hilden  Qiafilter Maxiprep Kit  
Qiafilter Maxiprep Kit, endotoxin-free 
Qiaprep spin Miniprep Kit 
Sigma-Aldrich Chemie GmbH, Deisenhofen  DEPC, 0.1% (v/v) DEPC in Millipore H2O, autoclaved  
Nonidet P-40 
 
3.1.1.1 RNA isolation of eukaryotic cells  
Isolation  of  total  RNA  was  performed  using  Trizol  reagent  according  to  the  supplier’s 
protocol. Cells grown in a monolayer were washed twice with PBS and lysed directly in the 
culture dish with 1ml Trizol reagent per 10 cm
2. Cells grown in suspension were pelleted by 
centrifugation, washed once with PBS and lysed in 1 ml Trizol reagent per 10 x 10
6 cells. 
RNA was redissolved in RNase free water and stored at -20° C or -80° C. RNA quality was 
checked on a denaturing agarose gel, showing two predominant ribosomal RNA bands at ~5 
kb (28S) and at ~2 kb (18S), and low molecular weight RNA between 0.1 and 0.3 kb (tRNA, 
5S).  
 
3.1.1.2 Ethanol precipitation of nucleic acids 
 
TE buffer:  10 mM Tris/HCl, pH 8.0 
  1 mM Na2EDTA 
 
DNA  or  RNA  from  dilute,  aqueous  solutions  can  be  precipitated  by  the  addition  of 
monovalent cations and ethanol. 2.5 volumes of ice-cold 95% ethanol and 0.1 volume of 3 M 
sodium acetate (pH 5.2) were added to the nucleic acid solution, mixed, and incubated at  
-20° C at least for 1 h. Following centrifugation for 30 min at 12,000 x g, 4° C, the supernatant 
was carefully discarded. The pellet was washed once with 70% ethanol to remove remaining 
salt  and  centrifuged  for  additional  10  min  at  12,000  x  g,  4° C  (Sigma  3K30  Laboratory 
Centrihuges). The DNA or RNA precipitate was briefly air dried and dissolved in sterile H2O 
(RNase-free) or TE buffer. 
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3.1.1.3 Quantification of nucleic acids 
Determination  of  DNA  or  RNA  concentration  was  done  by  spectrophotometry  at  260  nm 
(GeneQuant  Pro  RNA/DNA  calculator,  Amersham  Pharmacia  Biotech,  Freiburg).  Nucleic 
acids absorb UV light of 250 to 270 nm wavelength, with a maximum at 260 nm. The reading 
at  260  nm  allows  calculation  of  the  concentration  of  nucleic  acid  in  the  sample.  The 
absorbance of 1 unit at 260 nm (A260) corresponds to approximately 50 µg/ml for double-
stranded  DNA  and  40  µg/ml  for  single-stranded  DNA  and  RNA.  The  ratio  between  the 
readings at 260 nm and 280 nm provides an estimate for the purity of the nucleic acid. Pure 
preparations of DNA and RNA have ratios of 1.8 and 1.95, respectively. 
 
3.1.1.4 Isolation of nuclei and extraction of RNA 
 
NP-40 lysis buffer:  10 mM Tris/HCl, pH 7.4 
  10 mM NaCl 
  3 mM MgCl2 
  0.5% (v/v) Nonidet P-40  
 
Glycerol storage buffer:  50 mM Tris/HCl, pH 8.3 
  40% (v/v) glycerol 
  5 mM MgCl2 
  0.1 mM EDTA 
 
For cultures of adherent cells (~5 x 10
7 cells): The medium was removed from monolayer 
cultures and the cells were placed on ice. Cells were washed twice and scraped into ice-cold 
PBS and pelleted by centrifugation at 500 x g for 5 min, 4°  C (Hermle Labortechnik GmbH, 
Wehingen). The cell pellet was loosened by gently vortexing 5 sec, and 4 ml NP-40 lysis 
buffer were added, continuing to vortex as buffer was added, followed by incubation for 5 min 
on ice. After complete lysis, nuclei were pelleted by centrifugation at 500 x g for 5 min, 4°  C. 
The nuclear pellet was resuspended in 4 ml NP-40 lysis buffer as described, the nuclei were 
pelleted  by  centrifugation  again  and  the  supernatant  was  discarded.  Nuclei  were 
resuspended in 100 to 200 µl glycerol storage buffer and frozen and stored in liquid nitrogen 
up  to  one  year.  RNA  was  isolated  using  Trizol  reagent  according  to  the  manufacturer' s 
instructions. 
 
3.1.1.5 Isolation of plasmid DNA 
The  alkaline/SDS  lysis  describes  the  lysis  of  bacterial  cells  by  a  NaOH/SDS  solution. 
Chromosomal and plasmid DNA are denatured under these alkaline conditions. Addition of 
potassium acetate results in a precipitate containing chromosomal DNA and other cellular 
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Purification of plasmids from E.coli overnight cultures containing the appropriate antibiotics 
were  routinely  performed  using  the  QIAprep  spin  Miniprep  or  Maxiprep  according  to  the 
manufacturer’s  protocol.  Plasmids  for  transfection  of  eukaryotic  cells  were  purified  under 
endotoxin free conditions. Plasmid DNA was eluted in H2O or TE buffer and stored at -20° C. 
 
3.1.2 Gel electrophoresis 
 
Table 3-2. Materials electrophoresis 
AppliChem GmbH, Darmstadt  Acrylamide 30% 
Carl Roth GmbH, Karlsruhe 
 
Agarose  
APS 
Ethidium bromide  
MOPS 
TEMED 
Invitrogen GmbH, Karlsruhe  50 bp DNA marker 
MBI Fermentas, St. Leon-Roth  6 x DNA loading buffer  
2 x RNA loading buffer 
New England BioLabs, Beverly MA  X174 DNA HaeIII Digest 
Promega GmbH, Mannheim  RNA marker 
 
Gel electrophoresis allows separation and identification of nucleic acids based on charge 
migration. Migration of nucleic acid molecules in an electric field is determined by size and 
conformation,  allowing  nucleic  fragments  of  different  sizes  to  be  separated.  Agarose  gel 
analysis is the most commonly used method for analyzing DNA fragments between 0.1 and 
25 kb. The concentration of agarose (usually 0.7-1.5%) used for the gel depends primarily on 
the size of the DNA fragments to be analyzed.  
Ethidium bromide was included in the gel matrix to enable fluorescent visualisation of the 
DNA fragments under UV light. Agarose gels were submerged in electrophoresis buffer in a 
horizontal electrophoresis apparatus (Sub Cell Gel Electrophoresis Systems, BioRad). 
 
3.1.2.1 Analytical DNA gels  
 
50 x TAE buffer   2 M Tris·acetate  
50 mM EDTA, pH 8.0 
 
The  amount  of  agarose  depending  on  the  concentration  required  was  added  to  the 
appropriate volume of 1 x TAE buffer in a bottle and heated in a microwave until the agarose 
dissolved. Reduced volume of liquid was made up to the original volume with distilled water 
to  ensure correct  agarose  and  buffer  concentrations.  The  cooled agarose  (55-60° C)  was 
mixed with 1 µl of ethidium bromide (1 µl per 30 ml agarose) and poured onto the gel tray 
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pouring the gel, and the gel was left to set for 20 min. Following, the comb was removed and 
the tank containing the gel was filled with 1 x TAE buffer. For DNA sample preparation, 1 
volume of 6 x DNA loading buffer was mixed with 5 volumes of DNA solution, the samples 
were applied to the wells of the gel and a molecular-weight marker was included to enable 
analysis of DNA fragment sizes in the samples. Electrodes were connected so that the DNA 
would migrate towards the anode. The gel was run at 1-10 V/cm until the dyes have migrated 
an appropriate distance.  
Ethidium bromide–DNA complexes display increased fluorescence compared to the dye in 
solution. Illumination of a stained gel under UV light (254–366 nm) allows bands of DNA to 
be visualised against a background of unbound dye.  
 
3.1.2.2 Polyacrylamide gels 
 
Polyacrylamide gel (12.5%)   5.8 ml H2O 
  4 ml acrylamide (30%)  
  0.2 ml 50 x TAE  
  4 µl TEMED 
  100 µl 10% APS 
 
Polyacrylamide gels were chosen for small DNA fragments or electrophoretic mobility gel 
shift  assays  (EMSA).  Electrophoresis  was  performed  in  a  mini  vertical  electrophoresis 
system (BioRad). 
 
3.1.2.3 Denaturing RNA gels  
 
10 x MOPS buffer  200 mM MOPS 
  50 mM sodium acetate  
  10 mM EDTA, pH 7.0 
   
1 x FA gel buffer (1 l)  100 ml 10 x MOPS buffer 
  20 ml 37% formaldehyde  
  880 ml RNase-free water 
 
The integrity and size distribution of total RNA can be checked by denaturing agarose gel 
electrophoresis  and  ethidium  bromide  staining.  The  respective  ribosomal  bands  should 
appear as sharp bands on the stained gel. Unlike DNA, RNA has a high degree of secondary 
structure, making it necessary to use a denaturing gel. Formaldehyde in the gel disrupts 
secondary RNA structure so that RNA molecules can be separated by their charge migration.  
To prepare a gel of 15 x 15 cm, 1.5 g of agarose was mixed with 15 ml of 10 x MOPS buffer 
and 132.3 ml RNase-free water. The agarose was dissolved by heating in a microwave and ￿￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿   ￿￿ ￿ ￿ ￿￿￿ ￿ ! ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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cooled to 65-70° C in a water bath. After cooling, 2.7 ml of 37% formaldehyde and 1.5 µl of 
ethidium bromide were added. The agarose was poured onto the gel tray and the comb was 
inserted. Prior to running, the gel was equilibrated in 1 x FA gel buffer for at least 30 min. For 
RNA sample preparation, 1 volume of RNA was mixed with 1 volume of 2 x RNA loading 
buffer, denatured for 10 min at 65° C, and chilled on ice. For each run an appropriate RNA 
weight marker was included. The gel was run at 5 V/cm until the bromophenol blue dye has 
migrated approximately 2/3 through the gel. For longer runs overnight, electrophoresis was 
performed at 4° C at 0.75 V/cm, optimal with re-circulating the electrophoresis buffer. 
 
3.1.3 PCR 
 
Table 3-3. Materials PCR and RT-PCR 
Invitrogen GmbH, Karlsruhe  0.1 M DTT 
10 mM dNTP-Mix 
50 mM MgCl2 
Oligo (dT)n 
Pfx polymerase (2.5 U/µl) + buffer 
Random Hexamers 
RNase Out (40 U/µl) 
Taq polymerase (5 U/µl) + buffer 
ThermoScript RT-PCR System 
 
Table 3-4. Primers (Qiagen, Hilden) 
Primer  SEQUENCES 5’- 3’ 
T3rev  5’GCTACGTAATTAACCCTCACTAAAG 
T7for  5’GCTACGTAAATACGACTCACTATAG 
RANTES35for  5’GTACCA TGAAGATCTCTGC 
RANTES465rev-r  5’AGAGCCGGTCGGAGCGGAT 
MCP-1 104for  5’GCTCATAGCAGCCACCTTC 
MCP-1 608rev-r  5’GGTAGAACTGTGGTTCAAG 
fw_TVHygro  5’AGCAGAGCTCTCTGGCTAA 
rev_TVHygro  5’TCGGCGAGTACTTCTACAC 
pcDNA31/Hygro1_fw  5’TCTCCCTCTCTCCCACCTC 
pcDNA31/Hygro2_fw  5’GAGGTGGGAGAGAGGGAGA 
pcDNA31/Hygro3_fw  5’CTCTCTCCCTTCCTCTCCC 
pcDNA31/Hygro4_rev  5’TCACGCCATGTAGTGTAT 
pcDNA31/Hygro5_fw  5’GTGGTGGGTGTGTGGGTGT  
pcDNA31/Hygro6_fw  5’CACACACCCAACCACACCC 
pGL3_for  5’AGAGATACGCCCTGGTTCCT 
pGL3_rev  5’AGACCAGTAGATCCAGAGGA 
pGL3_for II  5’AAGCTTTCCTGCTTGACTCC 
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Polymerase chain reaction (PCR) is an in vitro method for enzymatically synthesizing defined 
sequences of DNA. The reaction uses two oligonucleotide primers that hybridise to opposite 
strands and flank the target DNA sequence that is to be amplified. The elongation of the 
primers is catalyzed by a heat-stable DNA polymerase (such as Taq DNA polymerase). A 
repetitive series of cycles involving template denaturation, primer annealing, and extension of 
the annealed primers by the polymerase results in exponential accumulation of a specific 
DNA  fragment.  The  ends  of  the  fragment  are  defined  by  the  5'   ends  of  the  primers. 
Prerequisites  for  successful  PCR  include  the  design  of  optimal  primer  pairs,  the  use  of 
appropriate primer concentrations, and optimisation of the PCR conditions.  
Routinely,  the  PCR  was  performed  in  a  total  volume  of  50  µl  in  a  DNA  thermal  cycler 
(Biometra, Göttingen), using Platinum Taq polymerase.  
 
3.1.3.1 Standard PCR 
Following conditions were chosen: 
 
Components   Volume   Final concentration 
10 x PCR buffer  5 µl   
50 mM MgCl2  1.5 µl  1.5 mM 
10 mM dNTP-Mix  1 µl  200 µM 
H2O  38 µl   
10 µM primer forward  1 µl  200 nM 
10 µM primer reverse  1 µl  200 nM 
Taq polymerase (5 U/µl)  0.5 µl  2.5 U 
DNA  2 µl  ~50-100 ng 
  ￿ 50 µl   
 
The program for standard PCR contained the following steps: 94° C for 2 min followed by 35 
cycles of 94° C for 30 sec, 55° C for 30 sec and 72° C for 1 min, and a final step of 72° C for 10 
min. The reaction was maintained at 4° C and stored at -20° C until analysis on a gel. 
 
Platinum  Pfx  DNA  polymerase  amplifies  genomic  templates  up  to  12  kb  and  plasmid 
templates  up  to  20  kb  and  can  be  used  for  demanding  PCR  applications  such  as  site-
directed  mutagenesis  and  expression  cloning.  Besides  providing  high  specificity,  the  Pfx 
polymerase  offers  the  benefit  of  proofreading  activity.  Its  3’,  5’  exonuclease  activity 
eradicates mismatched base pairings, resulting in fewer errors in the PCR product. 
The program for Pfx PCR contained the following steps: 94° C for 2 min followed by 25-30 
cycles of 94° C for 15 sec, 55° C for 30 sec and 72° C for 1 min, and a final step of 72° C for 10 
min. The reaction was maintained at 4° C and stored at -20° C until analysis on a gel.  
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Components   Volume   Final concentration 
10 x Pfx buffer  5 µl   
50 mM MgCl2  1 µl  1 mM 
10 mM dNTP-Mix  1.5 µl  300 µM 
H2O  38 µl   
10 µM primer forward  1 µl  300 nM 
10 µM primer reverse  1 µl  300 nM 
Pfx polymerase (2.5 U/µl)  0.5 µl  1.25 U 
DNA  2 µl  ~50-100 ng 
  ￿ 50 µl   
 
3.1.4 RT-PCR 
 
RNA Primer Mix  1-2 µg RNA 
  1 µl Oligo (dT)n 
  1 µl Random Hexamers 
  ad 10 µl H2O 
 
RT-Master Mix:  4 µl 5 x cDNA synthesis buffer 
  1 µl 0.1 M DTT 
  1 µl H2O 
  2 µl 10 mM dNTP mix 
  1 µl RNase Out (40U/µl) 
  1 µl ThermoScript RT (15 U/µl) 
 
Sensitive methods for the detection and analysis of rare mRNA transcripts or other RNAs 
present in low abundance are an important aspect of most cell/ molecular biology studies. 
RNA cannot serve as a template for PCR, so it must first be reverse transcribed into cDNA 
(e.g.  with  reverse  transcriptase  from  Moloney  murine  leukemia  virus  (MoMuLV)  or  avian 
myeloblastosis virus). RT-PCR is a combined technique in which reverse transcription (RT) is 
coupled with PCR amplification of the resulting cDNA. 
 
First strand synthesis was done with ThermoScript RT-PCR System using 1-2 µg RNA. The 
RNA-primer  mix  was  denatured  by  heating  for  5  minutes  at  65° C  and  chilled  on  ice. 
Following RNA denaturation, 10 µl of the RT-Master Mix was applied to the RNA-primer mix 
and incubated for the following cycles: 25° C 10 min, 50° C 45 min, 85° C 5 min. Optional, 1 µl 
RNaseH was added at 37° C for 20 minutes. 
PCR was performed using Platinum Taq DNA polymerase. Cycler conditions: 94° C for 2 min 
followed  by  30  cycles  of  94° C  for  30  sec,  55° C  for  30  sec  and  72° C  for  1  min. 
Oligonucleotide primers were used at a 200 nM final concentration. 
 
 ￿￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿   ￿￿ ￿ ￿ ￿￿￿ ￿ ! ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
￿ ￿￿￿
3.1.5 Cloning 
 
Table 3-5. Materials cloning 
  Vectors pSUPER and pHR’SIN-cPPT-SEW were provided by 
Dr. M. Grez, Georg-Speyer-Haus Haus, Frankfurt a. M. 
Invitrogen GmbH, Karlsruhe  Vector pcDNA3.1/Hygro 
MBI Fermentas, St. Leon-Roth  10 x buffer 0
+ 
10 x buffer R
+ 
ATP 
Calf intestine phosphatase (CIP) + buffer 
Restriction enzymes: ApaI, SmaI, BamHI, XhoI, BglII, HindIII, 
EcoRI 
SnaBI + 10 x buffer 
T4 DNA ligase + buffer 
T4 poly-nucleotide kinase (PNK) + buffer
 
New England BioLabs, Beverly, MA  NcoI 
Promega GmbH, Mannheim  pGL3 control vector 
Qiagen GmbH, Hilden  Qiaquick gel extraction kit 
Qiaquick nucleotide removal kit  
 
3.1.5.1 Vector system for short interfering RNA 
 
Annealing buffer  100 mM potassium acetate 
  30 mM HEPES 
  2 mM Mg-acetate 
  pH 7.4 
 
The  vector  pSUPER  is  designed  for  the  expression  of  double-stranded  short  interfering 
RNAs  (siRNA).  Therefore,  a  pair  of  64  nt  oligonucleotides  containing  the  siRNA  coding 
sequences  targeting  MCP-1  and  RANTES  were  annealed  and  ligated  into  the  vector 
between BglII and HindIII sites of the vector.  
Using  the  same  method,  oligonucleotides  containing  the  coding  sequences  for  single-
stranded RNA TFOs (without stem loop) targeting MCP-1 and RANTES were cloned. 
 
Table 3-6. Oligonucleotides (siRNA and TFO) for cloning pSUPER (Qiagen, Hilden) 
RANTESf_si1  5’GATCCCCGTGCTCCAATCTTGCAGTCTTCAAGAGAGACTGCAAGATTGGAGCACTTTTTGGAAA 
RANTESr_si1  5’AGCTTTTCCAAAAAGTGCTCCAATCTTGCAGTCTCTCTTGAAGACTGCAAGATTGGAGCACGGG 
MCP-1f_si1  5’GATCCCCCTTCACCAATAGGAAGATCTTCAAGAGAGATCTTCCTATTGGTGAAGTTTTTGGAAA 
MCP-1r_si1  5’AGCTTTTCCAAAAACTTCACCAATAGGAAGATCTCTCTTGAAGATCTTCCTATTGGTGAAGGGG 
MCP-1 19cufor  5’GATCCCCTCTCCCTCTCTCCCACCTCTTTTTGGAAA 
MCP-1 19curev  5’AGCTTTTCCAAAAAGAGGTGGGAGAGAGGGAGAGGG 
RANTES25Cufor  5’GATCCCCCTCCCCCTCCCCCTCCCCCTCCTTCTTTTTGGAAA 
RANTES25Curev  5’AGCTTTTCCAAAAAGAAGGAGGGGGAGGGGGAGGGGGAGGGG 
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Figure 3-1. Vector pSUPER 
 
The oligonucleotides were dissolved in sterile H2O to a concentration of 1 mM. The annealing 
reaction was assembled by mixing 1 µl of each oligonucleotide (forward and reverse) in 48 µl 
annealing  buffer.  The  mixture  was  incubated  for  4  min  at  95° C  in  a  cycler  (Biometra, 
Göttingen), followed by a slow cool-down to room temperature at a rate of 1° C/min. Samples 
were cooled further to 4° C and for longer storage kept at -20° C until needed.  
To prevent vector reclosures during the ligation step, the linearised vector was CIP-treated 
(CIP=calf  intestine  alkaline  phosphatase)  and  the  annealed  oligonucleotides  were 
phosphorylated.  
 
Phosphorylation of oligo  2 µl of annealed oligonucleotides 
  1 µl T4 poly-nucleotide kinase (PNK) buffer 
  1 µl 10 mM ATP (final concentration 1 mM) 
  5 µl H2O 
  1 µl T4 PNK  
 
The reaction was incubated for 30 min at 37° C, heat inactivated at 70° C for 10 min and 
chilled  on  ice.  Prior  to  ligation,  the  reaction  was  purified  using  the  Qiaquick  nucleotide 
removal kit and eluted in 30 µl H2O.  
 
Linearisation of pSUPER  Plasmid DNA 20 µg x µl 
  H2O y µl, x + y = 123 µl 
  HindIII 2 µl (100 U) 
  BglII 10 µl (100 U) 
  10 buffer R
+ 15 µl 
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The reaction was incubated for 3 h at 37° C, heat inactivated at 70° C for 10 min and chilled 
on  ice.  Following  digestion,  the  linearised  vector  was  gel  purified  on  a  1%  agarose  gel 
(Qiaquick gel extraction kit) to remove the insert sequence and separate the preparation from 
any undigested circular plasmid to decrease the background in ligation and transformation.  
 
CIP-treatment of linearised plasmid  7.25 µl H2O 
  1 µl 10 x CIP buffer 
  0.75 µl linearised plasmid (~0.5 µg) 
  1 µl CIP 
 
The  reaction  was  incubated  for  1  h  at  37° C,  heat  inactivated  at  70° C  for  10  min  in  the 
presence of 5 mM EDTA and chilled on ice. Prior to ligation, the reaction was purified using 
the Qiaquick nucleotide removal kit and eluted in 30 µl H2O.  
 
Ligation  2 µl of the annealed and phosphorylated oligos 
  5 µl H2O 
  1 µl 10 x T4 DNA ligase buffer  
  1 µl plasmid linearised and CIPed 
  1 µl T4 DNA ligase 
 
The  reaction  was  incubated  over  night  at  20° C  and  was  ready  for  transformation.  After 
transformation  and  plasmid  preparations  correct  inserts  were  confirmed  by  restriction 
analysis with BglII or HindIII/EcoRI for 1-2 h at 37° C: 
 
HindIII/EcoRI restriction  15.8 µl H2O 
  1 µl plasmid DNA (~1µg/µl) 
  2 µl 10 x buffer R
+ 
  1 µl EcoRI (10 U) 
  0.2 µl HindIII (10 U) 
   
 
BglII restriction  16 µl H2O 
  1 µl plasmid DNA (~1µg/µl) 
  2 µl 10 x buffer 0
+ 
  1 µl BglII (10 U) 
 
Insert sizes were analysed on a 1% agarose gel. Additionally, the presence of the correct 
insert was confirmed by sequencing (MWG, Ebersberg).  
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3.1.5.2 Cloning of a lentiviral transfer vector 
For SEW vector construction, confirmed inserts in the vector pSUPER were amplified by 
PCR  using  the  primers  T7for  and  T3rev  (Table  3-4)  which  both  contained  a  5’  SnaBI 
restriction  site.  Resulting  expression  cassettes  were  subcloned  into  the  SnaBI  linearised 
SEW.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Lentiviral transfer vector pHR’SIN-cPPT-SEW (SEW) 
 
 
Blunt end ligation  2 µl PCR product, SnaBI digested 
  4 µl H2O 
  1 µl 10 x T4 DNA ligase buffer  
  1 µl plasmid SnaBI linearised (~50-400 ng)  
  2 µl T4 DNA ligase 
 
PCR  products  (~378  bp  ±  different  inserts),  containing  the  SnaBI  restriction  sites  were 
purified  using  the  Qiaquick  nucleotide  removal  kit  and  eluted  in  30  µl  H2O.  The  whole 
reaction was SnaBI (10 U/µl) digested and additionally purified. 
Insert sizes were analysed on a 1% agarose gel. Additionally, the presence of the correct 
insert was confirmed by sequencing (MWG, Ebersberg).  
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3.1.5.3 Construction of vectors TVHygro-CU, TVHygro-GU and TVHygro-CA  
 
Table 3-7. Oligonucleotides (MWG, Ebersberg) for TVHygro 
TVHygro-CU_for  5’ GTCGACAAGCTTCTCGAGTCTCCCTCTCTCCCACCTCGGATCCCGCGAT 3’ 
TVHygro-CU_rev  3’ CAGCTGTTCGAAGAGCTCAGAGGGAGAGAGGGTGGAGCCTAGGGCGCTA 5’ 
TVHygro-CA_for  5’ AAGCTTCTCGAGCACACACCCAACCACACCCGGATCC 3’ 
TVHygro-CA_rev  3’ TTCGAAGAGCTCGTGTGTGGGTTGGTGTGGGCCTAGG 5’ 
TVHygro-GU_for  5’ AAGCTTCTCGAGACACCCACACACCCACCACGGATCC 3’ 
TVHygro-GU_rev   3’ TTCGAAGAGCTCTGTGGGTGTGTGGGTGGTGCCTAGG 5’ 
 
Transfection vectors were constructed to drive transcription of either RNA containing the 19 
nt  pyrimidine  triplex  forming  sequence  targeting  the  MCP-1  promoter  (CU-TFO)  or  RNA 
containing  two  different  19  nt  control  sequences  (GU-control  or  CA-control).  The  vector 
TVHygro  was  derived  from  the  eukaryotic  expression  vector  pcDNA3.1/Hygro  with  the 
sequences spanning the region 1002-2079 deleted by restriction with the enzymes ApaI and 
SmaI. The resulting ApaI overhang was end-filled and the vector re-ligated. Three different 
DNA  sequences  have  been  cloned  into  the  5’  untranslated  region  of  the  hygromycin 
resistance gene, resulting in the vectors TVHygro-CU, TVHygro-CA and TVHygro-GU. The 
constructs leading to TVHygro-CU and TVHygro-CA were digested with the enzymes HindIII 
and BamHI, and cloned into TVHygro in HindIII/BamHI orientation. The construct leading to 
vector TVHygro-GU was BamHI and XhoI digested and cloned into TVHygro in BamHI/XhoI 
orientation.  Each  of  the  cloned  sequences  is  transcribed  in  line  with  the  hygromycin 
resistance  mRNA  under  the  control  of  the  constitutive  cytomegalovirus  (CMV)  promoter, 
resulting in one fusion transcript. TVHygro served as an additional control vector without 
insert. 
Cloning of vector TVHygro was carried out by Dr. Mario Schwarz and correct inserts were 
confirmed by sequencing (MWG, Ebersberg). 
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Table 3-8. Summary vector constructs 
Construct   Vector   Modification   Cloning  
TVHygro  pcDNA3.1/Hgro  Deletion ApaI/SmaI  No insert 
TVHygro-CU  pcDNA3.1/Hgro  Deletion ApaI/SmaI  Insert between HindIII/BamHI, CU-TFO 
TVHygro-CA  pcDNA3.1/Hgro  Deletion ApaI/SmaI  Insert between HindIII/BamHI, CA-control 
TVHygro-GU  pcDNA3.1/Hgro  Deletion ApaI/SmaI  Insert between BamHI/XhoI, GU-control 
pS-MCP-1_si  pSUPER    Insert between HindIII/BglII, MCP-1 siRNA 
pS-RANTES-si  pSUPER    Insert between HindIII/BglII, RANTES siRNA  
pS-MCP-1_TFO  pSUPER    Insert between HindIII/BglII MCP-1 TFO 
SEW(-)  pHR’SIN-cPPT-SEW    T7/T3 amplification of vector pSUPER, insert in 
SnaBI  
SEW-RANTES-si  pHR’SIN-cPPT-SEW    T7/T3  amplification  of  vector  pS-RANTES-1_si, 
insert in SnaBI, RANTES siRNA 
SEW-MCP-1_si  pHR’SIN-cPPT-SEW    T7/T3 amplification of vector pS-MCP-1_si, insert 
in SnaBI, MCP-1 siRNA 
SEW-MCP-1_TFO  pHR’SIN-cPPT-SEW    T7/T3  amplification  of  vector  pS-MCP-1_TFO, 
insert in SnaBI, MCP-1 TFO 
pGL3-MCP-1  pGL3-control vector    Insert between HindIII/NcoI, 39 bp MCP-1 target 
sequence 
pGL3-MCP-1_a  pGL3-control vector    Insert between HindIII/NcoI, 39 bp MCP-1 target 
sequence, antisense orientation 
 
3.1.6 Northern blots 
 
Table 3-9. Materials Northern Blot 
Amersham Pharmacia Biotech, Freiburg  [a-
32P]-dCTP 
Hybond
TM-N nylon membrane 
Invitrogen GmbH, Karlsruhe  Denhardt’s reagent 
Salmon sperm DNA 
MBI Fermentas, St. Leon-Rot  HexaLabel
TM DNA Labelling  
Merck, Darmstadt  SDS 
Qiagen GmbH, Hilden  Qiaquick nucleotide removal kit 
Riedel-de Haën, Seelze  Formaldehyde 
 
20 x SSC  3 M NaCl 
  0.3 M sodium citrate  
  pH 7.0 
   
20 x SSPE   3 M NaCl 
  200 mM NaH2PO4 x H2O 
  20 mm EDTA 
 
After separating RNA molecules based on charge migration in a denaturing gel (standard 
formaldehyde agarose gel, prepared and run as described), RNA molecules in the gel were 
transferred  to  a  nylon  membrane  by  capillary  transfer.  The  RNA  of  interest  can  then  be 
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A buffer tray was filled with 1 l 20 x SSC and a glass plate was placed across the tray. 
Whatman 3MM filter paper (pre-soaked in 20 x SSC) was placed over the glass plate so that 
the ends contacted the bottom of the tray. Immediately after gel electrophoresis, the gel was 
soaked for 10 min in RNase-free water with gentle shaking, then for 15 min in 0.05 NaOH, 
and finally for 10 min in 10 x SSC to neutralise the NaOH. Following, the gel was positioned 
upside-down on the filter paper covering the plate. The pre-soaked nylon membrane was 
placed  on  top  of  the  gel  so  that  it  covered  the  entire  surface,  followed  by  3  sheets  of 
Whatman filter paper and a 10-15 cm stack of dry paper towels. A second glass plate was 
placed on top of the paper towels and fixed with a weight of about 500 g. The transfer was 
carried  out  for  16-18  h.  After  the  transfer  was  complete,  filters  and  paper  towels  were 
removed,  the  positions  of  the  gel  lanes  on  the  nylon  membrane  were  marked,  and  the 
membrane was washed for 1 min in 10 x SSC. The RNA was fixed by UV cross-linking (150 
mJ/cm
2). The blot could be stored at 4 ° C wrapped in plastic wrap.  
 
3.1.6.1 Preparation of the radioactive probe 
For detection of the TFO/hygromycin mRNA in the stable transfected cell lines, a part of the 
hygromycin resistance gene included in the vector pCDNA3.1/Hygro was amplified by PCR, 
resulting in a product of 522 bp. The DNA was [a-
32P]-dCTP labelled using Klenow fragment 
according  to  the  supplier' s  protocol  and  unbound  nucleotides  were  removed  using  the 
Qiaquick nucleotide removal kit. Before hybridisation, the radioactive probe was denatured 
for 10 min at 70° C.  
 
3.1.6.2 Prehybridisation and hybridisation 
 
Hybridisation buffer  50% deionised formamide 
  5 x Denhardt’s reagent  
  5 x SSPE 
  1% SDS 
  150 µg/ml salmon sperm DNA 
 
The nylon membrane was washed once in 5 x SSPE, placed into the hybridisation tube using 
tweezers,  and  prehybridysed  at  42° C  for  2  h  in  hybridisation  buffer  (~10  ml)  with  gentle 
rotation in a hybridisation oven (Kendro Laboratory Products GmbH). After prehybridisation, 
the buffer was removed and replaced with fresh hybridisation buffer containing the denatured 
radio-labelled probe. Hybridisation was performed for 22 h at 42° C. For stringency washes, 
membranes were washed sequentially, starting with 15 min in 1 x SSC/ 0.1% SDS at room 
temperature, then 15 min in 0.2 x SSC/ 0.1% SDS at 62° C. Washed membranes were left 
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Japan), visualised using a Fuji BAS-MS Phospho-Imager (Fuji Imaging, Tokio, Japan) and 
analyzed by Phospho-Imager software (TINA, Raytest Company, Straubenhardt) 
 
3.1.7 TFO targets 
 
Table 3-10. TFO targets 
Target  Acc.-nr.  Description 
Mouse RANTES  MMU02298  28 bp TFO target site from -265 to -238. +1 corresponds 
to  the  transcriptional  start  site  described  by  Danoff  
(Danoff et al. 1994) 
Human MCP-1  D26087  19 bp TFO target site from -66 to -48. +1 corresponds to 
the  major  transcriptional  start  site  described  by  Ueda  
(Ueda et al. 1994) 
 
3.1.7.1 Preparation of synthetic double-stranded RANTES promoter fragment 
 
annealing buffer  10 mM Tris/HCl, pH 8.0 
  1 mM EDTA 
  0.1 M NaCl 
 
The oligonucleotides for the 48 bp double-stranded promoter fragment corresponded to the 
region  between  -275  to  -228  of  the  mouse  RANTES  promoter.  For  radioactive  labelling, 
HindIII and NcoI restriction site were added to the 3’ and 5’ ends of the sequences, leading to 
a 5’ overhang after annealing (Table 3-11). Annealing of the oligonucleotides was achieved 
by mixing them in equimolar amounts in annealing buffer, incubation at 95° C for 10 min, 
followed  by  a  slow  cool-down  to  room  temperature  at  a  rate  of  1° C/min.  Quantitative 
annealing of the single-stranded oligonucleotides to duplex DNA was confirmed by native 
polyacrylamide  gel  electrophoresis  through  12.5%  gels,  followed  by  ethidium  bromide 
staining. The resulting 5’ overhang of the duplex DNA was end-filled and [a-
32P]-dCTP radio-
labelled using Klenow fragment exo
- (Fermentas) in the presence of 0.02 mM of each dGTP, 
dATP  and  dTTP  and  1.85  MBq  [a-
32P]-dCTP  (Amersham  Pharmacia  Biotech). 
Unincorporated nucleotides were removed by using the Qiaquick nucleotide removal kit. 
 
Table 3-11. Oligonucleotides (Qiagen, Hilden) for RANTES promoter fragment 
RANTES_for  5’AGCTTCGGCAGATCTGAGGGGGAGGGGGAGGGGGAGGAAGAAATTTTCCCCTAC 3’ 
RANTES_rev  5’CATGGTAGGGGAAAATTTCTTCCTCCCCCTCCCCCTCCCCCTCAGATCTGCCGA 3’ 
The 28 bp RANTES TFO target site is shown in bold letters. HindIII restriction site is shown in blue, and NcoI 
restriction site in red. 
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3.1.7.2 Preparation of radio-labelled double-stranded MCP-1 promoter fragment  
The 39 bp double-stranded promoter fragment corresponded to the region between bp –76 
and  bp  –38  of  the  human  MCP-1  promoter.  A  modified  luciferase  pGL3-control  vector 
(Promega) containing the 39 bp target sequence between HindIII and NcoI restriction sites 
(pGL3-MCP-1, see Table 3-8) was digested with the respective restriction enzymes HindIII 
(Fermentas) and NcoI (New England BioLabs). The resulting fragment contained the 39 bp 
MCP-1  promoter  duplex  plus  5’  overhang  on  each  side  due  to  the  restriction  sites.  The 
fragment was electrophoretically fractionated with a 1% agarose gel, excised by a scalpel 
and DNA extracted using the Qiaquick gel extraction kit. The resulting 5’ overhang of the 
duplex  DNA  was  end-filled  and  [a-
32P]-dCTP  radio-labelled  as  described  above. 
Alternatively,  synthetic  oligonucleotides  containing  the  same  39  bp  MCP-1  promoter 
sequence  or  oligonucleotides  containing  two  mismatches  in  the  triplex  binding  site  were 
annealed and radio-labelled as described above. 
 
Table 3-12. Oligonucleotides (Qiagen, Hilden) for MCP-1 promoter fragment 
MCP-1_for  5’AGCTTTCCTGCTTGACTCCGCCCTCTCTCCCTCTGCCCGCTTTCC 3’ 
MCP-1_rev  5’CATGGGAAAGCGGGCAGAGGGAGAGAGGGCGGAGTCAAGCAGGAA 3’ 
MCP-1_2Mfor  5’AGCTTTCCTGCTTGACTCCGCCCTCTATCCCTCGGCCCGCTTTCC 3’ 
MCP-1_2Mrev  5’CATGGGAAAGCGGGCCGAGGGATAGAGGGCGGAGTCAAGCAGGAA 3’ 
The 19 bp MCP-1 TFO target site is shown in bold letters. HindIII restriction site is shown in blue, and NcoI 
restriction site in red, respectively. Positions of mismatches are underlined. 
 
3.1.7.3 Labelling of the plasmid pGL3 control containing a MCP-1 promoter fragment 
For labelling of the plasmid pGL3 control containing the 39 bp MCP-1 promoter duplex the 
vector was linearised by BglII restriction digestion. About 100 ng were [a-
32P]-dCTP labelled 
using Klenow fragment (Fermentas) according to the supplier' s protocol. 
 
3.1.7.4 TFOs 
19  nt  MCP-1  TFO  and  28  nt  RANTES  TFO  were  designed  according  to  the  sequences 
described  in  Table  3-10.  Oligonucleotides  were  HPLC  purified  and  desalted. 
Oligonucleotides used in cell culture experiments were phosphorothioated.  
 
Table 3-13. TFOs with desoxyribonucleotide backbone targeting RANTES 
RANTES GT-TFO  5’TTTGTTGGTGGGGGTGGGGGTGGGGGTG 3’  Qiagen, Hilden 
RANTES GT-control  5’TGGTGGGTGGGTGTGTGGGTGGGTGGGT 3’  Qiagen, Hilden 
RANTES GT-pTFO  5’T*TTGTTGGTGGGGGTGGGGGTGGGGGT*G 3’  Qiagen, Hilden 
RANTES GT-pcontrol  5’T*GGTGGGTGGGTGTGTGGGTGGGTGGG*T 3’  Qiagen, Hilden 
* Phosphorothioate modification 
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Table 3-14. TFOs with desoxyribonucleotide backbone targeting MCP-1 
TFO MS1  5’G*TGGTGGGTGTGTGGGTGT* 3’  Thermo Hybaid, Ulm 
control MS2  5’G*GGTGTGGTTGGGTGTGTG* 3’  Thermo Hybaid, Ulm 
TFO MS3  5’G*TGGTGGGTGTGTGGGTGT* 3’  GeneScan, Freiburg 
control MS34  5’G*GGTGTGGTTGGGTGTGTG* 3’  GeneScan, Freiburg 
TFO MS5  5’G*TGGTGGGTGTGTGGGTGT* 3’ 
control MS6  5’G*GGTGTGGTTGGGTGTGTG* 3’ 
metabion, 
Martinsried 
* Phosphorothioate modification 
 
Table 3-15. TFOs with ribonucleotide backbone targeting MCP-1 
rCU-TFO  5’UCUCCCUCUCUCCCACCUC 3’  MWG, Ebersberg 
rGA-control  5’GAGGUGGGAGAGAGGGAGA 3’  MWG, Ebersberg 
rGU-control  5’GUGGUGGGUGUGUGGGUGU 3’  MWG, Ebersberg 
rCA-control  5’CACACACCCAACCACACCC 3’  MWG, Ebersberg 
19CU_M  5’UCACCCUCUCUCCCACCUC 3’  MWG, Ebersberg 
 
3.1.8 Electrophoretic mobility gel shift assay (EMSA) 
 
Triplex buffer  10 mM Tris/HCl, pH 7.4 
  10 mM MgCl2 
  5% sucrose 
   
10 x TB buffer + MgCl2  890 mM Tris 
  890 mM boric acid  
  100 mM MgCl2 
   
Polyacrylamide gel   4.9 ml H2O 
  4 ml acrylamide (30%)  
  1 ml 10 x TB buffer+ MgCl2  
  4 µl TEMED 
  100 µl 10% APS 
 
The double-stranded target DNA was end-labelled as described previously. About 10 nM of 
the labelled duplex DNA (~10 fmol/µl in a 25 µl reaction) was incubated for 1 h at room 
temperature  with  the  indicated  concentrations  of  triple  helix-forming  or  control 
oligonucleotides  in  triplex  buffer.  Immediately  following  incubation,  the  samples  were 
electrophoresed through 12.5% native polyacrylamide gels buffered with 1 x TB containing 
10 mM MgCl2. Electrophoresis was performed at 8 V/cm for 3 h at 4° C. Gels were dried on a 
gel dryer (Scie-Plas gel dryer, model GD5040, Southam, UK) for 2 h at 80° C and exposed to 
Phospho-Imager  screens  (Fuji),  visualised  using  a  Fuji  BAS-MS  Phospho-Imager  and 
analysed by Phospho-Imager software (TINA, Raytest Company). 
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3.1.9 Triplex blotting 
 
Blotting buffer:  17 mM NaH2PO4 
  8 mM Na2HPO4 
 
Wash buffer:  200 mM sodium acetate 
  2 mM EDTA adjusted to pH 5.5 or 6.7 
  0.1% SDS 
 
5xNAE:  500 mM sodium acetate 
  5 mM EDTA adjusted to pH 5.5 or 6.7 
 
Hybridisation buffer:  5xNAE, pH 5.5 or 6.7 
  5x Denhardt’s solution 
  1% SDS 
  20 µg/ml of salmon sperm DNA 
 
Triplex blots were started by electrophoretic separation of the 19 nt oligoribonucleotides by 7 
M  urea  (Roth),  6%  polyacrylamide  gels.  Nucleic  acids  were  transferred  to  nylon  filters 
(Hybond
TM-N, Amersham Pharmacia Biotech) in blotting buffer, followed by UV cross-linking 
(150 mJ/cm
2). Then, filters were pre-hybridised for 1 h at 30°  or 37° C in hybridisation buffer 
at pH 5.5 or 6.7. Following pre-hybridisation blots were hybridised overnight with the radio-
labelled duplex DNA containing the target sequence in the same solution at 30°  or 37° C with 
gentle shaking. Subsequently, filters were washed twice by shaking in wash buffer for 20 min 
at 30°  or 37° C. Filters were exposed to Phospho-Imager screens (Fuji), visualised using a 
Fuji BAS-MS Phospho-Imager and analyzed by Phospho-Imager software (TINA, Raytest 
Company). 
 
3.1.10 In vitro transcription  
 
The  vector  encoded  TFO  or  control  sequences  and  in  addition  part  of  the  hygromycin 
resistance gene were amplified by PCR using the upstream primer fw_TVHygro 5’ AGC AGA 
GCT CTC TGG CTA A 3’ and downstream primer rev_TVHygro 5’ TCG GCG AGT ACT TCT 
ACA C 3’ (Table 3-4) at a 200 nm final concentration and Platinum Taq DNA polymerase 
(Invitrogen GmbH, Karlsruhe). Cycler conditions: 94° C for 2 min followed by 35 cycles of 
94° C  for  30  sec,  55° C  for  30  sec and  72° C  for  1  min.  Products  were  purified  using  the 
Qiaquick  PCR  Purification  kit.  The  PCR  product  was  used  as  template  for  in  vitro 
transcription. Product amplification included the T7 promoter sequence of the vector. In vitro 
transcription was performed with the T7 Ribomax
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System  (Promega)  according  to  the  supplier’s  protocol.  Correct  sizes  (1.1  kb)  of  the 
transcribed RNA were proven by electrophoresis with 1% agarose gels. 
 
3.1.11 Magnetic capture of triplex complexes 
 
Table 3-16. Materials magnetic capture assay 
Miltenyi Biotec, Bergisch Gladbach  µMACS MicroBeads conjugated to streptavidin  
MACS separation columns, M columns 
VarioMACS 
 
Triplex buffer  20 mM Tris/HCl, pH 7.0 
  1.5 mM MgCl2 
  140 mM KCl 
  3% glycerol 
 
Annealing of the biotinylated oligonucleotide 5’ biotin - GCG CTT CTG CGG GCG ATT TGT 
GTA CGC CCG 3’, HPCL purified (MWG, Ebersberg) to in vitro transcribed RNA (denatured 
90° C  for  5  min)  was  achieved  by  mixing  400  pmol  RNA  with  400  pmol  biotinylated 
oligonucleotide  in  annealing  buffer  (100  mM  potassium  acetate,  30  mM  HEPES,  2  mM 
magnesium  acetate,  pH  7.4).  The  reaction  was  incubated  for  1  h  at  room  temperature. 
Quantitative annealing of the oligonucleotide to the single-stranded RNA was confirmed by 
gel electrophoresis through a 1% agarose gel. The annealing reaction was incubated with 2 
µg  of  the  vector  pGL3-MCP-1  (Promega)  containing  a  39  bp  MCP-1  promoter  target 
sequence. Incubation was performed in triplex buffer for 1 to 24 h to allow proper triplex 
formation (pH usually 7.0) in the presence of RNase inhibitor (100 U, Invitrogen). A small 
aliquot  of  each  reaction  was  saved  for  PCR  analysis  to  confirm  that  equal  amounts  of 
plasmid were used. The reaction was incubated with 100 µl of the streptavidin micro beads 
for 5 min at room temperature. Dilution of the beads in the binding reaction was between 1:2 
and  1:10.  For  magnetic  separation  the  column  was  placed  in  the  magnetic  field  of  the 
VarioMACS separator and rinsed once with 250 µl of the equilibration buffer provided by the 
manufacturer and 3 times with 250 µl of triplex buffer. After that the binding reaction was 
applied onto the top of the column matrix. The solution passed through the column by gravity 
and  the  magnetically  labelled  complexes  were  retained  in  the  column.  The  column  was 
rinsed 4 times with 250 µl of triplex buffer to remove non-specifically interacting plasmid. For 
elution the column was removed out of the magnetic field and 250 µl of triplex buffer or H2O 
were applied directly onto the top of the column. Elution and washing fractions were saved 
for RNA and PCR analysis. To evaluate the quantity of RNA which was bound to the micro 
beads, 40 µl of each fraction were subjected to electrophoresis through a 1% agarose gel 
and  the  relative  amount  of  RNA  in  the  elution  fraction  was  quantified  densitometrically 
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Table 3-17. Materials E.coli 
BD Biosciences Clontech, Heidelberg  S.O.C. medium 
Carl Roth GmbH, Karlsruhe   Tryptone 
Yeast extract 
Gibco RBL, Life Technologies, Eggenstein   E.coli strain: MAX Efficiency DH5a competent cells  
Genotype: F
-F80dlacZDM15 D(lacZYA-argF)U169 deoR 
recA1 endA1 hsdR17(rK
-, mK
+) phoA supE44 l
- thi-1 gyrA96 
relA1 
Sigma-Aldrich Chemie GmbH, Deisenhofen  Agar 
 
3.2.1 Cultivation of E.coli 
 
LB (Luria Bertani) medium  1% (w/v) NaCl 
  1% (w/v) tryptone 
  0.5% (w/v) yeast extract  
  pH 7.5, autoclave 
   
LB agar  LB medium 
  1.5% (w/v) agar, autoclave 
   
S.O.C. medium  2% (w/v) tryptone 
  0.5 % (w/v) yeast extract 
  10 mM NaCl 
  10 mM KCl, autoclave and cool to 55° C 
  20 mM Mg
2+ (10 mM MgCl2, 10 mM MgSO4 
  20 mM glucose  
  -Filter complete medium through a 0.22 µM filter unit 
 
Bacterial strains carrying plasmids or genes with antibiotic selection marker were cultured in 
liquid or on solid medium containing the selective agent. Stock solutions of antibiotics were 
sterilised  by  filtration  and  aliquots  stored  at  -20° C.  Antibiotics  were  added  to  freshly 
autoclaved medium (cooled to below 50° C), and stock and working concentrations for the 
antibiotics are shown in Table 3-18.  
 
Table 3-18. Concentrations of antibiotics 
Antibiotic   Stock solutions  Working concentrations 
  Concentration   Storage     Dilution 
Ampicillin  50 mg/ml in water  -20° C  100 µg/ml  1/500 
Tetracycline   5 mg/ml in ethanol  -20° C  50 µg/ml  1/100 
Streptomycin  10 mg/ml in water  -20° C  50 µg/ml  1/200 
Chloramphenicol  34 mg/ml in ethanol  -20° C  170 µg/ml  1/200 
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3.2.1.1 Agar plates  
E.coli  strains  can  be  streaked  and  stored  on  LB  plates  containing  1.5%  agar  and  the 
appropriate antibiotic. With a flamed and cooled wire loop an inoculum of bacteria from a 
glycerol stock was streaked on top of a fresh agar plate, and incubated upside down at 37° C 
for 12-14 h until colonies developed.  
 
3.2.1.2 Liquid cultures  
Bacterial liquid cultures were grown for plasmid preparations. A starter culture was prepared 
by inoculating a single colony from a freshly streaked selective plate into 2-5 ml LB medium 
containing the appropriate antibiotic. The culture was grown for ~8 h at 37° C with vigorous 
shaking (~250 rpm). The starter culture was diluted 1/500 to 1/1000 into a larger volume of 
selective LB medium and grown overnight (12-16 h) at 37° C with shaking (~250 rpm). Cells 
were harvested by centrifugation at 6000 x g for 15 min, and following the cell pellet was 
treated as indicated in the appropriate plasmid purification protocols.  
 
3.2.1.3 Glycerol stocks  
E.coli strains can be stored for many years at -80° C in 15% glycerol. 0.15 ml glycerol were 
placed into a 2 ml screw-cap vial and sterilised by autoclaving. 0.85 ml of the E.coli culture 
were added and vortexed to ensure even mixing of the bacterial culture and the glycerol. 
Samples were frozen in liquid nitrogen and stored at -80° C.  
 
3.2.2 Transformation of E.coli 
 
Competent cells were removed from the -80° C freezer and thawn on wet ice and aliquots of 
100 µl of cells were placed into chilled polypropylene tubes. Following, 1 µl from the ligation 
reaction (1-10 ng DNA) was added to the cells, moving the pipette through the cells while 
dispensing. Cells were incubated for 30 min on ice and heat-shocked for 45 sec in a 42° C 
water  bath  afterwards.  Then,  cells  were  placed  on  ice  for  2  min,  and  0.9  ml  of  room 
temperature  S.O.C  medium  was  added.  The  culture  was  incubated  for  1  h  at  37° C  with 
shaking  (225  rpm).  Following,  cells  were  centrifuged  at  10000  rpm  for  2  min  and 
resuspended the in 100 µl S.O.C. 90 and 10 µl of this suspension were plated on LB plates 
containing the antibiotic and incubated overnight upside-down at 37° C.  ￿￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿   ￿￿ ￿ ￿ ￿￿￿ ￿ ! ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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3.3.1 Enzyme-linked immunosorbent assay (ELISA) 
 
Wash buffer   0.05% Tween 20 in PBS, pH 7.4 
   
Block buffer  1% BSA 
  5% Sucrose 
  0.05% NaN3 
  In PBS 
   
Reagent diluent   1% BSA in PBS pH, 7.3 
  0.22 µm filtered 
   
Stop solution   2 N H2SO4 
 
Concentrations of secreted chemokines were measured by ELISA. ELISA is a method that is 
used for the quantitative assay of proteins in solution. In an ELISA, first antibody (capture 
antibody) is immobilised on a solid support (wells of a 96-well plate) and used as capture 
molecule  to  bind  the  protein  that  is  being  assayed.  After  a  wash  step  to  remove  non-
specifically  bound  material,  a  secondary  antibody  (detection  antibody)  is  added.  This 
secondary  antibody  is  usually  conjugated  to  an  enzyme  that  allows  its  detection  by 
chromogenic or chemiluminescent methods. 
The human MCP-1 ELISA and murine RANTES ELISA were performed with reagents from 
R&D Systems (Wiesbaden); IL-8 was determined with the OptEIA
TM human IL-8 Set from BD 
Bioscience Pharmingen (Heidelberg) according to the supplier’s protocol.  
In  general,  100  µl  of  diluted  capture  antibody  were  added  to  each  well  and  incubated 
overnight. After three aspiration/wash steps the plate was blocked for 1 h using 300 µl block 
buffer. Following three aspiration/wash steps 100 µl of standard or sample were added to 
each well for 2 h at room temperature. After washing, 100 µl of diluted detection antibody 
was added for 2 h. The wash steps were repeated and 100 µl of Streptavidin conjugated to 
horseradish peroxidase were incubated for 20 min. After three aspiration/wash steps 100 µl 
of substrate solution was added to each well for 20 min in the dark. 50 µl of stop solution 
were added, and absorbance was read at 450 nm (Tecan SpectraFluorPlus reader including 
XFluor-software  version  V3.21).  Readings  at  540  nm  were  subtracted  from  readings  at 
450nm for correction.  
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3.4.1 Cultivation of mammalian cells 
 
Table 3-19. Materials cell culture 
BioWhittaker, Verviers  Fetal calf serum (FCS) 
Bissendorf Peptides, Hannover  TNF-a 
Cell Concepts GmbH, Umkirch  IFN-g 
Gibco RBL, Life Technologies, Eggenstein  Dulbecco’s modified eagle medium (DMEM) 
PBS 
RPMI 1640 
Invitrogen GmbH, Karlsruhe  Penicillin/Streptomycin 
Trypsin 
NEA 
Pharmacia Diagnostics GmbH  Concanavalin A (ConA) 
Roche, Penzberg  Interleukin-2 (IL-2) 
Sigma-Aldrich Chemie GmbH, Deisenhofen  DMSO 
 
Table 3-20. Cells  
T helper-1 lymphocytes (Th1 IF12) 
brain microvascular endothelial cells (b-end3) 
Human embryonic kidney (HEK) 293 (CRL 1573, American Type Culture Collection) 
293T cells 
 
Th1 medium   500 ml RPMI 
  5 ml L-Glutamine 
  5 ml Penicillin/Streptomycin 
  5 ml NEA 
  50 ml 10% FCS 
  5 µg/ml IL-2 
   
Medium for b-end3 cells,  500 ml DMEM 
HEK 293 cells,   50 ml 10% FCS 
293T cells  5 ml Penicillin/Streptomycin 
 
Cells  were  incubated  in  an  incubator  (Kendro  Laboratory  Products  GmbH)  and  grown  at 
37° C and 5% CO2 with saturating humidity (95%), except brain microvascular endothelial 
cells were grown in 10% CO2.  
 
3.4.1.1 Passaging cells  
Cells  were  splitted  routinely  twice  a  weak.  Cells  were  harvested  either  by  trypsinisation 
(adherent cell cultures) or by centrifugation at 1000 rpm for 5 min (suspension cell cultures). ￿￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿   ￿￿ ￿ ￿ ￿￿￿ ￿ ! ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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For trypsinisation, the medium was removed from the flask and cells were washed carefully 
with PBS to remove residual medium. 1-2ml of prewarmed Trypsin solution was added to the 
flask (175 cm
2) and incubated at 37° C until cells have detached (1-2 minutes). Trypsinisation 
was  blocked  by  adding  a  few  ml  of  medium.  Following,  cells  were  resuspended  in  an 
appropriate volume of prewarmed growth medium containing serum.  
Appropriate dilutions of Th1 cells were transferred in 10 ml medium containing 5 µg/ml IL-2 to 
a fresh cell culture flask (175 cm
2).  
Typically, when splitting confluent HEK 293 cells in a 1:10 ratio, confluency was reached 
again after 3-4 days. 
 
3.4.1.2 Cell freezing and thawing  
The  cells  were  trypsinised  first  if  necessary,  resuspended  in  medium  containing  serum, 
centrifuged at 1000 rpm for 5 min, and then resuspended in freezing medium. 1 ml of the cell 
suspension (approximately  3-5  x  10
6  adherent  cells  or  5-10  x  10
6  suspension cells)  was 
transferred into each freezing vial. Freezing vials were placed into a Cryo freezing container 
(Nalgene) and stored in a -80° C freezer overnight. This allowed freezing of the cells at a rate 
of 1° C/min. The following day vials were transferred to a liquid nitrogen chamber.  
For cell thawing, a vial of frozen cells was removed from liquid nitrogen and placed in a 37° C 
water bath until thawed. To remove DMSO from the freezing medium, the cell suspension 
was pipetted into a centrifuge tube containing prewarmed medium, and centrifuged at 1000 
rpm  for  5  min.  The  supernatant  was  discarded,  cells  were  resuspended  in  fresh  growth 
medium and transferred to the cell culture flask. Cells were incubated overnight under their 
usual growth conditions, and the medium was replaced the next day.  
 
3.4.1.3 Cytokine treatment and mitogen activation 
For analysis of cytokine induced stimulation of chemokine production, HEK 293 and b-end3 
cells were plated in 6-well or 24-well plates in medium as described above (between 1.5 x 
10
5 and 6 x 10
5 cells/well) and grown overnight. After 18 h culture media were replaced with 
fresh medium, and cells were treated with different concentrations of the cytokines (500 U/ml 
TNF-a  and/or  200-1000  U/ml  IFN-g)  for  24  h.  Then,  culture  media  were  harvested, 
centrifuged for 5 min at 12,000 x g to remove cell debris and stored at –20° C until further 
analysis of secreted proteins by ELISA.  
 
Th1 cells plated in 6-well plates at a density of 1 x 10
6 cells/well were activated using 5 µg/ml 
ConA for 24 h. Following the incubation time, the culture media were harvested and the 
concentration of secreted RANTES was determined by ELISA.  
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3.4.2 Transfection of mammalian cells 
 
Table 3-21. Materials transfection 
Gibco RBL Life Technologies, Eggenstein  Lipofectamine 
PAA Laboratories GmbH, Cölbe  Hygromycin 
Qiagen GmbH, Hilden   Effectene reagent 
Enhancer 
Polyfect transfection reagent 
 
3.4.2.1 Transient transfection of plasmid DNA 
HEK  293  or  b-end3  cells  were  seeded  in  appropriate  dishes  overnight  until  40-80% 
confluent. Transfection was performed using Polyfect transfection reagent or Lipofectamine 
according to the supplier’s protocol. Suspension cells (Th1) were transfected using Effectene 
reagent and the enhancer. 
After  transfection,  cells  were  incubated  for  18-48  h,  followed  by  cytokine  treatment  as 
indicated. 
 
3.4.2.2 Transient transfection of double-stranded siRNA or TFOs 
Phosphorothioated TFOs (Table 3-13 and 3-14) or synthetic siRNA were usually transfected 
using  Lipofectamine.  After  transfection,  cells  were  incubated  for  18-24  h,  followed  by 
cytokine treatment as indicated. 
 
Table 3-22. Synthetic siRNA 
rRANTES si1  Accession-number  
NM_013653 
5’ GUGCUCCAAUCUUGCAGUCUU 
 UUCACGAGGUUAGAACGUCAG 
MWG, Ebersberg 
rMCP-1 si1  Accession-number  
NM_002982 
5’ CUUCACCAAUAGGAAGAUCUU 
 UUGAAGUGGUUAUCCUUCUAG 
MWG, Ebersberg 
control    5’ CUUCACCAAUAGAGAGAUCUU 
 UUGAAGUGGUUAUCUCUCUAG 
MWG, Ebersberg 
CCL2-361  Accession-number  
NM_002982 
5’ GGAUUCCAUGGACCACCUGtt 
 gtCCUAAGGUACCUGGUGGAC 
Ambion, 
Huntingdon, UK 
 
siRNA  sequences  were  screened  using  the  Ambion  siRNA  target  finder.  Single  strands 
ordered from MWG were mixed in equimolar amounts in annealing buffer composed of 100 
mM  potassium  acetate,  30  mM  HEPES,  and  2  mM  magnesium  acetate,  pH  7.4  and 
incubated at 95° C for 5 min, followed by a slow cool-down to room temperature at a rate of 
1° C/min.  The  sequence  CCL2-361  (double-stranded)  was  ordered  as  a  validated  siRNA 
sequence (Ambion). Usually, cells were transfected with 100-150 nM siRNA. 
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3.4.2.3 Transfection of HEK 293 cells with TFOs without transfection reagent 
HEK 293 cells plated in 24-well or 96-well plates at different densities (5 x 10
4 to 1.5 x 10
5 
cells/well)  were  pre-treated  with  0.5,  2.0  or  5.0  µM  phosphorothioated  TFO  or  control 
oligonucleotides for 24 h. Thereafter, the medium (200 µl/well) was replaced with medium 
containing the same concentration of oligonucleotides as before, and the cells were cultured 
for additional 24 h in the absence or presence of 500 U/ml TNF-a. At the end of incubation 
time,  the  culture  supernatants  were  harvested  and  the  concentrations  of  MCP-1  were 
determined by ELISA. 
 
3.4.2.4 Stable transfection of HEK 293 cells 
HEK  293  cells  were  transfected  with  the constructed  vectors  TVHygro-CU,  TVHygro-GU, 
TVHygro-CA  or  TVHygro  (no  insert)  using  Polyfect  transfection  reagent  according  to  the 
manufacturer' s  instructions.  Selection  of  TVHygro-CU,  TVHygro-GU,  TVHygro-CA  and 
TVHygro  transfectants  was  carried  out  in  the  presence  of  250  µg/ml  hygromycin.  Single 
transfectants were isolated and single cell clones of each of the transfectants were expanded 
under continuing selection pressure. 
 
3.4.3 Production of lentiviral vectors by transient transfection 
 
Table 3-23. Materials lentiviral vectors  
Sigma-Aldrich Chemie GmbH, Deisenhofen  0.1 x TE buffer, filtered 0.22 µm 
100 µM chloroquine stock solution, dissolved in PBS, filtered 
0.22 µm 
2.5 M CaCl2 tissue culture grade, filtered 0.22 µm 
Double processed tissue culture water dH2O, endotoxin-free 
HEPES 
Na2HPO4 
Polybrene 
 
2 X HBS  281 mM NaCl 
  100 mM HEPES 
  1.5 mM Na2HPO4 
  0.22 µm filtered 
   
Fixing solution   1% formaldehyde in PBS 
   
FACS buffer  1% FCS in PBS 
  0.1% sodium azide 
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3.4.3.1 Production of lentiviral VSV-G pseudotyped vectors 
One day before transfection 5 x 10
6 293T cells were plated in a 10 cm tissue culture dish in 
10 ml DMEM and incubated overnight. At the time of transfection cells should be around 80% 
confluent. 2 h before transfection, the medium was replaced with 10 ml fresh DMEM. Cells 
were  co-transfected  with  10  µg  pHR’SIN-cPPT-SEW,  6.5  µg  packaging  plasmid  pCMV 
D8.91,  and  3.5  µg  envelope  plasmid  pMD2.VSV.G  using  the  calcium  phosphate  DNA 
precipitation  method.  The  components  were  placed  in  12  ml  snap  cap  tube  (Greiner, 
Kremsmünster) in the following order: 
 
H2O: 0.1 x TE (1:3)  ad 450 µl 
pHR’SIN-cPPT-SEW  10 µg 
pCMV D8.91  6.5 µg 
pMD2.VSV.G  3.5 µg 
2.5 M CaCl2  50 µl 
  ￿ 500 µl 
 
500  µl  2  x  HBS  were  added  dropwise  to  this  mixture  under  vigorous  vortexing,  and  the 
solution was incubated at room temperature for no longer than 5-10 min. During that time 1 
µl chloroquine (100 mM) was added to the cells to a final concentration of ~10 µM, and the 
DNA precipitation mix was added to the cells, followed by an incubation overnight (14-16 h) 
under normal cell culture conditions. Next morning the medium was exchanged for 5 ml fresh 
medium.  Supernatants  containing  the  virus  were  collected  after  24  and  48h  and  cleared 
through a 0.45 µm filter (prewashed with 1 ml PBS) and stored in aliquots at -80° C.  
 
3.4.3.2 Titration of lentiviral vectors 
One day before transfection, 1 x 10
5 cells were plated in 0.5 ml DMEM per well in a 24-well 
plate. The following day medium was replaced with 0.5 ml of fresh DMEM containing 4 µg/ml 
polybrene per well. Serial ten-fold dilutions of the viral stocks were prepared and added to 
the cells resulting in final dilutions from 10
-2 to 10
-4. Plates were centrifuged for 90 min at 
1250 x g, 32° C, followed by incubation for 2.5 h and a medium exchange (0.5 ml DMEM per 
well). Cells were incubated under normal cell culture conditions for 2-3 days.  
For FACS  analysis, cells were harvested, washed twice in PBS containing 1% FCS and 
0.1% sodium azide and fixed in PBS containing 1% formaldehyde. FACS
 analyses for eGFP 
expression  and  titre  calculation  were  performed  using  a  FACScan  flow  cytometer  (BD 
Biosciences)
 and Cell Quest software (BD Biosciences). 
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3.4.3.3 Transduction of target cells 
Th1 cells (1 x 10
5 cells/400 µl in a 24-well plate) were transduced with different dilutions of 
the viral supernatant in the presence of 4 µg/ml protamine sulfate. After spinoculation (1250 x 
g,  90  minutes,  32° C),  the  cells
  were  incubated  for  16  hours  at  37° C  with  the
  virus.  The 
following day, 200 µl per well were removed, and an additional transduction of the virus (200 
µl + 400 µl = 600 µl) was performed as described (1250 x g, 90 minutes, 32° C). After 6 h 
incubation, 1 ml of fresh medium was added, followed by a medium exchange the next day. 
EGFP  expression  was  analyzed  by  FACS  analysis  and  fluorescence
  microscopy  (Nikon 
Eclipse TE300) at various time points. 
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4 Results 
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Triplex formation was examined with two different chemokine targets, RANTES and MCP-1. 
The  ability  of  synthetic  TFOs  to  bind  to  the  duplex  DNA  was  investigated  by  gel  shift 
analysis. Furthermore it was tested whether the 28 nt and 19 nt TFOs, respectively, were 
able to specifically inhibit gene transcription of their target genes in different cell lines. A 
triplex formed in gene regulatory regions can interfere with the initiation complex, while a 
triplex formed in the coding region of the target gene may block transcription elongation. 
Different  backbone  modifications  of  oligonucleotides  exist  that  have  been  proposed  to 
increase the half-life of TFOs and the stability of the triple-helical complexes. With regard to 
those findings phosphorothioated TFOs were used in cell culture experiments.  
 
4.1.1 Binding of a 28 nt TFO to the murine RANTES promoter 
 
The  murine  RANTES  promoter  was  tested  as  a  new  target  for  triplex  formation.  This 
homopurine/homopyrimidine  target  sequence  of  28  bp  in  length  was  chosen  as  a 
proinflammatory chemokine of interest out of a high number of possible TFO targets in the 
mammalian genome, which have been found with a proprietary gene bank search algorithm 
(Radeke HH & Bruno B, unpublished data). Here specifically, the purine binding motif (GT) 
was selected, leading to an antiparallel binding of the TFO to its target. Within the RANTES 
promoter the TFO target site is located at nucleotide position -265 to -238 relative to the 
transcriptional  start  site  and  about  78  bp  downstream  of  a  putative  NF-kB1  binding  site. 
Interactions  between  NF-kB  and  an  interferon  regulatory  factor  (IRF)  are  crucial  for  the 
induction of RANTES promoter activity. The capacity of the TFO to interfere with RANTES 
gene  transcription  was  evaluated  in  T  helper-1  lymphocytes  and  brain  microvascular 
endothelial cells.  
 
4.1.1.1 In vitro binding of the TFO to the RANTES promoter 
To assess the ability of the TFO to form triple helices with the target site in the RANTES 
promoter, gel mobility shift assays were performed. In gel mobility shift assays, triplex DNA 
migrates more slowly than duplex DNA because of its decreased charge density. A 48 bp 
promoter  fragment  spanning  the  TFO  target  sequence  and  flanking  regions  was  
[a-
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different concentrations of the unmodified TFO based on the antiparallel (GT) purine binding 
motif  (for  details  of  the  sequences  see  “Materials  and  Methods”,  Table  3-13)  or  control 
oligonucleotide  which  was  a  scrambled  oligonucleotide  of  the  same  base  composition. 
(Figure 4-1). The RANTES TFO binds in a sequence-specific manner to the duplex DNA  
(10 nm), and a shift from duplex to triplex formation is visible at a TFO concentration of  
4.0 x 10
-7 M. No shift occurs using the scrambled control oligonucleotide, even at the highest 
concentration (1.6 x 10
-5 M), demonstrating sequence-specific binding of the TFO. 
 
 
 
 
 
 
 
 
Figure 4-1. In vitro determination of triple helix formation by gel mobility shift analysis. Binding of the TFO 
to duplex DNA was assayed by native gel electrophoresis through 12.5% polyacrylamide gels. The target duplex 
was the [a-
32P]-dCTP end-labelled 48 bp fragment spanning bp -275 to -228 of the murine RANTES promoter. 
The  duplex  DNA  was  incubated  for  1  h  at  room  temperature  with  different  concentrations  of  the  TFO,  as 
indicated, in a buffer consisting of 10 mM Tris/HCl (pH 7.4), 5% sucrose, and 10 mM MgCl2. Electrophoresis was 
performed at 4° C with 80 V. After electrophoresis the gels were dried and exposed to Phospho-Imager screens. 
 
In the experiment shown in Figure 4-2 A, TFO was added at increasing concentrations to 
samples containing 10 nM of the corresponding radio-labelled RANTES duplex DNA.  
Figure  4-2.  Electrophoretic  mobility  shift  assay  of  triplex  formation  by  RANTES  targeting  TFO.  (A): 
RANTES duplex DNA (10 nM) was incubated with increasing concentrations of TFO. (B): Graphic representation 
of the titration curve. 
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Binding of the TFO to the target sequence resulted in a shift from duplex to triplex DNA. The 
28  nt  RANTES  TFO  formed  a  triplex  DNA  even  at  low  concentrations.  A  distinct  band 
migrating  more  slowly  than  duplex  DNA  was  already  detected  at  TFO  concentrations  of  
4.0  x  10
-8 M,  which  is  a  4-fold  molar  excess  relative  to the  target DNA.  The  equilibrium 
dissociation constant (Kd) for third strand binding was evaluated as the concentration of TFO 
at which apparent binding was half maximal (Durland et al. 1991). Figure 4-2 B represents 
the titration curve, and a Kd of 2.5 x 10
-7 M was determined.  
 
4.1.1.2 Biological effects of the TFO on endogenous RANTES gene expression 
Inflammatory  cytokines  such  as  TNF-a  and  INF-g  synergistically  activate  expression  of 
RANTES. The murine RANTES promoter contains one putative interferon regulatory factor, 
IRF,  and  three  putative  NF-kB  binding  sites.  Both  NF-kB  and  IRF-1  transcription  factors 
mediate  the  induction  of  RANTES  expression  when  cells  are  stimulated  by  TNF-a  and  
IFN-g. Here, brain microvascular endothelial cells (b-end3 cells) were incubated for 24 h with 
TNF-a and IFN-g (Figure 4-3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4-3.  Cytokine-induced  secretion  of  the  chemokine  RANTES  by  murine  brain  microvascular 
endothelial cells. B-end3 cells plated in 6-well plates at a density of 600,000 cells/well were left unstimulated or 
treated with the indicated cytokines for 24 h. Following cytokine treatment, the culture media were harvested and 
the concentrations of secreted RANTES were determined by ELISA; error bars indicate the SEM.  
 
In this experimental setup cytokine treatment resulted in a 135-fold upregulation of RANTES 
protein secretion as measured by ELISA. As a next step the ability of the 28 nt RANTES TFO 
to bind to the RANTES promoter target sequence and inhibit endogenous RANTES gene 
expression was analysed. B-end3 cells were transfected with 4.5 µM phosphorothioated TFO 
(5’, 3’ end-modified) or scrambled control oligonucleotide (Figure 4-4). ￿￿"￿   ￿ ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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Figure 4-4. Transfection of b-end3 cells with TFOs. B-end3 cells plated in 6-well plates at a density of 600,000 
cells/well were transfected with 4.5 µM phosphorothioated 28 nt TFO or control oligonucleotide targeting murine 
RANTES. After 18 h the cells were left unstimulated or treated with 500 U/ml TNF-a and 200 U/ml IFN-g for 
additional  24  h.  Following  the  incubation  time,  the  culture  media  were  harvested  and  the  concentration  of 
secreted RANTES was determined by ELISA. One experiment of three with similar results is shown. 
 
Although  there  was  a  sequence-specific  binding  of  the  TFO  detectable  in  the  gel  shift 
assays,  there  was  no  inhibitory  effect  of  the  exogenously  added  and  phosphorothioate 
stabilised TFO on endogenous RANTES gene expression visible, neither in the unstimulated 
nor in the cytokine treated cells. Furthermore, potential inhibitory effects of the TFO were 
examined in another cell line. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. Secretion of RANTES by Th1 cells. Th1 cells plated in 6-well plates at a density of 1 x 10
6 cells/well 
were left unstimulated or treated with 5 µg /ml ConA for 24 h. Following the incubation time, the culture media 
were harvested and the concentration of secreted RANTES was determined by ELISA. 
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Murine Th1 cells exhibited an inducible RANTES protein secretion to up to 10 ng/ml after 
incubation  with  5  µg/ml  ConA  for  24  h,  but  there  was  no  basal  RANTES  secretion 
measurable in untreated cells (Figure 4-5).  
In  a  subsequent  experiment,  Th1  cells  were  transfected  with  phosphorothioated  TFO  or 
scrambled control oligonucleotide at the indicated concentrations (Figure 4-6). Here, TFO 
treatment did not result in the proposed inhibition of RANTES gene expression, but led to 
variable and inconsistent effects on RANTES protein secretion. These results might be due 
to different efficiencies of oligonucleotide transfection.  
 
 
 
 
 
 
 
 
 
 
Figure 4-6. Transfection of Th1 cells with TFO. Th1 cells were plated in 6-well plates at a density of 1 x 10
6 
cells/well and transfected with 4.7 µM phosphorothioated 28 nt TFO or control oligonucleotide against murine 
RANTES. After 18 h the cells were left unstimulated or treated with 5 µg/ml ConA for additional 24 h. Following 
the  incubation  time,  the  culture  media  were  harvested  and  the  concentration  of  secreted  RANTES  was 
determined by ELISA. 
 
In  summary,  with  respect  to  the  chemokine  RANTES,  binding  of  the  28  nt  TFO  to  the 
promoter target sequences could be shown in a cell-free system in vitro, but the TFO did not 
functionally  inhibit  endogenous  RANTES  gene  expression  in  two  different  cell  systems 
tested. Even when lower or higher oligonucleotide concentrations were used they had no 
inhibitory effect (data not shown).  
Oligonucleotides must be delivered to the cell nucleus in adequate concentrations and must 
be stable in extracellular and intracellular environments. The use of synthetic TFOs in vivo 
might be limited by their susceptibility to endogenous nucleases or inefficient cellular uptake. 
The RANTES TFO is G-rich and contains several Gs in a row (5’TTT GTT GGT GGG GGT 
GGG GGT GGG GGT G 3’), therefore it might tend to self-association into unfavourable 
structures in the presence of intracellular concentration of K
+, which then would compete with 
triplex  formation.  Thus,  to  increase  the  capacity  of  TFOs  as  gene  modifying  agents,  it 
appeared necessary to establish an improved TFO delivery system. 
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4.1.2 Binding of a 19 nt TFO to the MCP-1 promoter 
 
A possible TFO target site consisting of 19 bp was identified in the promoter region of the 
human MCP-1 at bp -66 to -48 relative to the transcriptional start site. The TFO target site 
includes  the  binding  site  for  the  transcription  factor  SP-1  and  a  partially  overlaps  with  a 
putative AP-1 binding site.  
 
4.1.2.1 Triplex formation with the MCP-1 promoter 
As described before, triplex formation was demonstrated by gel  mobility shift analysis. A  
39 bp promoter fragment (10 nM) spanning the TFO target sequence and flanking regions 
was [a-
32P]-dCTP end-labelled to allow detection. The promoter fragment was incubated with 
10 µM of the 19 nt TFO based on the antiparallel purine binding motif (GT) or the control 
oligonucleotide which was a scrambled oligonucleotide of the same base composition (for 
details of the sequences see “Materials and Methods”, Table 3-14). The aim was to develop 
a TFO that could be tested in biological systems, therefore oligonucleotides contained a 3’ 
and 5’ phosphorothioate modification since it confers resistance to nuclease degradation. 
Under  the  conditions  used,  triple  helical  complexes  are  stable  during  the  course  of  the 
electrophoresis run and migrate significantly slower than the corresponding duplex target 
(Figure  4-7).  The  triple  helix  formation  was  sequence-specific,  because  the  control 
oligonucleotide did not bind to the MCP-1 promoter fragment. To further confirm sequence-
specificity, the TFO and control were incubated with a RANTES promoter sequences as a 
control duplex DNA. No binding occurred using this unrelated target sequence.  
 
 
 
 
 
 
 
 
 
Figure 4-7. In vitro determination of triple helix formation by gel mobility shift assay. Binding of the TFO or 
control oligonucleotide to duplex DNA was assayed by native gel electrophoresis through 12.5% polyacrylamide 
gels. The target duplex was the [a-
32P]-dCTP end-labelled 39 bp fragment spanning bp -76 to -38 of the human 
MCP-1 promoter. The promoter fragment was incubated with 10 µM TFO or control oligonucleotide. The RANTES 
promoter served as a control duplex to exclude unspecific binding. 
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4.1.2.2 Inhibition of the expression of endogenous MCP-1 in cultured cells 
A next aim was to test whether the TFO can inhibit expression of MCP-1 in cultured cells. 
Human MCP-1 is produced in a wide variety of cell types, including monocytes, fibroblasts, 
vascular endothelial cells, and smooth muscle cells, in response to various stimuli such as 
LPS, IL-1b, TNF-a, PDGF, IFN-g and TPA: Here, HEK 293 cells were screened by ELISA for 
cytokine  induced  secretion  of  MCP-1.  These  cells  were  found  to  produce  low  basal 
concentrations of MCP-1, and TNF-a and IFN-g alone or in combination dose dependently 
induced secretion of higher levels of this chemokine (Figure 4-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8. Cytokine inducible secretion of the chemokine MCP-1 by HEK 293 cells. HEK 293 cells plated in 
24-well plates at a density of 250,000 cells/well were left unstimulated or treated with the indicated cytokines for 
24 h. Following cytokine treatment, the culture media were harvested and the concentrations of secreted MCP-1 
were determined by ELISA. The cell cultures were performed in duplicates; the error bars indicate the SEM. 
 
After 24 h, TNF-a increased the amount of secreted MCP-1 up to 16-fold and IFN-g up to 3.8-
fold in comparison to unstimulated cells. PDGF (5-25 ng/ml) was used as another stimulus 
but had no significant inducing effect in these cells (data not shown). HEK 293 cells can 
therefore serve as a model system to study MCP-1 gene expression, and this cell line was 
chosen  for  additional  experiments,  employing  TNF-a  as  an  effective  and  concentration 
dependent stimulus. To analyse the effect of the TFO on MCP-1 gene expression, cells were 
treated  with  various  concentrations  of  phosphorothioated  TFO  for  24  h  (Figure  4-9). 
Incubation of the cells with 0.5 µM TFO inhibited TNF-a stimulated MCP-1 protein secretion 
about 23% in comparison to the scrambled control oligonucleotide, as determined by ELISA. 
At  2  µM  concentration  the  inhibition  was  25%  in  comparison  to  the  control.  But,  at  this 
concentration, the control oligonucleotide itself resulted in a slight decrease of MCP-1 protein 
secretion  in  comparison  to  the  medium  control,  suggesting  that  higher  concentrations  of 
medium
50 U/ml
100 U/ml
500 U/ml
1000 U/ml
500 U/ml
1000 U/ml
0
100
200
300
400
500
600
700
800
900
TNF-a
IFN-g
M
C
P
-
1
 
[
p
g
/
m
l
]￿￿"￿   ￿ ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
￿ ￿￿￿
oligonucleotides might not be beneficial in this experimental setup. Higher concentrations of 
the oligonucleotides resulted in decreased cell viability with decreased secretion of MCP-1 
(data not shown). No inhibitory effect of the TFO at different concentrations was observed in 
unstimulated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9. Inhibition of MCP-1 secretion by incubation with the TFO. HEK 293 cells plated in 96-well plates 
at  a  density  of  50,000  cells/well  were  pre-treated  with  0.5  µM  or  2  µM  phosphorothioated  TFO  or  control 
oligonucleotides,  as  indicated,  for  24  h.  Thereafter,  the  medium  (200  µl/well)  was  replaced  with  medium 
containing the same concentration of oligonucleotides as before, and the cells were cultured for additional 24 h in 
the  absence  or  presence  of  500  U/ml  TNF-a.  At  the  end  of  incubation  time,  the  culture  supernatants  were 
harvested  and  the  concentrations  of  MCP-1  were  determined  by  ELISA.  The  cell  culture  was  performed  in 
quadruplicates; the error bars indicate the SEM. 
 
As the TFO activity depends on the amount of oligonucleotides reaching the nucleus, the 
procedure  of  administration  of  the  oligonucleotides  to  the  cell  is  an  important  issue. 
Oligonucleotides are anionic molecules whose capacity to cross the cell membranes is poor 
and dependent on the type of cells. Apart from other possible solutions to approach these 
problems  an  intracellular,  vector-based  delivery  of  TFOs  seemed  promising.  Generating 
oligonucleotides  in  vivo  avoids  the  problems  of  e.g.  immunogenicity,  cellular  uptake  and 
dosing. In the following experiments, establishment of the intracellular synthesis of a RNA 
TFO targeting the human MCP-1 gene will be described.  
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TVHygro-CU
5´ GTCGACAAGCTTCTCGAGTCTCCCTCTCTCCCACCTCGGATCCCGCGAT 3´
3´ CAGCTGTTCGAAGAGCTCAGAGGGAGAGAGGGTGGAGCCTAGGGCGCTA 5´
HindIII XhoI BamHI
RNA: CU-TFO  5´…UCUCCCUCUCUCCCACCUC…Hygromycin…3´
TVHygro-GU
5´ AAGCTTCTCGAGACACCCACACACCCACCACGGATCC 3´
3´ TTCGAAGAGCTCTGTGGGTGTGTGGGTGGTGCCTAGG 5´
HindIII XhoI BamHI
RNA: GU-control 5´…GUGGUGGGUGUGUGGGUGU…Hygromycin…3´
TVHygro-CA
5´ AAGCTTCTCGAGCACACACCCAACCACACCCGGATCC 3´
3´ TTCGAAGAGCTCGTGTGTGGGTTGGTGTGGGCCTAGG 5´
HindIII XhoI BamHI
RNA: CA-control 5´…CACACACCCAACCACACCC…Hygromycin…3´
A
B
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In  order  to  generate  TFOs  directly  inside  the  cell  an  expression  vector  was  constructed 
generating single-strand RNA transcripts, which may act as TFOs and thereby inhibit MCP-1 
expression (Figure 4-10 A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10. Schematic representation of the vector construction. (A): The vector TVHygro was derived from 
the eukaryotic expression vector pcDNA3.1/Hygro with the sequences spanning the region 1002-2079 deleted by 
restriction digestion with ApaI and SmaI. The resulting ApaI overhang was end-filled and the vector re-ligated. 
TFO-RNA  or  control-RNA  coding  sequences  were  cloned  into  the  5’  untranslated  region  of  the  hygromycin 
resistance gene. Transcription of this TFO/hygromycin and control/hygromycin fusion transcript, respectively, is 
driven by the constitutive CMV promoter. Vectors were constructed to drive transcription of either a pyrimidine 
triplex forming RNA sequence targeting the MCP-1 promoter (CU-TFO) or two different control sequences (CA-
control and GU-control). The three different constructs which were cloned into TVHygro are shown in (B), leading 
to  the  vectors  TVHygro-CU,  TVHygro-GU  and  TVHygro-CA,  respectively.  Vector  TVHygro  without  insert  was 
used as a third control vector.  ￿￿"￿   ￿ ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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DNA fragments coding for a 19 nt parallel binding CU-TFO or different control sequences 
were  inserted  into  the  5’  untranslated  region  of  the  hygromycin  resistance  gene  of  the 
eukaryotic expression vector TVHygro (Figure 4-10 B). The pyrimidine motif carrying TFO 
was  chosen  because  triplex  formation  is  unlikely  to  occur  in  the  purine  motif  with  RNA 
binding to a DNA duplex (RNA*DNA:DNA) (Noonberg et al. 1994a; Semerad and Maher, III 
1994).  Furthermore,  the  formation  of  undesired  structures  which  compete  for  triplex 
formation  is  reduced  with  a  pyrimidine  oligoribonucleotide  (Lacroix  et  al.  1996). In  a  first 
experiment it was analysed whether the 19 nt pyrimidine TFO binds to the MCP-1 promoter 
sequence. 
 
4.2.1 Triplex formation with RNA-TFOs 
 
The experiments revealed that the synthetic 19 nt TFO (rCU-TFO) effectively and specifically 
initiated triplex formation with the 39 bp MCP-1 promoter duplex in vitro. The capacity of 
synthetic oligoribonucleotides to bind to the MCP-1 promoter was investigated by a method 
termed triplex blotting. Triplex blotting is a general technique described for the detection of 
specific RNA molecules capable of triplex formation (Noonberg et al. 1994b). Here, different 
concentrations  (0.025  –  1.0  nmol)  of  the  oligoribonucleotides  were  electrophoretically 
fractionated, transferred to a nylon filter, and hybridised with the radio-labelled 39 bp MCP-1 
promoter template.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11. Participation of the pyrimidine rCU-TFO in triplex formation at pH 6.7. (A): The synthetic 19 nt 
oligonucleotides rCU-TFO, rGU-control and rCA control  (0.025-1.0  nmol)  were electrophoretically fractionated 
through a 6% polyacrylamide gel containing 7 M urea and blotted to a nylon membrane. Hybridisation with the 
radioactive  labelled  39  bp  MCP-1  promoter  duplex  (~3  x  10
-3  nmol)  was  carried  out  overnight  at  30° C. 
Hybridisation and stringency washes were performed at pH 6.7. (B): Concentration dependent binding of rCU-
TFO to the duplex is shown. 
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5` AGCTTTCCTGCTTGACTCCGCCCTCTCTCCCTCTGCCCGCTTTCCCATG 3`
3` TCGAAAGGACGAACTGAGGCGGGAGAGAGGGAGACGGGCGAAAGGGTAC 5`
*******************
TFO      3` CUCCACCCUCUCUCCCUCU 5`
5` AGCTTTCCTGCTTGACTCCGCCCTCTATCCCTCGGCCCGCTTTCCCATG 3`
3` TCGAAAGGACGAACTGAGGCGGGAGATAGGGAGCCGGGCGAAAGGGTAC 5`
pGL3-MCP1
Figure 4-11 A demonstrates the predicted and specific detection of triplex-forming rCU-TFO 
by triplex blotting with a minimum of 0.25 nmol transferred RNA at pH 6.7. rCA-control and 
rGU-control were not detected by the labelled double-stranded probe even at the highest 
concentration  (1  nmol),  suggesting  that  these  RNA  species  are  not  able  to  form  triplex 
structures. Concentration dependent binding of the rCU-TFO at pH 6.7 is shown in Figure  
4-11 B. The concentration of the 39 bp MCP-1 promoter was calculated to be 3 x 10
-3 nmol. 
Under these conditions binding of the duplex DNA to the rCU-TFO could be observed at an 
83.3 fold molar excess of the TFO in comparison to the duplex DNA. Notably, binding of the 
duplex DNA to the rCU-TFO was more pronounced at low pH 5.5 (data not shown) These 
results are in agreement with other investigations (see “Discussion”), as triplex formation 
involving the pyrimidine binding motif is dependent on cytosine protonation and therefore 
more likely to occur at low pH. At pH 5.5 binding of the duplex to 0.25 nmol rCU-TFO was 19 
times stronger than binding at pH 6.7. Nevertheless, the data clearly show that there is a 
strong  triplex  formation  at  pH  6.7  close  to  the  physiological  intracellular  pH  range.  To 
underline  binding  specificity  employing  the  pyrimidine  motif  an  oligoribonucleotide  with  a 
single mismatch (19CU_M) was tested.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12. Specific binding of the 19 nt rCU-TFO to the MCP-1 promoter duplex. (A): Synthetic 19 nt 
oligoribonucleotides  (0.25-1.0  nmol)  were  electrophoretically  fractionated  through  a  6%  polyacrylamide  gel 
containing 7 M urea and blotted to a nylon membrane. Hybridisation with the radioactive labelled 39 bp MCP-1 
promoter  (~3  x  10
-3  nmol)  was  carried  out  overnight  at  37° C.  Hybridisation  and  stringency  washes  were 
performed at pH 5.5. (B): Hybridisation was performed as described but with a MCP-1 promoter duplex containing 
2 mismatches at position 1 and 8 of the TFO binding site. (C): Blots were stripped for 1 h at 70° C in 0.5 x NAE (50 
mM sodium acetate, 0.5 mM pH 7.5) and re-probed with the linearised plasmid pGL3 control containing the 39 bp 
MCP-1 promoter sequence as described above. ￿￿"￿   ￿ ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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mismatches 3`TCGAAAGGACGAACTGAGGCGGGAGATAGGGAGCCGGGCGAAAGGGTAC 5`
no 2 5`AGCTTTCCTGCTTGACTCCGCCCTCTATCCCTCGGCCCGCTTTCCCATG 3` MCP-1_2M
3`TCGAAAGGACGAACTGAGGCGGGAGAGAGGGAGACGGGCGAAAGGGTAC 5`
yes 5`AGCTTTCCTGCTTGACTCCGCCCTCTCTCCCTCTGCCCGCTTTCCCATG 3` MCP-1
triplex formation properties sequence duplex
no none scrambled 5`CACACACCCAACCACACCC rCA-control
no antiparalell, purine binding motif 5`GUGGUGGGUGUGUGGGUGU  rGU-control
weak binding antiparalell, purine binding motif 5`GAGGUGGGAGAGAGGGAGA rGA-control
no paralell, pyrimidine binding motif 1 mismatch 5`UCACCCUCUCUCCCACCUC 19CU_M
yes paralell, pyrimidine binding motif 5`UCUCCCUCUCUCCCACCUC rCU-TFO
triplex formation motif properties sequence oligo
In Figure 4-12 A it was demonstrated that the duplex DNA did not bind to 1.0 nmol 19CU_M, 
confirming the sequence dependent specificity of triplex formation in this experimental setup. 
No triplex formation occurred using the rGA-control, which represents an antiparallel, purine 
binding motif. As a further control it was demonstrated that a 39 bp MCP-1 duplex with two 
mismatches  exhibited  no  interaction  with  any  of  the  shown  oligos  (Figure  4-12  B).  In  a 
following  experiment  it  could  be  excluded  that  the  observed  binding  was  due  to  non-
sequence-specific interactions of the rCU-TFO with the duplex DNA. In principle it would be 
possible that binding occurs through D-loop formation with partial melting of the 39 bp target 
duplex  DNA.  Therefore,  a  circular  double-stranded  plasmid  containing  the  39  bp  MCP-1 
promoter duplex as a target was used for hybridisation in triplex blotting experiments, which 
drastically reduces the likelihood of D-loop formation. Figure 4-12 C confirms that a specific 
binding of the 19 nt rCU-TFO to the plasmid encoded target duplex occurred, whereas the 
control  19CU_M  with  one  mismatch  failed  to  bind  to  the  target.  Interestingly,  in  this 
experimental setting (pH 5.5) a weak binding of the antiparallel rGA-control to the target 
duplex was observed, indicating a marginal binding affinity. These results are summarised in 
Table 4-1.  
 
  Table 4-1. Summary triplex formation 
 
 
 
 
 
 
 
 
 
 
Summary of the analysed oligoribonucleotides and duplexes in triplex blotting experiments. Participation of the 
different synthetic 19 nt oligos in triplex formation, the 39 bp MCP-1 promoter duplex, and the duplex-containing 2 
mismatches. Positions of mismatches are underlined. 
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4.2.2 Intracellular expression of TFO in HEK 293 cells 
 
After demonstrating that the synthetic rCU-TFO binds in a sequence-specific fashion to the 
MCP-1  promoter,  the  presence  of  the  three  different  intracellular  generated  RNA 
oligonucleotides in the stable transfected cell lines was verified. Because on the one hand the 
interfering CU-TFO had to be present in the nuclei to exert its function and on the other hand 
the template for the hygromycin resistance protein had to reach cytosol, nuclear RNA and total 
RNA containing the cytosolic fraction were separately isolated from each cell line carrying the 
vectors TVHygro-CU, TVHygro-GU or TVHygro-CA. Isolated RNA was reverse transcribed and 
subjected to PCR (Figure 4-13).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-13. Presence of CU-TFO, GU-control and CA-control in the nuclei of stable transfected HEK 293 
cells.  (A):  RNA  from  cell  nuclei  was  isolated  as  described  in  “Materials  and  Methods”  from  each  cell  line 
TVHygro-CU, TVHygro-GU and TVHygro-CA and reverse transcribed. RT-PCR was performed using a specific 
upstream primer located in the 19 nt TFO and control-RNA coding sequence, respectively, and a downstream 
primer located in the hygromycin resistance gene. The calculated length of the amplified products were 578 bp 
(CU-TFO  and  CA-control)  and  522  bp  (GU-control).  RT-PCR  products  were  electrophoretically  fractionated 
through  a  12.5%  native  polyacrylamide  gel.  (B):  Total  RNA  was  isolated  from  each  cell  line  and  reverse 
transcribed. RT-PCR was carried out as described and products were electrophoretically fractionated through a 
1% agarose gel. Lane 1: product CU-TFO, lane 4: product GU-control, lane 7: product CA-control. Lane 2, 5 and 
8: Control reactions without reverse transcription to exclude DNA contamination. Lane 3: Control reactions with 
primer pair combination specific for GU-control. Lane 6 and 9: Control reactions with primer pair combination 
specific for CU-TFO. (C): For Northern blot analysis, 5 or 10 µg RNA per lane were electrophoresed through a 
formaldehyde-agarose gel and transferred to a nylon membrane. Hybridisation  was performed using a radio-
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Because  the  TFO  and  control  sequence,  respectively,  were  transcribed  in  line  with  the 
hygromycin  resistance  gene  as  one  fusion  transcript,  the  RT-PCR  was  performed  using 
specific  upstream  primers  for  the  19  nt  CU-,  GU-  or  CA-RNA  coding  sequences  and  a 
downstream  primer  located  within  the  hygromycin  resistance  gene.  These  primer  pair 
combinations should result in an amplified product of 578 bp in TVHygro-CU and -CA cell lines 
and of 522 bp in TVHygro-GU cell lines, because different restriction enzymes were used for 
the cloning (see "Materials and Methods"). Figure 4-13 A shows that the expected specific 
RNA sequence was present in each cell line (lane 1, 4 and 7) in the nuclei. Additionally, Figure 
4-13 B confirms this finding when total RNA containing the cytosolic fraction was used as PCR 
template.  Control  reactions  were  performed  without  reverse  transcription  to  exclude  DNA 
contamination (lane 2, 5 and 8). To confirm the exclusive presence of the CU-TFO generated 
in TVHygro-CU cell lines and the control-RNA generated in TVHygro-CA and -GU cell lines, 
control reactions were performed using the primer pair for CU-TFO detection with the two 
control-RNA  templates,  and  the  primer  pair  for  the  control-RNA  for  the  CU-TFO  extract. 
Excluding  vector  cross-contamination  no  PCR  product  was  detectable  in  the  respective 
samples (see lane 3, lanes 6 and 9, respectively). The different RNA species are synthesised 
in equal amounts in each cell line as shown by Northern blot analysis using a specific 522 bp 
antisense probe for the hygromycin resistance gene mRNA (Figure 4-13 C).  
4.2.3 Binding of the TFO/ hygromycin fusion transcript to the MCP-1 promoter 
 
The predicted CU-TFO produced inside HEK 293 cells is a fusion transcript of the 19 nt 
triplex  forming  sequence  and  the  messenger  RNA  of  the  hygromycin  resistance  gene. 
Therefore, an in vitro experiment was established to demonstrate that not only the synthetic 
19 nt CU-TFO but also the large single-stranded RNA fusion transcript containing the CU-
TFO  binds  to  the  MCP-1  promoter  duplex  in  a  sequence-specific  manner.  The  RNA 
transcripts of different vectors TVHygro (without insert), TVHygro-CU, -CA and –GU were 
generated by in vitro transcription using T7 polymerase. Transcripts in the length of about  
1.1 kb contained the TFO or control sequence plus the hygromycin resistance gene mRNA. 
Binding of the fusion transcript to its MCP-1 target sequence was characterised in vitro with 
the  set-up  of  a  novel  magnetic  capture  technique.  The  principle  of  these  experiments  is 
shown in Figure 4-14. ￿￿"￿   ￿ ￿ ￿   ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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Figure 4-14. Capture assay for the evaluation of specific TFO binding to the MCP-1 promoter fragment. 
The 39 bp MCP-1 promoter fragment containing the TFO binding site was cloned into a plasmid and could be 
captured  using  a  biotin/streptavidin-based  mechanism.  The  captured  target-plasmid  was  identified  by  PCR 
amplification.  To  compare  the  relative  amount  of  bound  plasmid  to  the  TFO  or  control  transcripts,  a  semi-
quantitative PCR was performed. 
 
4.2.3.1 In vitro transcription of the 1.1 kb TFO/hygromycin fusion transcript 
Vector  fragments  containing  the  TFO  or  control  sequences  and  part  of  the  hygromycin 
resistance  gene  were  amplified  by  PCR  (Figure  4-15  A).  PCR  products  included  the  T7 
promoter sequence and were used for in vitro transcription using T7 polymerase. In Figure  
4-15 B it is shown that the in vitro transcription resulted in intact RNA transcripts in the length 
of about 1.1 kb.  
 
 
 
 
 
 
 
 
Figure 4-15. In vitro transcription of the vector encoded CU-TFO or control sequences. Vector sequences 
including the T7 promoter sequence were amplified by PCR and used as templates for in vitro transcription. 
Correct sizes of the PCR products and the transcribed RNA were proven by electrophoresis on 1% agarose gels. 
The sizes of the different PCR products for in vitro transcription are shown in (A); empty vector 1212 bp (lane 1), 
vector coding CU-TFO 1219 bp (lane 2), and vector coding GU-control 1181 bp (lane 3) (B): Estimated sizes of 
transcribed RNA due to the transcriptional start site at the T7 promoter; 1142 bp (empty vector, lane 1), 1149 bp 
(CU-TFO, lane 2) and 1111 bp (GU-control, lane 3). K= in vitro transcribed control template provided by the 
supplier produces two transcripts of 2.3 and 1.1 kb in size.  
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For magnetic capture the RNA transcripts were annealed to a complementary biotinylated 
oligonucleotide  of  30  nt.  This  oligonucleotide  was  positioned  at  the  3’  end  of  the  RNA 
transcript, whereas the 19 nt TFO binding site was located at the 5’ end. Hybridisation was 
performed  for  1  h  at  RT.  Annealing  of  the  oligonucleotide  to  the  RNA  transcript  was 
confirmed by gel electrophoresis, analysing the hybridisation complex and the biotinylated 
oligonucleotide  alone,  respectively.  In  Figure  4-16,  lane  1  and  2,  it  is  demonstrated  that 
almost the complete amount of oligonucleotide was bound to the complementary part of the 
RNA, indicating that in the subsequent experiments intact and correctly biotinylated RNA 
transcripts were used. 
 
 
 
 
 
 
 
Figure 4-16. Labelling of the in vitro transcribed RNA with a biotinylated oligonucleotide. Annealing of the 
biotinylated  oligonucleotide  to  in  vitro  transcribed  RNA  was  confirmed  by  gel  electrophoresis  through  a  1% 
agarose gel. Lane 1: 57 pmol (~20 µg) in vitro transcribed RNA were denatured for 5 min at 90° C and mixed with 
57 pmol of biotinylated oligonucleotide in annealing buffer (100 mM potassium acetate, 30 mM HEPES, 2 mM 
magnesium  acetate,  pH  7.4)  and  incubated  for  1  h  at  room  temperature.  Lane  2:  57  pmol  of  biotinylated 
oligonucleotide without RNA. Lane 3: 1 µg of the in vitro transcript. Lane 4: 1 µg of RNA transcript plus 57 pmol of 
biotinylated oligonucleotide without annealing reaction.  
 
4.2.3.2 Semi-quantitative PCR 
To compare the relative amount of bound plasmid containing the 39 bp MCP-1 promoter 
fragment  to  the  TFO  or  control  transcripts,  a  semi-quantitative  PCR  was  established. 
Therefore, PCR was performed with 15-34 cycles, using 1.1 ng of the plasmid as a template 
(Figure 4-17). For product amplification two different primer pairs have been used: primer 
pair I contained an upstream primer which was set at the MCP-1 promoter target site and a 
downstream primer which was specific for the pGL3 vector, leading to a PCR product of 658 
bp in length. The upstream primer was chosen to detect only recombinant vectors with the 
MCP-1  insert  and  not  the  wild-type  vector  without  the  target  sequence.  Primer  pair  II 
contained the same downstream primer but the upstream primer was vector-specific as well 
and did not include the MCP-1 promoter target site, leading to a product of 520 bp. 
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Figure 4-17. Amplification of the vector pGL3 control containing the 39 bp MCP-1 promoter fragment. PCR 
was performed using Platinum Taq DNA polymerase. Cycler conditions: 94° C for 2 min followed by 15-34 cycles 
of 94° C for 30 sec, 55° C for 30 sec and 72°C for 1 min. The following oligonucleotide primers were used at a 200 
nM final concentration. (A): Primer pair I with upstream primer 5’AAGCTTTCCTGCTTGACTCC and downstream 
primer 5’AGACCAGTAGATCCAGAGGA, leading to a PCR product of 658 bp. (B): Primer pair II with upstream 
primer 5’AGAGATACGCCCTGGTTCCT and downstream primer 5’AGACCAGTAGATCCAGAGGA, leading to a 
PCR product of 520 bp.  
 
A series of PCRs
 was carried out to determine the linear amplification range
 as a function of 
the number of cycles. In theory, DNA amplification is an infinite logarithmic process. But, 
DNA amplification at higher cycle numbers begins to slow down. This may be due to lower 
Taq  polymerase  activity,  availability  of  substrates,  or  saturation  of  PCR  products.  The 
plateau phase can be visualised and quantified densitometrically after gel electrophoresis of 
the PCR products taken from different cycle numbers.  
 
Here, amplification was linear between 25 and 28 cycles for both primer pairs. Thus, for the 
following  experiments  25  cycles  were  chosen  (Figure  4-18).  PCR  was  performed  with 
increasing  amounts  of  template  from  1.4  pg  to  1.4  ng  to  ensure  that  the  amplification 
remained in the linear phase and does not extend to the plateau phase. The products were 
then  analysed  by  densitometry.  These  control  experiments  showed  that  the  chosen 
conditions resulted in linear amplification for both primer pairs.  
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Figure 4-18. Semi-quantitative PCR. PCR was performed with 25 cycles and increasing amounts template as 
indicated. (A): PCR with primer pair I leading to a product of 520 bp in length; the respective densitometry is 
shown in (B). (C, D): PCR with primer pair II leading to a product of 658 bp in length. 
 
4.2.3.3 Magnetic capture of triplex complexes 
As a next step, the ability of the TFO/ fusion transcript to selectively bind to its MCP-1 target 
sequence was tested. Before each experiment, the amount and the quality of the control and 
TFO  transcripts,  respectively,  were  checked  by  gel  electrophoresis  to  confirm  that  equal 
amounts of RNA were used (Figure 4-19 A). Then, the transcribed RNA (control and TFO) was 
annealed  to  the  biotinylated  oligonucleotide  at  equimolar  amounts  and  incubated  with  the 
MCP-1  target  sequence  integrated  within  the  pGL3  plasmid  for  1  h.  The  results  in  
Figure 4-12 C already demonstrated that the synthetic 19 nt CU-TFO was able to recognise 
and bind to the vector embedded MCP-1 target duplex in a sequence-specific manner via 
triplex  formation.  Here,  the  triplex  complexes  or  control  reactions  were  captured  via  the 
annealed  and  biotinylated  RNA  onto  streptavidin  coated  magnetic  beads  and  applied  to 
separation columns in a magnetic field. To remove unbound RNA and plasmid, four washing 
steps were performed using the triplex binding buffer and in a final step the complexes were 
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eluted.  Each  fraction  was  saved  for  RNA  analysis  on  a  gel.  In  Figure  4-19  B  one  typical 
example of the washing and elution fractions during the magnetic separation is shown.  
 
 
 
 
 
 
Figure 4-19. Stability of the magnetically labelled RNA during the separation steps. (A): Concentration and 
quality of the in vitro transcripts containing the control or CU-TFO sequence were analysed by electrophoresis 
through  a  1%  agarose  gel  before  each  individual  experiment.  (B):  The  biotinylated  RNA  transcripts  were 
incubated with the plasmid pGL3 control containing the 39 bp MCP-1 promoter duplex to allow triplex formation. 
The RNA was magnetically labelled using streptavidin micro beads and the binding reaction was applied on top of 
the column. The magnetically labelled triplex complexes are retained on the column. All washing and elution 
fractions were saved and 40 µl of each fraction were subjected to electrophoresis through a 1% agarose gel.  
1: binding reaction, flow-through; 2-5: wash; 6: eluate.  
 
The entire unbound RNA was removed in the flow through and the first washing step (lanes 1 
and 2), whereas the captured RNA-plasmid complexes remained on the column during further 
washing  steps  (lanes  3-5).  At  the  elution  step  (lane  6)  the  RNA  was  released  again  and 
represented  the  amount  of  specifically  bound  RNA  to  the  streptavidin  beads.  The  relative 
amount of RNA in the elution step of the TFO and control samples, respectively, was quantified 
densitometrically.  To  allow  quantitative  comparison  of  bound  plasmid  to  TFO  and  control 
transcripts,  the  template  volume  for  PCR  analysis  was  normalised  to  the  amount  of  RNA 
present in the elution fraction. The relative amount of bound plasmid to the RNA transcripts 
was quantified by PCR, leading to a PCR product of 520 bp (primer pair II). When samples that 
had not been subjected to magnetic capture were used for PCR, the signals which could be 
observed in the TFO and in the control portion were equal (Figure 4-20, left panel). This result 
underlined that the same amount of plasmid was present in each reaction and that the plasmid 
was intact before magnetic separation. After magnetic separation, there was a stronger binding 
of MCP-1 target to the TFO rather than to the control detectable (right panel, lane 1).  
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Figure  4-20.  Capture  assay  for  the  evaluation  of  specific  binding  of  the  1.1  kb  TFO/hygromycin  fusion 
transcript  to  vector  encoded  MCP-1  promoter  target  duplex.  Plasmid  pGL3  containing  the  39  bp  MCP-1 
promoter target sequence was treated with biotinylated CU-TFO transcript (lane 1) or with biotinylated GU-control 
transcript (lane 2). After incubation aliquots of each sample were: (i) saved for control of intact plasmid present in 
each  reaction  and  successful  PCR  amplification  (“before  capture”,  left  panel),  and  (ii)  subjected  to  magnetic 
separation (“after capture”, right panel). Streptavidin-coated magnetic beads bind to the biotinylated RNA transcripts 
and allow magnetic capture of triplex complexes. The captured DNA was detected by PCR with pGL3 specific 
primers leading to a PCR product of 520 b. 
Another primer pair was used to verify the enhanced binding of the plasmid containing the 
MCP-1 promoter sequence to the TFO. The upstream primer was set at the MCP-1 promoter 
target site and the downstream primer was specific for the pGL3 vector leading to a PCR 
product of 658 bp in length (primer pair I), and similar results were obtained. Figure 4-21 A 
demonstrates a stronger binding of the plasmid to the 1.1 kb TFO transcript rather than to the 
control  transcript,  resulting  in  a  stronger  PCR  amplification  (lanes  2  and  3).  In  lane  1  the 
reaction  was  performed  without  a  biotinylated  RNA  transcript,  and  no  PCR  fragment  was 
detected. The latter finding allows excluding non-specific, biotin-independent binding of the 
plasmid to the magnetic beads during the separation step, which would produce false positive 
PCR results. When summarizing results of three independent experiments, the binding of the 
TFO transcript to the plasmid containing the MCP-1 promoter target was three times stronger 
in comparison to the binding of control transcripts (Figure 4-21 B). 
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Figure 4-21. Plasmid encoded target duplex binds to the 1.1 kb CU-TFO transcript. (A): The amount of 
plasmid bound to the transcribed RNA (control or TFO) in each elution fraction was compared by PCR and a 658 
bp fragment of the plasmid carrying the triplex target site was amplified. Plasmid encoded target DNA was treated 
without biotinylated RNA (lane 1), with control-RNA containing the 19 nt GU sequence (lane 2), or with the RNA 
transcript containing the CU-TFO sequence (lane 3). (B): The relative amount of bound plasmid to the TFO or 
control  was  quantified  densitometrically.  Binding  was  demonstrated  in  three  independent  experiments,  using 
different  in  vitro  transcribed  controls  without  insert  or  with  GU  or  CA  sequences,  respectively.  The  error  bar 
indicates the SD and * significance level of p<0.05 as determined by unpaired student t test. 
 
4.2.4 Sequence-specific inhibition of MCP-1 protein synthesis 
 
Following these control experiments the effects of intracellular generated CU-TFO versus 
control-RNA  on  endogenous  MCP-1  gene  expression  were  analysed.  Specifically  the 
question whether the TFO-based antigene strategy is both limited to the target gene and 
effective also with different known stimuli of MCP-1 protein expression should be answered. 
Non-stimulated HEK 293 cells produced low basal amounts of MCP-1 in culture. As shown 
before  protein  secretion  could  be  induced  by  pro-inflammatory  cytokines  like  TNF-a  and  
IFN-g in these cells. HEK 293 cell lines TVHygro-CU, releasing CU-TFO, and control cell 
lines,  releasing  control-RNA  (GU-control,  CA-control  or  RNA  without  insert  derived  from 
vector TVHygro) were plated in 24-well plates at a density of 1.5x10
5 cells/well and cultured 
for  24  h  in  the  absence  or  presence  of  500  U/ml  TNF-a.  In  a  series  of  13  independent 
experiments with six different stable transfected cell lines generating intranuclear CU-TFOs a 
mean inhibition by 76 ± 10.2% of MCP-1 protein secretion was measured after stimulation 
with TNF-a alone as compared to measurements in two control cell lines (n=7). The basal 
MCP-1 protein secretion in unstimulated TVHygro-CU cell lines was reduced by 58 ± 13.1% 
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Figure 4-22. Inhibition of MCP-1 expression by intracellular generated CU-TFO in HEK 293 cells. Stable 
transfected HEK 293 cells lines generating CU-TFO, GU-control and CA-control, respectively, were plated in 24-
well plates at a density of 1.5x10
5 cells/well and cultured for 24 h in the absence or presence of 500 U/ml TNF-a. 
At the end of incubation time culture supernatants were harvested and MCP-1 concentrations determined by 
ELISA.  The  means  of  13  independent  measurements  of  6  different  CU-TFO  generating  cell  lines  and  7 
independent measurements of 2 different control-RNA generating cell lines are shown. The error bars indicate the 
SD and *** significance level of p<0.001 as determined by unpaired student t test. 
 
To further confirm that the inhibition of MCP-1 protein secretion indeed represents a gene 
specific effect, respective HEK 293 cell lines were plated in 24-well plates at different cell 
densities of 9x10
4, 1.5x10
5, and 3x10
5 cells/well and cultured for 24 h in the absence or 
presence of 500 U/ml TNF-a. In addition to MCP-1 the release of the chemokine IL-8 was 
determined by ELISA. Also in this experimental series a marked reduction of MCP-1 protein 
secretion by up to 85% became apparent in the TNF-a stimulated TVHygro-CU transfected 
cell line when compared to the control vector transfected cell line (Figure 4-23 A). Analysing 
these supernatants for IL-8 protein secretion by ELISA no inhibition of IL-8 protein secretion 
could be shown in CU-TFO releasing cells, indicating that there was a sequence-specific 
inhibitory effect of CU-TFO only at the MCP-1 promoter site, whereas IL-8 as suitable TNF-a 
inducible control gene was not affected at all (Figure 4-23 B).  
Extending these results IFN-g induced MCP-1 expression was inhibited by 83% in CU-TFO 
releasing cell lines. Combined stimulation with IFN-g and TNF-a resulted in an enhanced 
MCP-1 protein secretion in HEK 293 cell lines in comparison to single cytokine stimulation 
suggesting an additive effect. MCP-1 protein secretion was inhibited by up to 88% in co-
stimulated CU-TFO generating cells in comparison to control cells (Figure 4-24). 
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Figure  4-23.  Sequence-specific  inhibition  of  MCP-1  protein  secretion.  Stable  transfected  HEK  293  cells 
generating  CU-TFO  and  control-RNA,  respectively,  were  plated  in  24-well  plates  at  densities  of  9.x10
4, 
1.5x10
5and 3.x10
5 cells/well and cultured for 24 h in the absence or presence of 500 U/ml TNF-a. At the end of 
incubation time culture supernatants were harvested and MCP-1 (A) and IL-8 concentrations (B) determined by 
ELISA. One experiment representative of three independent experiments is shown; the error bars indicate SD. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-24. Sequence-specific inhibition of MCP-1 protein secretion. Stable transfected HEK 293 cells lines 
generating CU-TFO or control-RNA were plated in 24-well plates at a density of 3.x10
5 cells/well and cultured for 
24 h in the presence of 500 U/ml TNF-a, 1000 U/ml IFN-g or TNF-a and IFN-g together as indicated. At the end of 
incubation time culture supernatants were harvested and MCP-1 and IL-8 concentrations determined by ELISA. 
One experiment of three with similar results is shown. The error bars indicate the SD and *** significance level of 
p<0.001 as determined by unpaired student t test. 
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Short  RNAs  regulate  gene  expression  in  many  species.  Some  are  generated  from  any 
double-stranded RNA and degrade complementary RNAs; others are encoded by genes and 
repress  specific  mRNAs.  RNA  interference  (RNAi)  depends  on  the  formation  of  double-
stranded  RNA  (dsRNA)  whose  antisense  strand  is  complementary  to  the  transcript  of  a 
targeted gene. Two distinct steps are involved. In the first, the enzyme Dicer cleaves long 
dsRNA into short interfering RNA (siRNA) molecules in the length of 21-23 bp. In the second, 
a  multi-component  RNA-induced  silencing  complex  (RISC)  uses  siRNA  to  guide  the 
sequence-specific cleavage of the RNA transcripts of the targeted gene.  
Here, the siRNA approach was tested as another strategy to inhibit expression of the pro-
inflammatory  chemokines  MCP-1  and  RANTES.  Two  different  methods  were  pursuit, 
describing  transient  transfection  with  a)  vector  derived  and  b)  synthetic  siRNA.  siRNA 
sequences were screened using a commercial siRNA target finder.  
Two vector derived siRNAs against RANTES and MCP-1 were created and several cell lines 
were transiently transfected. Sense and antisense strands have been paired in a manner to 
have  a  UU  3’  overhang.  The  21  bp  siRNA  against  murine  RANTES  (NM_013653)  was 
located at position 205 in the target mRNA sequence with a GC content of 47.6%, and the 
siRNA (21 bp) against human MCP-1 (NM_002982) was located at position 180 in the target 
mRNA sequence with a GC content of 38.1%.  
 
4.3.1 Vector system for expression of siRNA in mammalian cells 
   
The vector pSUPER (Figure 4-25) is a mammalian expression vector that directs intracellular 
synthesis  of  siRNA  like  transcripts.  The  vector  uses  the  polymerase-III  H1-RNA  gene 
promoter, as it produces a small RNA transcript lacking a polyadenosine tail and has a well-
defined start of transcription and a termination signal consisting of five thymidines in a row. 
The cleavage of the transcript at the termination site is taking place after the second uridine 
(Baer et al. 1990), yielding a transcript with the ends resembling synthetic siRNAs, which 
also contain two 3’ overhanging T or U nucleotides. A gene-specific insert was designed 
containing a unique 19-nt sequence derived from the target transcript and was cloned into 
the HindIII and BglII restriction sites of the vector. The 19-nt target appears in both sense 
and antisense orientation, separated by a 9-nt spacer sequence. The resulting transcript is 
predicted to fold back on itself to form a 19 bp stem-loop structure. Analysis indicated that 
the stem loop precursor transcript was quickly cleaved in the cell to produce a functional 
siRNA (Brummelkamp et al. 2002).  
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Figure 4-25. Transcription of 64 nt oligonucleotide to hairpin RNA, subsequently processed to functional 
siRNA. The pSUPER vector is based on a pBlueScript KS-phagemid vector, a 3176 bp DNA vector with ampicillin 
resistance.  pSUPER  also  features  the  H1-RNA  promoter  for  RNA  transcription  under  the  control  of  the 
polymerase-III expression system.  
 
 
4.3.1.1 Design of siRNA vectors targeting RANTES and MCP-1 mRNA 
Two  different  vectors  were  constructed  directing  the  synthesis  of  double-stranded  siRNA 
against RANTES and MCP-1; sequences are shown in Figure 4-26.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-26. Schematic drawing of the pSUPER  vector and the predicted secondary  structures of the 
transcripts.  Different  vectors  were  constructed  to  generate  double-stranded  siRNA  targeting  (A)  the  human 
MCP-1 mRNA and (B) the murine RANTES mRNA. 
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After ligation and transformation into competent E. coli the presence of positive clones was 
checked by restriction digestion with EcoRI and HindIII. Positive clones should have inserts 
of about 290 bp in length (Figure 4-27 A). Upon ligation, the BglII site is destroyed to allow a 
better selection of positive clones. Recombinant plasmids containing the inserts were not 
linearised when digested with BglII, whereas the wild type vector was linearised (Figure 4-27 
B).  But:  The  MCP-1  siRNA  insert  contains  an  additional  BglII  restriction  site  (AGATCT); 
therefore the recombinant vector was linearised like the empty vector after digestion with 
BglII  (Figure  4-27  B,  lanes  1,  2  and  9).  Endotoxin-free  maxi  plasmid  preparations  were 
performed,  and  before  transfecting  mammalian  cells  with  the  different  constructs  the 
presence of the correct inserts was confirmed by DNA sequencing using T7 and T3 primers. 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 4-27. Cloning of vectors expressing siRNA: presence of positive clones. The 64 nt oligonucleotides 
containing the coding sequences for siRNA against the human MCP-1 or murine RANTES were annealed and 
ligated into the pSUPER vector. After transformation of recombinant pSUPER vector into competent cells (DH5a), 
several  single  colonies  were  picked,  grown  in  LB  amp+  broth  for  an  additional  cycle  and  minipreps  were 
performed.  (A):  The  presence  of  positive  clones  was  analysed  by  digestion  with  HindIII  and  EcoRI.  Positive 
clones should have inserts approximately 290 bp in length. An empty vector has an insert of approximately 227 
bp. (B): Linearisation of the plasmids with BglII. Lane 1-2: vector with siRNA-insert against MCP-1; lane 3-8: 
vector with siRNA-insert against RANTES; lane 9: wild type vector; lane 10: wild type vector without restriction. 
 
4.3.1.2 Transfection of mammalian cells with pSUPER 
The ability of vector encoded siRNA to inhibit endogenous RANTES was tested in b-end3 
cells  and  Th1  cells.  Th1  cells  were  transfected  with  0.5  µg  of  the  pSUPER  vector.  To 
examine sequence-specificity, a vector harbouring the siRNA targeting human MCP-1 mRNA 
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Murine brain microvascular endothelial cells have been transfected with 0.2 to 1 µg of the 
siRNA vector, and the unrelated siRNA sequence against MCP-1 served as a control (Figure 
4-29).  But,  transient  transfection  of  these  constructs  failed  to  suppress  RANTES  gene 
expression. 
 
 
 
 
 
 
 
 
 
 
Figure 4-28. Treatment of Th1 cells with siRNA. Th1 cells were plated in 6-well plates at a density of 1 x 10
6 
cells/well and transfected with 0.5 µg of the vector pSUPER, which contained either a siRNA sequence against 
murine RANTES or an unrelated siRNA sequence against human MCP-1 which served as a control. After 18 h 
the cells were left unstimulated or treated with 5 µg/ml ConA for additional 24 h. Following the incubation time, the 
culture  media  were  harvested  and  the  concentration  of  secreted  RANTES  was  determined  by  ELISA.  One 
experiment of two with similar results is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-29. Treatment of brain microvascular endothelial cells with siRNA. B-end3 cells were plated in 6-
well plates at a density of 600,000 cells/well and transfected with different concentrations of the vector pSUPER, 
which contained either a siRNA sequence against murine RANTES or an unrelated siRNA sequence against the 
human MCP-1 which served as a control. After 18 h the cells were left unstimulated or treated 500 U/ml TNF-a 
and 200 U/ml IFN-g for additional 24 h. Following the incubation time, the culture media were harvested and the 
concentration of secreted RANTES was determined by ELISA. One experiment of three with similar results is 
shown. 
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But, interestingly, in b-end3 cells basal RANTES expression was increased by vector derived 
siRNA treatment in comparison to basal expression in the medium control. Induction caused 
by plasmid transfection was up to 45-fold. There seemed to be no correlation between the 
induction and the concentration of transfected vector. Enhancement was not visible any more 
after treatment with TNF-a and IFN-g. Additionally to the stimuli used there is no effect of the 
siRNA detectable. 
 
Furthermore HEK 293 cells were transfected with vector encoded siRNA against the human 
MCP-1. An empty vector without RNA sequence served as a control. Inhibition due to the 
siRNA was measured in stimulated and unstimulated cells (Figure 4-30). In TNF-a stimulated 
cells MCP-1 protein synthesis was decreased by 35 ± 11% after siRNA transfection. Cells 
transfected with the empty vector (no RNA transcript) revealed a decrease of MCP-1 protein 
synthesis by 18 ± 7%. These result demonstrate that the vector itself has an effect in HEK 
293  cells,  leading  to  a  slight  inhibition  of  gene  expression,  but  inhibition  was  more 
pronounced by the vector derived MCP-1 siRNA.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-30. Transfection of HEK 293 cells with siRNA against MCP-1. HEK 293 cells plated in 6-well plates 
at a density of 600,000 cells/well were transfected with 2 µg of vector pSUPER which contained a siRNA against 
human MCP-1. An empty vector without siRNA sequence served as a control. After 18 h the cells were left 
unstimulated or treated with 500 U/ml TNF-a for additional 24 h. Following the incubation time, the culture media 
were harvested and the concentration of secreted MCP-1 was determined by ELISA. Cell culture was performed 
in duplicates; the error bars indicate the SEM.  
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4.3.2 Transfection with synthetic siRNA targeting MCP-1 and RANTES 
 
Additionally, transient transfections with synthetic siRNA were performed. Selected 21 bp 
sequences were the same as described and used in the pSUPER RNAi system. The siRNA 
against  MCP-1  and  RANTES  were  purchased  as  single  21  nt  RNA  strands  (sense  and 
antisense),  therefore  they  had  to  be  annealed  first  to  obtain  double-stranded  siRNA  for 
transfection. Figure 4-31 shows the conversion from single to double strands after annealing 
and confirms that the siRNA was not degraded before transfection. 
 
 
 
 
 
 
 
 
 
Figure 4-31. Annealing of single-stranded siRNAs to a double-stranded siRNA. Single strands were mixed in 
equimolar amounts in annealing buffer composed of 100 mM potassium acetate, 30 mM HEPES, and 2 mM 
magnesium acetate, pH 7.4 and incubated at 95° C for 5 min, followed by a slow cool-down to room temperature 
at a rate of 1°C/min. Quantitative annealing of the single strands to double strands was confirmed by native 
polyacrylamide gel electrophoresis through 12.5% gels, analysing 1 µg RNA per lane. 
 
In a following experiment it was tested whether the siRNA against murine RANTES was 
functional in cells to inhibit RANTES gene expression (Figure 4-32).  
 
 
 
 
 
 
 
 
 
 
Figure 4-32. Transfection of microvascular brain endothelial cells with siRNA against RANTES. B-end3 
cells plated in 6-well plates at a density of 600,000 cells/well were transfected with 2 µg siRNA (150 nM) against 
murine RANTES. An unrelated siRNA sequence against human MCP-1 served as a control. After 18 h the cells 
were left unstimulated or treated with 500 U/ml TNF-a and 200 U/ml IFN-g for additional 24 h.  
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B-end3 cells were transfected with 2 µg of intact siRNA (~150 nM). An unrelated double-
stranded RNA sequence with a length of 21 bp served as a control to rule out unspecific 
effects.  After  transfection  the  siRNA  effects  have  been  measured  on  protein  level  using 
ELISA.  As  a  result,  siRNA  treatment  did  not  lead  to  an  inhibition  of  RANTES  gene 
expression in b-end3 cells. No difference was visible using the siRNA or control sequence in 
comparison to the medium control. RANTES expression was inducible by TNF-a and IFN-g 
treatment,  but  the  expression  rate  was  not  changed  by  the  siRNA  in  stimulated  and 
unstimulated cells, respectively. 
 
The siRNA against human MCP-1 was tested in HEK 293 cells. Effects on basal and TNF-a 
induced MCP-1 expression were examined (Figure 4-33). As described above, an unrelated 
RNA  sequence  was  used  as  a  control.  After  transfection  of  2  µg  siRNA  (~150  nM),  the  
MCP-1  expression  was  reduced  about  30%  in  unstimulated  cells  and  23%  in  TNF-a 
stimulated  cells.  Conversely,  the  control  RNA  resulted  in  a  decreased  MCP-1  protein 
synthesis  as  well  (37%  in  unstimulated  and  15%  in  stimulated  cells),  indicating  that  the 
inhibitory  effect  was  not  sequence-specific  but  treatment  resulted  in  a  general  slight 
decrease of protein synthesis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4-33. Transfection of HEK 293 cells with siRNA against MCP-1. HEK 293 cells plated in 6-well plates 
at a density of 600,000 cells/well were transfected with 2 µg siRNA (150 nM) against human MCP-1. A scrambled 
siRNA sequence served as an unrelated control. After 18 h the cells were left unstimulated or treated with 500 
U/ml  TNF-a  for  additional  24  h.  Following  the  incubation  time,  the  culture  media  was  harvested  and  the 
concentration of secreted MCP-1 was determined by ELISA. 
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In a subsequent experiment a validated siRNA sequence targeting the MCP-1 mRNA was 
tested (for details of the sequence see “Materials and Methods, Table 3-22). According to the 
supplier’s information (Ambion), the siRNA was confirmed in HeLa cells. Validation results 
were  expressed  as  the  relative  amount  of  target  mRNA  remaining  (9.78%  +  2.35/-1.03) 
compared to that of cells transfected with negative control.  
 
Here, HEK 293 cells were transfected with 100 nM of the siRNA and incubated with TNF-a 
afterwards  (Figure  4-34).  In  four  independent  experiments  MCP-1  protein  secretion  was 
reduced by 62.3 ± 10.3%.  
 
 
 
 
 
 
 
 
 
Figure 4-34. Transfection of HEK 293 cells with a validated siRNA sequence targeting MCP-1 mRNA. HEK 
293 cells plated in 6-well plates at a density of 600,000 cells/well were transfected with 100 nM siRNA against 
human MCP-1. After 18 h the cells were treated with 500 U/ml TNF-a for additional 24 h. Following the incubation 
time, the culture media was harvested and the concentration of secreted MCP-1 was determined by ELISA. Cell 
culture was performed in duplicates, and the mean of four independent experiments is shown. The error bars 
indicate the SD and *** significance level of p=0.0009 as determined by unpaired student t test. 
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The resistance of cells to transfection of siRNA and TFOs may limit their successful use in 
vitro and in vivo. To overcome these limitations, lentiviral vectors can be used as efficient 
and  stable  gene  delivery  tools  in  mammalian  cells.  Gene  transfer  vectors  derived  from 
lentiviruses, such as HIV-1, are potentially important tools in clinical gene therapy due to their 
ability to transduce several types of target cells independently of their proliferation status 
both ex vivo and in vivo. Lentiviral vectors are replication-defective viral particles made by 
the core proteins and enzymes of a lentivirus, and the envelope of a different virus. Here, the 
production  of  lentiviral  vectors  by  transient  transfection  of  HEK  239T  cells  is  described. 
Vector  plasmids,  including  the  transfer  construct  (“SEW”),  packaging  construct  (“pCMV 
D8.91”), and envelope plasmid (“pMD2.VSV.G”) were kindly provided by Dr. Manuel Grez, 
Georg-Speyer-Haus, Frankfurt, and production of lentiviral VSV-G pseudotyped vectors was 
performed in S2-laboratories of the Georg-Speyer-Haus.  
The  following  results  show  the  cloning  of  recombinant  transfer  vectors  and  the  transient 
transfection of lentiviral vector plasmids into a HEK 293T cell line for packaging lentiviral 
vector genomes into infectious lentiviral particles. For the determination of infectious particles 
per ml (transducing units per ml; TU/ml), the supernatants were titrated on HEK 293T cells 
and  analysed  using  FACS.  Finally,  Th1  cells  were  transduced  with  infectious  lentiviral 
particles and transduction efficacy was measured by FACS.  
 
4.4.1 Recombinant lentiviral vector plasmids 
 
The  expression  constructs  used  for  lentiviral  production  were  maintained  in  the  form  of 
bacterial  plasmids  and  could  be  transfected  into  mammalian  cells  to  produce  replication 
defective  virus  stocks.  The  transfer  vector  SEW  contains  a  coding  sequence  for  the 
enhanced green fluorescent protein (eGFP). 
Four  different  recombinant  SEW  transfer  vectors  have  been  constructed.  Therefore,  the 
expression cassette of the vector pSUPER (chapter 4.3.1) containing the H1 promoter was 
amplified using T7 and T3 primers. Each primer contained a 5’ SnaBI restriction site for blunt 
end  ligation  into  the  SnaBI  linearised  SEW.  The  principle  of  the  cloning  is  shown  in  
Figure  4-35.  The  following  constructs  derived  from  pSUPER  were  cloned  into  SEW:  
a)  expression  cassettes  coding  for  the  21  bp  siRNA  against  MCP-1  and  RANTES, 
respectively (see chapter 4.3.1.1), b) an expression cassette coding for the 19 nt single-
stranded CU-TFO against MCP-1 with no stem loop formation, c) an expression cassettes 
without coding insert sequence (Figure 4-35 B-E).  
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Figure 4-35. Cloning of the transfer vector SEW. (A): The siRNA expression cassette from the vector pSUPER 
including the H1 promoter was PCR amplified using T7 and T3 primers which contained SnaBI restriction sites. 
PCR products were digested with SnaBI and ligated into the SnaBI linearised transfer vector SEW. (B-E) shows 
the four different constructs cloned into SEW; the siRNA or TFO coding sequences are signed in red.  
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Correct ligation of the different expression cassettes into SEW was confirmed by restriction 
digestion of the recombinant vectors with SnaBI and PCR amplification using T7 and T3 
primers.  Restriction  digestion  of  the  constructs  containing  coding  sequences  for  siRNA 
against RANTES and MCP-1 resulted in fragments of 448 bp (Figure 4-36, right panel). PCR 
amplification of the sequences resulted in products of 458 bp (Figure 4-36, left panel).  
 
 
 
 
 
 
 
 
 
Figure 4-36. Recombinant vector SEW containing siRNA coding sequences against RANTES and MCP-1. 
Lanes  1  and  3:  MCP-1  siRNA,  lanes  2  and  4:  RANTES  siRNA.  Controls  were  performed  using  PCR  and 
restriction digestion.  
 
Restriction digestion of the construct containing coding sequences for the 19 nt CU-TFO 
against MCP-1 resulted in fragments of 420 bp (Figure 4-37, right panel); PCR amplification 
resulted in a product of 430 bp (Figure 4-37, left panel).  
 
 
 
 
 
 
 
 
 
Figure 4-37. Recombinant vector SEW containing TFO coding sequences against MCP-1, 2 clones (I and 
II). Lanes 1 and 3: TFO clone I, lanes 2 and 4: TFO clone II. Controls were performed using PCR and restriction 
digestion.  
 
An expression cassette without insert was cloned into the SEW vector. PCR amplification 
resulted in a product of 394 bp (Figure 4-37).  
Additionally,  correct  inserts  of  all  the  four  constructs  described  were  confirmed  by  DNA 
sequencing.  
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Figure  4-38.  Recombinant  vector  SEW  containing  the  expression  cassette  from  the  vector  pSUPER 
without insert, 4 clones. Controls were performed using PCR amplification with T7 and T3 primers.  
 
In the following experiments the production of infectious lentiviral particles is described. The 
recombinant SEW transfer vector containing the expression cassette without insert was used 
for transfection of HEK 293T cells.  
 
4.4.2 Production of lentiviral VSV-G pseudotyped vectors 
 
HEK 293T cells were co-transfected with 10 µg lentivirus construct SEW (see Figure 4-35 E), 
6.5 µg packaging plasmid pCMV D8.91 and 3.5 µg VSV.G-expressing plasmid pMD2.VSV.G 
using  the  calcium  phosphate  DNA  precipitation  method,  and  two  transfections  were 
performed in parallel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-39. Transient transfection of HEK 293T cells. Transfection efficiencies were determined by analysis 
of eGFP expression with untransfected cells as negative controls (in blue). 
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Microscopy of the cells revealed a very small granular precipitate of the calcium phosphate-
DNA  complexes,  initially  floating  above  the  cell  layer  and  after  incubation  in  the  37° C 
incubator overnight, visible on the bottom of the plate in the spaces between the cells. The 
calcium phosphate-DNA precipitate was allowed to stay on the cells for 14-16 h, after which 
the medium was replaced with fresh medium for vector collection to begin. Cell supernatants 
were collected 24 and 48 h after changing the medium. The supernatants were filtered and 
stored  in  aliquots  at  -80° C.  Transfection  efficiency  was  determined  after  48  h  by  FACS 
analysis (Figure 4-39) and was higher than 99%.  
 
4.4.3 Titration of lentiviral vectors 
 
Relative concentrations of vectors were measured as a titre. The vector titre was determined 
as the number of complete particles that were able to transduce cells. The titre of infectious 
particles in the supernatant can be determined by FACS, if the vectors contain cell surface 
markers or reporter genes like GFP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-40. Titration of lentiviral vectors. (A): Cells expressing eGFP were measured by FACS analysis. Non-
transduced cells served as negative controls. HEK 293T cells were transduced with different dilutions of viral 
supernatants collected after 24 (B) and 48 h (C).  
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HEK 293T cells were transduced with different dilutions of the viral samples collected after 
24 and 48 h (final dilutions 10
-2 to 10
-4). The day after transduction the medium was changed 
and cells were grown for additional 2-3 days. The titre was performed by FACS measuring 
the percentage of cells expressing eGFP in the total population. In Figure 4-40 one of two 
transductions of HEK 293T cells is shown. The titre is expressed in TU/ml and calculated as 
follows:  
 
Titre [transducing units/ml] =  2 x seeded cell number x dilution factor x 
  (positive transduced cells [%] / 100 [%]) 
 
The portion of positive transduced cells should be between 5% and 20% to be in the linear 
range of dilutions. The results are summarised in Table 4-2.  
 
Table 4-2. Titration of lentiviral vectors 
Viral stocks    Dilution   [%] eGFP  Cell number  Titre [TU/ml] 
Transduction 1  24 h  10
-3  8.72  1 x 10
5  1.7 x 10
7 
(Figure 4-40)  48 h  10
-3  6.30  1 x 10
5  1.3 x 10
7 
Transduction 2  24 h  10
-3  5.85  1 x 10
5  1.2 x 10
7 
(data not shown)  48 h  10
-3  4.82  1 x 10
5  9.6 x 10
6 
 
Dilutions of the viral stocks of 10
-3 appeared to be best and were chosen for calculation of 
viral titres. In comparison of the supernatants collected after 24 and 48 h the titre was slightly 
decreased after 48 h. Titres ranged from 10
6 to 10
7 TU/ml.  
 
4.4.4 Transduction of Th1 cells 
 
After determination of viral titres on HEK 293T cells, Th1 cells were transduced with the 
lentiviral particles.  
The multiplicity of infection (MOI) describes the average number of viral particles that infect a 
single cell in a specific experiment and may serve as a parameter for the prediction of gene 
transfer events. For transduction, viral samples collected after 24 h with titres of 1.7 x 10
7 
and 1.2 x 10
7 were used. Percentage of cells expressing eGFP was measured 7 days after 
transduction by FACS analysis.  
The average transduction efficiency (n = 2) at a MOI of 0.5 was 25.92%, at a MOI of 5 = 
67.46% and at a MOI of 50 = 81.76% (Figure 4-41).  
Furthermore,  positively  transduced Th1  cells  were  visualised  by  fluorescence  microscopy 
(Figure 4-42). EGFP expression occurred in almost all cells three weeks after transduction.  
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Figure 4-41. Expression of eGFP in transduced Th1 cells. Cells expressing eGFP at MOI between 0.5 and 50 
were measured by FACS analysis. (A): Non-transduced cells served as negative controls. Transduction of Th1 
cells was performed in duplicate (B and C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-42. Phenotype of transduced Th1 cells. Three weeks after transduction with SEW (MOI 50) cells were 
examined for eGFP expression by fluorescence microscopy. 
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￿ ￿￿￿
5 Discussion 
 
￿￿￿￿ ￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿"￿￿￿￿￿+ ’ ( ￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿"￿￿￿￿￿+ ’ ( ￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿"￿￿￿￿￿+ ’ ( ￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿"￿￿￿￿￿+ ’ ( ￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿
 
The specific interference with gene expression has wide-ranging applications in experimental 
biology and is an attractive approach to the development of therapeutics. Numerous gene 
therapy strategies are under development, some of which use nucleic-acid based molecules 
to  inhibit  gene  expression  at  either  the  transcriptional  (e.g.  triple  helix-forming 
oligonucleotides) or post-transcriptional level (e.g. antisense oligonucleotides, siRNA).  
 
5.1.1 TFOs targeting the chemokines MCP-1 and RANTES  
 
Triple helix formation offers a direct means of selectively manipulating gene expression in 
cells.  Synthetic  triple  helix-forming  oligonucleotides  (TFOs)  bind  with  high  affinity  and 
specificity to the purine strand in the major groove of homopurine/homopyrimidine sequences 
in double-stranded DNA. TFOs have proofed effective in various gene strategies in living 
cells and in animals (Casey and Glazer 2001). Triplex formation can disrupt the regulation of 
gene  expression  at  several  points.  Triplex  formation  was  demonstrated  to  interfere  with 
sequence-specific binding of transcription factors both in vitro and in cultured cells (Liu et al. 
2001), and in addition it was shown to inhibit DNA replication when directed against DNA 
polymerase binding sites (Hacia et al. 1994a). Triplex mediated inhibition of transcription may 
be achieved by interfering with transcription initiation or transcription elongation.  
Purine-rich tracts are frequently found in gene promoter regions and TFOs directed to these 
regulatory sites have been shown to selectively reduce transcription of the targeted genes, 
likely by blocking binding of transcriptional activators and/or formation of initiation complexes 
(Winters  2000).  Triplex  mediated  modulation  of  transcription  has  potential  application  in 
therapy  since  it  can  be  used,  for  example,  to  reduce  levels  of  proteins  thought  to  be 
important  in  disease  processes.  TFOs  can  also  be  molecular  tools  for  studying  gene 
expression and function.  
 
In this study a triplex approach was investigated as a means of down-regulating expression 
of the proinflammatory chemokines MCP-1 and RANTES, which both play a crucial role in 
various diseases. The RANTES target was a 28 bp homopurine/homopyrimidine sequence at 
the  promoter  of  the  gene  that  appeared  suitable  for  triplex  mediated  gene  targeting  with 
respect to the targeted DNA double-strand sequence. A GT-TFO, directed to this sequence, 
was  able  to  bind  to  the  target  DNA  in  a  sequence-specific  manner  according  to  the 
antiparallel purine triplex binding motif. Analysis of the binding properties of the RANTES ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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TFO  showed  that  it  bound  with  high  affinity.  This  was  consistent  with  previous  reports 
showing that antiparallel GT-rich oligonucleotides were able to form stable triplex DNA at low 
concentrations and physiological pH and temperature (Catapano et al. 2000; Durland et al. 
1991).  The  high  binding  affinity  of  the  RANTES  TFO  was  probably  due  to  the  perfect 
homopurine/homopyrimidine composition of the target sequence. Any pyrimidine interruption 
in  the  purine  strand  would  possibly  decrease  stability  of  the  triple  helix  and  lower  TFO 
binding affinity. Triplex formation was already detectable at a TFO concentration of 40 nM. 
Despite its high affinity, binding of the RANTES TFO required exact pairing with the target 
sequence according to the triplex DNA code. A control oligonucleotide with the same length 
but  a  scrambled  base  composition  did  not  form  a  triplex  DNA,  even  at  the  highest 
concentration (16 µM).  
Subsequently  it  was  tested  whether  the  RANTES  TFO  exhibited  any  functional  anti-
transcriptional  activity  in  cells.  Convincing  evidence  of  triplex  formation  on  chromosomal 
targets has been reported previously (Faria et al. 2000; Wang et al. 1996). In the present 
study, binding of the 28 nt TFO to the promoter target sequences could be shown in a cell-
free  system  in  vitro,  but  the  TFO  did  not  functionally  inhibit  endogenous  RANTES  gene 
expression  in  two  different  cell  systems  tested.  The  TFO  contained  a  phosphorothioate 
modification at each end to increase its intracellular stability. However, the RANTES TFO 
appeared to be not effective on the endogenous gene, which might be due to various factors. 
Accessibility  of  a  chromosomal  target  site  might  be  restricted  to  and  depend  on  the 
transcriptional state of the gene. Faria (Faria et al. 2000) reported significant variability in 
gene expression levels in single cells over time and markedly different temporal responses to 
a TFO among individual cells in an unsynchronised cell population.  
The use of synthetic TFOs in vivo might be limited by their susceptibility to endogenous 
nucleases  or  inefficient  cellular  uptake.  Thus,  the  possible  restricted  accessibility  of  the 
endogenous RANTES gene promoter combined with heterogeneity of cellular and nuclear 
uptake of the TFO among cells may have contributed to the apparently poor efficacy of the 
TFO in inhibiting the endogenous gene.  
Furthermore, the RANTES TFO is G-rich and contains several Gs in a row (5’TTT GTT GGT 
GGG GGT GGG GGT GGG GGT G 3’). Triplex formation in the purine binding motif often 
requires a high divalent cation concentration, and the third strand, which is G-rich, might tend 
to self-association into unfavourable structures in the presence of intracellular concentration 
of K
+. Such complexes reduce the ability of TFOs to bind to its intended target (Cheng and 
Van Dyke 1993; Olivas and Maher, III 1995a). This tendency led to the design of guanine 
analogues unable to form G-quartets but still having the potential to establish one or more 
hydrogen bonds with a C-G base pair (Olivas and Maher, III 1995b; Rao et al. 1995). Purine ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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oligonucleotides also have the potential to form another competing structure, a G-A parallel 
duplex, which can also interfere with triplex formation (Noonberg et al. 1995a).  
Another target was the human MCP-1. A TFO target site consisting of 19 bp was identified in 
the promoter region at bp -66 to -48. The TFO target site in the MCP-1 promoter includes the 
binding site for the transcription factor SP-1 and partially overlaps a putative AP-1 binding 
site; both are sites which been implicated in the regulation of MCP-1. A 19 nt TFO based on 
the antiparallel purine motif was designed according to the known rules; T opposite A:T pairs 
G opposite G:C pairs. T was placed opposite the G-C inversion, because this base was 
previously shown to be tolerated opposite C:G pairs in triple helix motifs without adverse 
effect on the binding affinity of the TFO (Durland et al. 1994; Marchand et al. 2000).  
To assess the ability of the TFO to form triple helices with the target site in the MCP-1 
promoter, gel mobility shift assays were performed. The aim was to develop a TFO that could 
be  tested  in  biological  systems,  therefore  oligonucleotides  contained  a  3’  and  5’ 
phosphorothioate modification since it confers resistance to nuclease degradation. The 5’, 3’ 
phosphorothioated GT oligonucleotide was found to form stable triple helical complexes with 
the  duplex  DNA.  According  to  the  literature,  phosphorothioated  TFOs  are  able  to  bind 
specifically  to  the  duplex  DNA  with  only  a  slightly  reduced  affinity  compared  with  the 
unmodified phosphodiester TFOs (Hacia et al. 1994b; Lacoste et al. 1997; Marchand et al. 
2000). But, phosphorothioated TFOs have been found to form triplex DNA more efficiently 
than  their  phosphodiester  counterparts  in  the  presence  of  intracellular  concentrations  of 
potassium  ions  (Tu  et  al.  1995),  suggesting  that  phosphorothioated  TFOs  may  be 
advantageous for binding in vivo.  
The  observed  interaction  was  sequence-specific,  because  a  scrambled  control 
oligonucleotide did not bind to the MCP-1 promoter fragment. To further confirm sequence-
specificity, the TFO and control were incubated with a RANTES promoter sequences as a 
control duplex DNA. No binding occurred using this unrelated target sequence.  
 
A next aim was to test whether the TFO can inhibit expression of MCP-1 in cultured cells. 
MCP-1 is a member of the CC chemokine family and is expressed in vascular endothelial 
cells, vascular smooth muscle cells, monocytes, fibroblasts, and several cancer cell lines. 
MCP-1 can be induced by a variety of mediators including PDGF, IL-1b, TNF-a, VEGF, LPS 
and IFN-g (Murao et al. 2000; Thibeault et al. 2001). In this study it was further demonstrated 
that it is possible to use the TFO to partially inhibit MCP-1 expression in HEK 293 cells. 
Incubation of the cells with 2.0 µM TFO inhibited TNF-a stimulated MCP-1 protein secretion 
about 25% in comparison to the scrambled control oligonucleotide, as determined by ELISA. 
In a previous study Marchand (Marchand et al. 2000) demonstrated via gel shift assays that 
the same 19 nt purine TFO binds to the SP-1 site of the MCP-1 gene promoter, but not to the ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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SP-1 region of the IL-6 gene as a control target. Binding experiments with nuclear extract 
proteins from HEK 293 cells, including the transcription factor SP-1, have shown that binding 
of the TFO replaces binding of nuclear proteins to the target duplex DNA, indicating that the 
binding  of  oligonucleotides  or  protein  to  the  target  are  competing  reactions.  The  in  vitro 
findings support the hypothesis that triplex formation at the MCP-1 promoter can serve as a 
mechanism for transcriptional repression by replacing or preventing the binding of necessary 
transcription  factors.  In  cell  culture  experiments,  Marchand  et  al.  used  a  TFO  which 
contained phosphorothioate modifications at each oligonucleotide in comparison to a 5’, 3’ 
phosphorothioated TFO which was used in this study, and they could show 45% inhibition of 
TNF-a  induced  MCP-1  expression  in  comparison  to  25%  inhibition  demonstrated  here. 
These results suggest that a complete phosphorothioate modification of the oligonucleotide 
might  be  more  effective  than  only  a  partial  one  in  cell  culture  experiments.  Notably,  the 
inhibitory effect of the TFO was hardly visible in the unstimulated cells and more pronounced 
in TNF-a stimulated cells. This observation might be related to differences in the accessibility 
of the target sequence due to transcriptional activation. The TFO must overcome possible 
steric hindrance by the chromatin structure, which can undergo major changes upon up-
regulation of transcription. The hypothesis that the TFO target region in the MCP-1 gene can 
change accessibility under cytokine stimulation is supported by a study that showed that  
IFN-g induced signalling resulted in changes in the genomic footprinting pattern of the MCP-1 
promoter SP-1 site in astrocytoma cells (Zhou et al. 1998).  
In the present study it could be shown that transcription inhibition by a TFO targeting the 
MCP-1 promoter was sequence-specific and triplex mediated. Although the overall efficacy of 
inhibition demonstrated with the purine GT-TFO was only moderate, specific DNA binding 
molecules may prove useful for the development of therapeutics and as tools the for further 
understanding of DNA associated functions in the cellular context. TFOs can be used as 
sequence-specific DNA ligands and they can affect cellular processes such as transcription. 
The ability to block the synthesis of a chemokine in vivo during in inflammatory reaction 
might have a beneficial effect on the course of the disease. A substantial increase in the 
intracellular efficacy of triplex-induced effects will be achieved by chemical modifications of 
the  oligonucleotide  that  could  improve  triplex  stability,  or  by  optimised  delivery  methods 
enhancing cellular uptake of the oligonucleotide. A successful solution to improve delivery 
systems is the in vivo generation of the TFO, as described in chapter 5.2.  
 
 
 
 
 ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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5.1.2 RNA interference 
 
RNA interference (RNAi) is a post-transcriptional process triggered by the introduction of 
double-stranded RNA which leads to gene silencing in a sequence-specific manner. RNAi 
has been reported to naturally occur in organisms as diverse as nematodes, trypanosomes, 
plants  and  fungi.  Introduction  of  double-stranded  RNA  into  the  cells  leads  to  sequence-
specific destruction of endogenous RNAs that are complementary to the dsRNA (Hammond 
et  al.  2000;  Nykanen  et  al.  2001).  During  RNA  interference,  long  dsRNA  molecules  are 
processed into 19 to 23 nt RNAs known as small interfering RNAs (siRNA) that serve as 
guides for enzymatic cleavage of complementary RNAs. In addition, siRNAs can function as 
primers for an RNA-dependent RNA polymerase that synthesises additional dsRNA, which in 
turn is processed into siRNAs, amplifying the effects of the original siRNAs.  
Tuschl and co-workers observed that transfection of synthetic 21 nt siRNA duplexes into 
mammalian cells effectively interfered with mRNA translation in a sequence-specific manner 
(Elbashir et al. 2001; Harborth et al. 2001). These siRNA duplexes are too short to trigger 
non-specific  dsRNA  responses,  but  they  still  cause  destruction  of  complementary  RNA 
sequences (Hutvagner et al. 2001).  
In this study, different strategies have been tested to destruct the targeted mRNA of the 
human MCP-1 and murine RANTES in various cell lines. One approach was the production 
of siRNA from a transfected expression vector (pSUPER) containing the polymerase-III H1-
RNA gene promoter. The vector produces a small RNA transcript lacking a polyadenosine 
tail and has a well-defined start of transcription and a termination signal consisting of five 
thymidines in a row. The cleavage of the transcript at the termination site is taking place after 
the second uridine (Baer et al. 1990) yielding a transcript with the ends resembling synthetic 
siRNAs, which also contain two 3’ overhanging T or U nucleotides. The vector pSUPER was 
used to suppress endogenous MCP-1 translation in HEK 293 cells. An empty vector without 
RNA sequence served as a control. Inhibition due to the siRNA was measured in stimulated 
and unstimulated cells. In TNF-a stimulated cells MCP-1 protein synthesis was decreased by 
35  ±  11%  after  siRNA  transfection.  Cells  transfected  with  the  empty  vector  (no  RNA 
transcript)  revealed  a  decrease  of  MCP-1  protein  synthesis  by  18  ±  7%.  These  result 
demonstrate that the vector itself has an effect in HEK 293 cells, leading to a slight inhibition 
of gene expression, but inhibition was more pronounced by the vector derived MCP-1 siRNA. 
Transfection experiments were performed using the same sequence as a synthetic double-
stranded siRNA. This led to similar results, but the inhibitory effect of the siRNA was even 
less pronounced (30% inhibition in unstimulated cells and 23% in TNF-a stimulated cells). 
Additionally,  another  synthetic  siRNA  sequence  was  tested,  which  was  ordered  from  the 
manufacturer as a validated siRNA targeting the human MCP-1. Using this sequence, the ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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TNF-a induced MCP-1 protein secretion could be successfully inhibited about 62.3 ± 10.3% 
in  HEK  293  cells,  indicating  that  the  siRNAs  are  functional  in  these  cells  to  suppress 
chemokine expression. It would be very interesting and worthwhile to transcribe this siRNA 
from the vector pSUPER and analyse its efficacy in direct comparison to the TFO-RNA (see 
below).  
 
The siRNA approach targeting murine RANTES in TH1 cells and b-end3 cells revealed no 
inhibition of endogenous gene expression. But, in this study only one siRNA sequence was 
tested, which seems to have no functional relevance in the tested cell lines. It would be 
necessary to test several different siRNA sequences with respect to their ability to inhibit 
RANTES gene expression.  ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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Triple helix-forming oligonucleotides bind to the duplex DNA in a sequence-specific manner. By 
forming a local triple helix structure, e.g. in the promoter, they are able to inhibit transcription of 
the target gene. In this study the in vivo generation of a TFO targeting the human MCP-1 is 
described.  A  pyrimidine  triplex  forming  RNA  sequence  generated  within  HEK  293  cells  by 
specific expression vectors was effective in inhibiting the transcription of the human MCP-1 
gene.  The  19  bp  target  sequence  is  located  in  the  promoter  region  of  this  gene  and 
encompasses binding sites for the transcription factors SP-1 and AP-1.  
 
Specific binding of the 19 nt CU-TFO to the MCP-1 promoter target site was shown in vitro at 
pH 6.7, and additionally it was proven that the 1.1 kb TFO/ hygromycin fusion transcript binds 
to  the  MCP-1  promoter  duplex  at  pH  7.  This  was  demonstrated  by  a  newly  developed 
technique measuring the relative binding of the plasmid encoded MCP-1 promoter duplex to 
the  TFO/hygromycin  fusion  transcript  in  comparison  to  control  transcripts  via  magnetic 
separation of the triplex complexes. As shown, the binding of the specific TFO/ hygromycin 
fusion  transcript  to  the  plasmid  embedded  MCP-1  promoter  duplex  was  three  times  more 
efficient than the binding of control-RNA. The TFO or control transcripts were present in the 
cytosol  and  nucleus,  the  site  of  triplex  formation,  as  shown  by  RT-PCR.  Finally,  a  highly 
effective and specific inhibition of MCP-1 protein secretion was detectable as compared to IL-8 
in cytokine stimulated cells which express the CU-TFO unlike cell lines carrying control vectors. 
These results proof that the triplex formation we observed in cell-free experiments was readily 
transferable to intact target cells by using RNA TFO expressing vectors and led to a functional 
blockade of the target gene (Kautz et al. 2005). 
 
The potential of ribonucleotide sequences to form triplexes is supported by several in vitro 
studies (Escude et al. 1993; Han and Dervan 1993; Roberts and Crothers 1992). Triplex 
formation  with  RNA  oligonucleotides  and  double-stranded  DNA  may  provide  a  means  of 
controlling  gene  expression  from  specific  promoters  and/or  creating  more  selective  DNA 
cleaving agents. Triple-helical complexes have been shown to inhibit gene expression when 
introduced into eukaryotic cells. Thus, oligonucleotides that bind duplex DNA via triple helix 
formation have potential as gene specific repressors. Conventional triple helix formation in the 
pyrimidine  motif  allows  the  design  of  RNA  oligonucleotides  that  can  recognise  cognate 
sequences  in  duplex  DNA:  However,  mildly  acidic  conditions  are  often  required  for  strong 
binding. In addition, the pyrimidine recognition sequence must be optimally represented within 
a longer RNA transcript when produced in vivo (McDonald and Maher, III 1995). 
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5.2.1 The pyrimidine binding motif 
 
Pyrimidine-rich  triplex  forming  oligoribonucleotides  have  a  considerable  higher  binding 
affinity  to  the  duplex  DNA  in  comparison  to  their  triplex  forming  DNA  oligonucleotide 
counterparts  as  described  by  Roberts  (Roberts  and  Crothers  1992).  They  observed  a 
markedly  higher  stability  for  triplexes  in  which  the  third  strand  was  RNA.  The  observed 
variability in the complexes must be due to the chemical differences between RNA and DNA; 
the 2’OH and the thymine methyl groups, respectively. They emphasised that the stability of 
the triplex with an RNA third strand + DNA duplex points to novel strategies and opens the 
possibility of an in vivo role of these structures. But triplex formation alongside the pyrimidine 
binding  motif  typically  requires  mildly  acidic  conditions  to  protonate  cytosines.  Several 
potential  cytosine  analogues  like  8-oxoadenine  derivatives  exist  which  can  overcome  the 
need for cytosine protonation (Chan and Glazer 1997; Miller et al. 1992). On the other hand, 
Soukup  (Soukup  et  al.  1996)  selected  RNA  transcripts  which  all  contained  a  pyrimidine 
recognition sequence and were able to bind to the target duplex between pH 6.5 and pH 7.4. 
RNAs  have  been  selected  for  binding  to  a  homopurine/homopyrimidine  duplex  DNA 
sequence under pH conditions that ranged from slightly acidic to neutral. They found that all 
RNAs  appeared  to  form  conventional  triple  helices  with  the  DNA  target  sequence  via  a 
pyrimidine recognition sequence within the longer RNA molecule. Furthermore, pyrimidine 
recognition  sequences  within  longer  RNAs  may  be  subject  to  important  context  effects 
because of their secondary structures that may modulate their binding affinities.  
 
Noonberg (Noonberg et al. 1994a) suggested that the high concentration of a triplex RNA 
oligonucleotide, which is generated in the nucleus in vast excess over its DNA duplex target, 
may drive triplex binding to a critical element on a gene promoter, and block subsequent 
gene expression. To circumvent the problems extracellular degradation, cellular uptake, and 
intracellular sequestration they described a system for producing large quantities of short, 
sequence-specific RNA oligonucleotides for use in gene regulation strategies.  
 
The  pH  within  the  cell  is  different  for  various  organelles,  and  compartments  of  the 
biosynthetic pathway are described to have a neutral pH, endosomes are slightly acidic (pH 
6.2) and lysosomes range between pH 4.8 and 5.2 (Weisz 2003). Llopis (Llopis et al. 1998) 
detected a pH of 6.58 for the trans-Golgi network, a major sorting site for newly synthesised 
molecules. In triplex blotting experiments described below a pH of 5.5 was chosen to perform 
experiments with the control oligonucleotide (single mismatch) and mismatched duplex DNA 
under optimal conditions for the pyrimidine motif. A possible unspecific effect was excluded 
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positive evidence for a specific interaction of the long mRNA containing the CU-RNA TFO. 
These  data  together  with  the  expected  pH  of  6.8  to  7.2  in  the  respective  subcellular 
compartments and the highly specific functional effect underline that pH conditions did not 
interfere with triplex formation using the pyrimidine binding motif inside the cells. 
 
Few  studies  have  been  published  which  excluded  the  possibility  that  purine 
oligoribonucleotides form triplex structures with duplex DNA (Escude et al. 1993; Semerad 
and Maher, III 1994; Skoog and Maher, III 1993), but more recently Cogoi (Cogoi et al. 2000) 
convincingly  demonstrated  triplex  formation  using  CU-,  GU-  as  well  as  GA-
oligoribonucleotides. Based on these promising results there is a growing interest to develop 
methods to produce repressor RNA transcripts inside the target cell in vivo (Cogoi et al. 
2000; Noonberg et al. 1994a; Rininsland et al. 1997). Another strategy was discussed by 
Datta (Datta and Glazer 2001). They tested a vector system for the production of single-
stranded DNA to serve as a TFO in mouse cells and assayed TFO induced recombination, 
but no inhibition on endogenous gene expression was measured. Rininsland (Rininsland et 
al.  1997)  described  the  specific  suppression  of  IGF-1  receptor  gene  expression  in  rat 
glioblastoma cells in culture as well as in animals by using a plasmid-encoded homopurine 
(AG) RNA effector sequence. They showed that this RNA TFO formed a triple helix with the 
target DNA, whereas a homopyrimidine RNA sequence had no effect. Shevelev (Shevelev et 
al. 1997) demonstrated tumour growth inhibition in an animal model employing a eukaryotic 
expression vector encoding a purine GA-TFO corresponding to the IGF I gene. Additionally, 
an antiparallel GA oligoribonucleotide binding to the rat a1(I) procollagen promoter inhibits 
procollagen gene transcription (Ririe and Guntaka 1998). Here, the authors demonstrated 
formation of a triplex structure by an antiparallel RNA oligonucleotide corresponding to the 21 
bp polypurine/polypyrimidine stretch from -141 to -162 of the rat a1(I) procollagen promoter 
with a Kd of 0.1-0.2 µM, and triplex formation was observed under physiological conditions. In 
vitro  transcription  run-off  experiments  showed  that  triplex  formation  results  in  inhibited 
transcription of the rat a1(I) procollagen gene.  
 
Over all, while these studies suggested that triplex formation inside the cell nuclei led to the 
observed  inhibitory  effect,  no  clear  experimental  proof  has  been  delivered.  The  data 
presented in this study, however, clearly show that the CU-sequence was capable of triplex 
formation with the target duplex at the human MCP-1 promoter not only with a short target 
duplex in triplex blots but moreover even when expressed within a large transcript and with 
the target duplex embedded in a complete plasmid.  
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5.2.2 Sequence-specific binding of the TFO to the MCP-1 target sequence 
 
In this study the binding of a 19 nt CU oligoribonucleotide to the MCP-1 promoter duplex and 
the formation of a triplex structure was verified by triplex blotting, a technique first described 
by Noonberg (Noonberg et al. 1994b). This technique is designed to detect RNA species 
capable of triplex formation with radio-labelled duplex DNA probes. Triplex blotting offers a 
new  approach  for  screening  potential  RNA  sequences  for  triplex  formation  with  double-
stranded  DNA  targets,  for  comparing  relative  binding  affinities  of  various  triplex-forming 
RNAs and confirming the specificity of triplex formation of a DNA target probe. Using this 
technique, specific binding of the synthetic 19 nt CU-TFO to the 39 bp MCP-1 promoter 
target at pH 6.7 was shown. While a mismatch at position 15 (C/G inversion) was tolerated 
well in the triple helix motif without adverse effects on TFO binding, no triplex formation was 
observed using an oligoribonucleotide with CA base composition in a scrambled order (rCA-
control) or using an oligoribonucleotide in the purine binding motif (rGU-control). The CU-
TFO was able to bind to the short 39 bp duplex DNA, but binding might occur through D-loop 
formation with partial melting of the target duplex. Therefore a plasmid containing the triplex 
site as a target was used for hybridisation in a subsequent experiment since it should be less 
favourable to a DNA opening phenomenon. Using this target in triplex blotting experiments a 
specific binding of the 19 nt CU-TFO to the plasmid encoded MCP-1 promoter duplex DNA 
was seen. However, only a weak binding of the GA-sequence to the plasmid encoded MCP-
1 promoter target duplex occurred, indicating a stronger binding affinity of the CU-sequence 
to the target. Binding of the GA-sequence did not occur using the short 39 bp target.  
 
Because  the  TFO  sequence  contains  a  symmetric  sequence  in  the  length  of  11  nt  
(5’ ucuCCCUCUCUCCCaccuc 3’), a short double helix might form between CU-RNA and the 
GA-rich strand of the MCP-1 promoter instead of a triplex structure. Therefore, the binding 
capacity  of  a  TFO  sequence  containing  only  one  mismatch  which  did  not  interrupt  the 
symmetric  structure  (5’  ucaCCCUCUCUCCCaccuc  3’,  mismatch  underlined)  was  tested. 
Here, an antisense double helix might be still possible but triplex formation should be less 
favourable.  The  data  clearly  show  that  no  binding  occurred  using  this  kind  of  control, 
indicating that the observed binding indeed must represent triplex formation. Another control 
employed consisted of a duplex DNA containing two mismatches, which did not bind to the 
TFO. This finding is a strong argument that the binding of the RNA TFO shown herein is not 
a result of unspecific duplex/oligo interaction.  
 
According to the literature, the binding affinity is stronger at low pH because of cytosine 
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formation  in  the  pyrimidine  binding  motif  occurred  at  pH  6.7,  which  is  close  to  the 
physiological pH. Moreover, the magnetic capture assay, involving the TFO fusion transcript, 
raised additional evidence for triplex formation at pH 7.0 and showed three fold stronger 
binding of the TFO to the target in comparison to controls.  
 
The effector molecule which is produced in stable transfected HEK  293 cells is a fusion 
transcript  of  the  CU  TFO  sequence  tethered  to  the  messenger  RNA  of  the  hygromycin 
resistance  gene.  Therefore  it  is  critical  to  demonstrate  the  triplex  forming  ability  of  the 
TFO/hygromycin  fusion  transcript  rather  than  the  synthetic  19  nt  CU-TFO  alone.  A  new 
assay for the detection of TFO/hygromycin fusion transcripts binding to the MCP-1 target 
sequence was established to evaluate whether the fusion transcript is able to interact with 
the  MCP-1  target  duplex  DNA  in  a  sequence-specific  and  in  a  triplex  mediated  manner. 
Triplex  complexes  could  be  captured  using  a  biotin/streptavidin-based  mechanism  and 
identified by PCR amplification of a portion of the captured fragment. To prepare for the 
magnetic  separation  of  triplex  complexes,  the  in  vitro  transcribed  single-stranded 
TFO/hygromycin fusion transcript was annealed to a biotinylated oligonucleotide. The aim 
was to clearly demonstrate that the 1.1 kb fusion transcript recognises in a sequence-specific 
manner the double-stranded 39 bp MCP-1 promoter target sequence which was integrated 
into a plasmid. In the final step, triplex complexes were captured via magnetic separation 
using  magnetic  streptavidin  coated  beads  which  bind  to  the  biotinylated  RNA/DNA 
complexes  and  a  magnetic  separator.  This  technique  of  magnetic  capture  of  triplex 
complexes has been used successfully before by Besch (Besch et al. 2002). They performed 
a  capture  assay  for  the  evaluation  the  specific  TFO  binding  to  genomic  DNA,  using  a 
psoralen- and biotin-modified TFO which was UV cross-linked to a 16 bp target sequence of 
the  ICAM-1  gene.  Quantification  of  bound  duplex  DNA  was  done  by  PCR.  Adapting  this 
technique to the situation described in this study a biotinylated RNA strand was annealed to 
the  TFO  and  control  fusion  transcripts,  respectively,  and  the  interaction  with  a  plasmid 
containing the 39 bp MCP-1 promoter target duplex was tested.  
The relative amount of bound plasmid was quantified using a semi-quantitative PCR with 25 
cycles, where product amplification was shown to be in a linear range. In this experimental 
setting the binding of the TFO fusion transcript to the plasmid was three times stronger in 
comparison  to  the  controls,  meaning  a  fusion  transcript  containing  the  19  nt  GU  or  CA 
sequence or no insert. Notably, these experiments were performed at pH 7.0 indicating that 
triplex formation in the pyrimidine binding motif is likely to happen at physiologic pH. Some 
problems might occur in this experimental set up, like differences in the grade of degradation 
of the RNA fusion transcript in the control- and TFO samples or even unspecific binding of 
the plasmid to RNA or the streptavidin microbeads, which might easily lead to false results. ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
￿ ￿￿ ￿￿
To minimise these problems, RNase inhibitor was included in all steps and the integrity of the 
RNA  was  tested  before  each  experiment  to  ensure  that  equal  amounts  of  the  fusion 
transcripts (TFO or control) were used. Next, the relative amount of intact RNA in the elution 
fractions after four washing steps was quantified densitometrically and then normalised to 
compare the quantity of bound plasmid. Bound plasmid to RNA was analysed by PCR with 
the  template  volume  calculated  according  to  the  amount  of  RNA  present  in  the  elution 
fractions. An unspecific binding of the controls to the RNA could be observed in the shown 
experiments, but summarised, the binding of the TFO was three times stronger. By using the 
magnetic capture technique, Besch et al. observed 23% binding of the control to the ICAM-1 
duplex  target,  when  the  binding  of  the  TFO  to  the  duplex  was  set  to  100%.  In  the 
experiments described here, there was no PCR amplification when the experiments were 
performed  without  biotinylated  RNA,  indicating  that  the  “background”  might  be  due  to 
unspecific RNA/plasmid interaction but not to unspecific plasmid and streptavidin interaction. 
Together with the significant results of the triplex blotting experiments one can conclude that 
the stronger binding of the TFO fusion transcript to the plasmid is a result of triplex formation 
involving the pyrimidine 19 nt CU sequence. Finally, this experiment was done to underline 
that triplex formation might be the correct mechanism of action in the cells being responsible 
for the marked inhibition of MCP-1 expression. There is no publication demonstrating the 
binding of an intracellular generated RNA-TFO to the endogenous target duplex in a triplex 
mediated manner leading to an inhibitory effect. For example, Rininsland (Rininsland et al. 
1997) used a large GA-TFO fusion transcript expressed intracellular and showed convincing 
data in cell culture experiments and in animal models as well, but there was no functional 
analysis of triplex formation in the cell nucleus. Last but not least one cannot exclude that 
binding reaction in the cell nucleus is far more complex and difficult to reproduce in vitro, 
taking into account that the secondary structure of the RNA or mRNA binding proteins and 
the chromosomal structure of the MCP-1 gene after stimulation might be important.  
 
5.2.3 Inhibition of endogenous MCP-1 gene expression 
 
With respect to the functional antigene activity, in this study a vector mediated synthesis of 
pyrimidine triplex-forming RNA species inside HEK 293 cells was successfully developed, 
leading to up to 88% inhibition of TNF-a  and IFN-g co-stimulated MCP-1 protein secretion. 
Vector constructs used for transfection to generate stable cell lines had to cross the plasma 
membrane, move through the cytoplasm, and be transported into the nucleus before any 
transcription  of  their  encoded  genes  can  take  place.  The  intracellular  trafficking  and 
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Transcription  of  the  TFO  coding  sequence  was  driven  together  with  the  hygromycin 
resistance gene as one fusion transcript from the constitutive CMV promoter. The presence 
of each of the intracellular generated CU-, GU-, and CA-RNA sequences in the nucleus and 
the cytosolic fraction was confirmed by RT-PCR, leading to the conclusion that the vector 
constructs  successfully  entered  the  nucleus.  Furthermore,  the  transcript  was  sufficiently 
stable given that the RNA translocated into the cytosol, where it was translated into protein 
and enabled stable transfected HEK 293 cells to be cultured under continued hygromycin 
selection pressure. The evidence of transcription and the cell culture conditions show that the 
vector constructs reached the nucleus where the action of TFO binding to the endogenous 
MCP-1 promoter target sequences takes place. No quantitative experiments were performed 
to evaluate the exact copy numbers or concentration of expressed transcripts, which would 
be possible with nuclear run-off assays.  
 
In direct comparison with the previous data this investigation convincingly shows that vector 
mediated delivery of triplex forming RNA sequences is much more efficient than adding DNA 
TFOs  against  the  human  MCP-1  extracellular,  which  lead  to  45%  inhibition  of  gene 
expression  (Marchand  et  al.  2000).  A  76  to  88%  inhibition  was  reached  herein  with  an 
intracellular generated CU triplex RNA sequence. To exclude the possibility that the TFO 
inhibited MCP-1 expression by interfering with TNF-a signalling, it was evaluated whether the 
TFO  interfered  with  the  expression  of  IL-8,  which  is  also  induced  by  TNF-a.  In  samples 
identical  to  those  with  the  mentioned  reduction  of  MCP-1,  no  reduction  of  IL-8  protein 
secretion was measured. Again, the control GU- and CA- sequences had neither an effect on 
IL-8 protein secretion nor on MCP-1 protein secretion. Binding of the CU-TFO to the MCP-1 
RNA appeared to be unlikely, because there is no matching sequence in the MCP-1 RNA for 
stable duplex formation with the TFO; thus an “antisense” effect could also be excluded.  
 
The inhibitory effect of the TFO is more pronounced in TNF-a stimulated HEK 293 cells in 
comparison to unstimulated cells (76% versus 53%, respectively), leading to the question of 
accessibility of chromosomal DNA targets to TFOs. Macris (Macris and Glazer 2003) 
detected binding of TFOs to a chromosomal site even in the absence of transcription when 
high concentrations of the TFO were used for transfection, demonstrating that transcription at 
a chromosomal site increased duplex site accessibility to the TFO. Comparably, the data 
suggest that induction of transcription enhanced TFO-binding to the MCP-1 promoter target 
site resulting in a stronger inhibitory effect of MCP-1 expression.  
 
In  summary,  these  data  strongly  suggest  that  a  specific  RNA  TFO  inhibited  MCP-1 
expression by a triplex mediated blockade of transcription, and moreover that this can be ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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achieved  by  transfectable  shuttle systems.  Unlike  siRNAs and  antisense  oligonucleotides 
which have to deal with a high number of mRNA targets, triplex-forming oligonucleotides 
selectively inhibit expression of specific genes directly. Released from transfectable RNA 
vectors they only have to reach the two alleles of the gene which opens the perspective for a 
longer lasting pharmacologic effect. Recently developed siRNA generating vector systems 
are  also  suitable  to  generate  RNA  TFOs  in  vivo.  Combining  these  improved  expression 
vectors with the knowledge of hundreds of suitable TFO targets in the mammalian genome 
(Radeke HH and Bruno B, unpublished data) warrants that the intracellular TFO delivery 
technique may be developed to a successful gene therapeutic approach.  ￿￿#￿   ￿ ￿     ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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￿￿￿￿-￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿ ￿￿￿￿-￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿ ￿￿￿￿-￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿ ￿￿￿￿-￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿
 
Several  recently  developed  vector  based  strategies  that  contain  stem-loop  constructs 
encoding  hairpin  RNAs  lead  to  the  intracellular  generation  of  siRNA  like  species 
(Brummelkamp et al. 2002; McCaffrey et al. 2002; Paul et al. 2002). Dicer cleavage of hairpin 
RNA can generate small dsRNA that silence expression of genes whose transcription are 
complementary  to  one  of  the  two  strands  of  the  hairpin  RNA.  Most  vector-based  hairpin 
expression systems have demonstrated only transient knockdown of gene expression. More 
recently, inhibition of gene expression has been achieved using retroviral vector constructs 
that express hairpin RNAs within vector infected cells and produce long-term knockdown 
within cultured cell lines (Barton and Medzhitov 2002; Devroe and Silver 2002).  
Rubinson  (Rubinson  et  al.  2003)  demonstrated  that  lentiviruses  can  be  used  to  deliver 
siRNAs and reduce gene expression in cycling and non-cycling cells, as well as in chimeric 
and  transgenic  mice.  They  suggested  that  lentiviral  expression  vectors  might  be  used 
therapeutically  to  silence  disease  causing  genes,  to  render  cells  resistant  to  infectious 
organisms, and to facilitate the creation of tissues deficient in specific antigens as a source of 
transplant organs. Further modifications to lentiviral expression vectors, such as the inclusion 
of inducible or tissue-specific promoters, might extend the range of cells and situations in 
which they can induce RNA interference.  
 
Although  lentiviral  vectors  promise  great  utility  for  gene  therapy,  there  might  be  some 
concern about their safety since HIV-1 is the etiologic agent of AIDS. One major concern is 
the generation of replication-competent virus during the production of vectors. The possibility 
for generating replication-competent virus through recombination was minimised by using a 
three plasmid expression system which consists of packaging, envelope, and transfer vector 
constructs (Follenzi and Naldini 2002). Furthermore, all accessory genes can be eliminated 
from a packaging construct without losing the ability to transduce non-dividing cells. Another 
modification is the construction of a self inactivating (SIN) vector in which the viral enhancer 
and promoter sequences have been deleted (Follenzi and Naldini 2002; Vigna and Naldini 
2000).  Concerning  biosafety,  a  self-inactivating  vector  diminishes  the  risk  of  oncogene 
activation by promoter insertion and alleviates substantially the risk of vector mobilisation and 
recombination with wild-type virus (Bukovsky et al. 1999). Additionally, the replacement of 
the  U3  region  of  the  5’  long  terminal  repeat  with  the  cytomegalovirus  (CMV)  promoter 
resulted  in  tat-independent  transcription  with  no  decreases  in  viral  titre.  SIN  vectors 
combined with this hybrid 5’ LTR further reduce the possibility of recombination because 
there is no complete U3 sequence in the virus production system (Miyoshi et al. 1998).  
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In principle, lentiviral vectors capable of generating siRNA might be modified and used for 
the in vivo synthesis of specific TFO-like transcripts in several cell lines. Of course one has to 
take into account that the place of action of TFOs and siRNAs is different (nucleus versus 
cytosol), and siRNA producing vectors might be optimised for the rapid translocation of the 
transcript into the cytosol, which would be disadvantageous for the TFO technology. But, 
lentiviral vectors have been demonstrated to achieve high levels of transduction and gene 
expression in vivo after a single exposure to viral supernatant and therefore they are highly 
effective for gene transfer to several cells and possibly suitable for the TFO technique.  
 
In this study the cloning of recombinant transfer vectors and the transient transfection of 
lentiviral vector plasmids into a HEK 293T cell line for packaging lentiviral vector genomes 
into infectious lentiviral particles were performed. The transfer vector pHR’SIN-cPPT-SEW 
(“SEW”) was used, which contained the spleen focus forming virus (SFFV) long terminal 
repeat sequences, and the woodchuck hepatitis virus posttranscriptional element (WPRE) to 
enhance the level of transcription (Demaison et al. 2002). By including the central polypurine 
tract (cPPT) sequence of HIV-1, high levels of transduction could be achieved.  
Here, Th1 cells were transduced with infectious lentiviral particles and transduction efficacy 
was measured. Th1 have been shown to be difficult to transfect using synthetic TFOs or 
double-stranded  siRNAs.  But  a  transduction  efficacy  higher  than  82% could  be achieved 
using the lentiviral vector SEW, opening optimal possibilities for the TFO or siRNA approach. 
 
 
 ￿￿$￿ ￿ ￿ ￿ ￿ % ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
￿ ￿￿￿￿
6 Outlook 
 
In the present study gene and sequence-specific inhibition of MCP-1 transcription was shown 
due  to  interference  of  intracellular  generated  single-stranded  RNA  (CU-TFO)  with  an 
overlapping SP-1/AP-1 target. CU-TFO inhibited MCP-1 protein release about 76 to 88% in 
comparison  to  intracellular  generated  control  oligonucleotides  which  did  not  show  any 
activity. IL-8 as a control target gene was not affected by CU-TFO. The data proof effective 
and  specific  inhibition  of  MCP-1  expression  by  TFOs  generated  by  transfectable  shuttle 
vectors opening the possibility of in vivo gene therapeutic application of the TFO technique. 
Another  successful  approach  was  the  use  of  synthetic  siRNA  to  inhibit  MCP-1  protein 
secretion in TNF-a stimulated HEK 293 cells about 62%.  
To date, the successes achieved with TFOs in cell cultures and animal models indicate that 
TFOs constitute a new class of molecules potentially useful in therapy. But, in order to think 
about clinical applications with these compounds, their delivery to cells must be improved. 
Before reaching the level of clinical trials, the TFOs have to be improved in their capacity to 
penetrate the cells and target the DNA in a sequence-specific manner. When they will be 
properly delivered to the tissues, TFOs may become strong anti-gene drugs to treat several 
types of diseases, in particular those in which a partial reduction of the level of protein is 
sufficient to improve the phenotype of the disease.  
To achieve this goal, lentiviruses might be used to deliver TFOs or siRNA to specific tissues 
or cells in order to suppress expression of the targeted gene. For the siRNA approach, the 
sequence  of  the  synthetic  siRNA  targeting  MCP-1  can  be  cloned  with  the  appropriate 
expression cassette into the lentiviral transfer vector SEW using the sequences 5’GAT CCC 
CGG ATT CCA TGG ACC ACC TGT TCA AGA GAC AGG TGG TCC ATG GAA TCC TTT 
TTG GAA A and 5’AGC TTT TCC AAA AAG GAT TCC ATG GAC CAC CTG TCT CTT GAA 
CAG GTG GTC CAT GGA ATC CGG G, where the siRNA sequence is presented in sense 
and antisense orientation to build a stem-loop structure.  
For the TFO technology different cloning strategies are possible. The successful 19 nt TFO 
sequence  targeting  the  human  MCP-1  can  be  represented  as  a  single  copy,  or  the 
recognition sequence might be represented in larger a RNA in several copies in a row, as 
presented by McDonald (McDonald and Maher, III 1995). Alternatively, the TFO sequence 
might be embedded in larger RNA fusion transcript as described in the present study. Finally, 
different cells of interest can be transduced with the resulting constructs, and strategies to 
suppress gene expression using siRNAs or TFOs might be compared or even combined. It 
should be helpful to generate different TFO sequences, because secondary structure of the 
RNA might have influence on the intracellular processes and binding affinities. The further 
development of oligonucleotide-based reagents with improved binding affinities and delivery ￿￿$￿ ￿ ￿ ￿ ￿ % ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
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systems could be an alternative therapeutic strategy to modulate gene expression not only of 
proinflammatory chemokines.  
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A  Adenine 
AP-1  Activating protein-1 
APS  Ammonium peroxo-disulfate 
bp  Basepairs 
BSA  Bovine serum albumin 
C  Cytosine 
cAMP  Cyclic adenosine monophosphate 
cDNA  Copy DNA, complementary DNA 
CIP  Calf intestine phosphatase 
CMV  Cytomegalovirus 
ConA  Concanavalin A 
cPPT  Central polypurine tract 
DEPC  Diethyl pyrocarbonate 
DMSO  Dimethyl sulfoxide 
DNA  Desoxy ribonucleic acid 
dNTP  Desoxynucleoside triphosphate 
ds  Double-stranded 
DTT  Dithiotreitol 
E.coli  Escherichia coli 
EDTA  Ethylendiaminetetraacetic acid 
ELISA  Enzyme linked immunosorbent assay 
ELR  Glutamic acid-leucine-arginine motif 
EMSA  Electrophoretic mobility shift assay 
ENA-78  Epithelial neutrophil activating factor-78 
EtOH  Ethanol  
FA  Formaldehyde 
FACS  Fluorescence activated cell sorting 
FAK  Focal adhesion kinase 
FCS  Fetal calf serum 
G  Guanine 
GAGs  Glycosaminoglycans 
GAS  Interferon gamma activated site 
GFP, eGFP  (Enhanced) green fluorescent protein 
GM-CSF  Granulocyte macrophage-colony stimulating factor 
GPCR  G-protein coupled receptor 
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HEK 293  Human embryonic kidney cells 
HEPES  N-(2-Hydroxyethyl)piperazine-N' -ethanesulfonic acid 
HIV  Human immunodeficiency virus 
HPLC  High Performance Liquid Chromatography 
ICAM-1  Intercellular adhesion molecule-1 
IFN-g  Interferon-g 
IGF-IR  Insuline-like growth factor I receptor 
IL  Interleukin 
IP-10  Interferon-inducible protein-10 
IRF  Interferon regulatory factor 
I-TAC  Interferon-inducible T cell alpha chemoattractant 
JAK  Janus kinase 
kb  Kilobase 
kDa  Kilodalton 
LB-medium  Luria Bertani-medium 
LFA-1  Lymphocyte-function-associated antigen-1 
LPS  Lipopolysaccharide 
LTR  Long terminal repeat 
MCP-1  Monocyte chemoattractant protein-1 
MIG  Monokine induced by interferon-g 
MIP-1a   Macrophage inflammatory protein-1a 
MoMuLV  Moloney murine leukemia virus 
MOPS  3-(N-Morpholino)propanesulfonic acid 
NEA  Non-essential amino acids  
NF-kB  Nuclear factor kB 
NP-40  Nonidet P-40 
nt  Nucleotides 
OD  Optical density 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDGF  Platelet derived growth factor 
PF4  Platelet factor 4 
PNA  Peptide nucleic acid 
PNK  T4 poly-nucleotide kinase 
PTK  Protein tyrosine kinase 
RANTES  Regulated upon activation normal T cell expressed and secreted 
RCR  Replication competent recombinants 
RNA, mRNA  (Messenger) ribonucleic acid 
RNAi  RNA interference 
rpm  Rounds per minute 
RSV  Rous sarcoma virus ￿￿’( ( ￿ ￿ ￿ ￿ ￿ ￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿￿ ￿ ￿ ￿ ￿
￿ ￿￿￿￿
RT-PCR  Reverse transcribed-polymerase chain reaction 
SD  Standard deviation 
SDF-1  Stromal cell-derived factor-1 
SDS  Sodiumdodecyl sulfate 
SEM  Standard error of the mean 
SFFV  Spleen focus forming virus 
SIN  Self-inactivating transfer vector 
siRNA  Small interfering RNA 
STAT  Signal transducer and activator of transcription 
T  Thymine 
TEMED  N,N,N' ,N'  - tetramethylethylene diamine 
TFO  Triple helix-forming oligonucleotide 
TNF-a  Tumour necrosis factor-a 
TPA  Tetradecanoyl phorbol acetate 
tRNA  Transfer RNA 
U  Units  
UTR  Utranslated region 
UV  Ultraviolet (light)  
v/v  Volume per volume 
VCAM-1  Vascular-cell adhesion molecule-1 
VLA-4  Very late antigen 4 
VSV  Vesicular stomatitis virus 
w/v  Weight per volume 
WPRE  Woodchuck hepatitis virus 
wt  Wild type 
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Die Chemokine sind eine Unterfamilie der Zytokine mit starker chemotaktischer Aktivität und 
übernehmen  bei  der  Positionierung  von  Zellen  im  Organismus  wichtige  Aufgaben. 
Chemokine  sind  strukturell  verwandte  Moleküle  zwischen  8  und  14  kDa.  Sie  können  an 
verschiedene Chemokinrezeptoren binden und vermitteln ihre Signale über G-Proteine. Man 
unterteilt  die  Chemokine  funktionell  in  homöostatische  (konstitutiv  exprimierte)  und 
inflammatorische  (induzierbare)  Chemokine.  Im  Falle  einer  Infektion  mobilisieren  sie 
Effektorzellen und leiten sie zu den Infektionsherden und ins lymphatische Gewebe. Darüber 
hinaus  spielen  Chemokine  in  der  Organentwicklung,  Wundheilung,  Angiogenese, 
Angiostase,  bei  der  homöostatischen  Leukozytenrezirkulation  und  Immunregulation  eine 
Rolle.  MCP-1  (monocyte  chemoattractant  protein-1)  ist  ein  Mitglied  der  CC-Chemokin 
Familie und lockt eine Vielzahl von Zelltypen wie Monozyten, T-Lymphozyten und Basophile 
zum Entzündungsherd. MCP-1 wird von verschiedenen Zellen wie Monozyten, Fibroblasten, 
vaskulären  Endothelzellen  und  glatten  Muskelzellen  nach  Stimulation  mit 
Tumornekrosefaktor-a  (TNF-a),  Interferon-g  (IFN-g)  oder  Interleukin-1b  (IL-1b)  produziert. 
Eine  Überexpression  von  MCP-1  wird  in  vielen  entzündlichen  Erkrankungen  wie 
rheumatoider Arthritis, Multipler Sklerose und Glomerulonephritis gefunden.  
Ziel  dieser  Arbeit  war  es,  molekulare  Strategien  auf  dem  Weg  zu  einer  therapeutischen 
Anwendung  zu  entwickeln,  um  die  Aktivität  z.B.  pro-inflammatorischer  Chemokine  wie  
MCP-1 und RANTES (regulated upon activation normal T cell expressed and secreted) zu 
modulieren. In der Literatur sind verschiedene erfolgreiche Prinzipien beschrieben, die auf 
dem Einsatz von kurzen Oligonukleotiden basieren, um die Expression spezifischer Gene zu 
hemmen. Hierzu gehören die Antisense-Oligonukleotide, triple helix-forming oligonucleotides 
(TFOs) und auch die small interfering RNA (siRNA). Im Unterschied zur Wirkung von siRNA 
und Antisense-Oligonukleotiden auf die mRNA Translation geht es in dieser Arbeit um das 
Design von therapeutischen Agenzien, die auf der DNA-Ebene durch sequenzspezifische 
Interaktionen die Transkription verändern können. Dieser Ansatz hat den prinzipiellen Vorteil, 
dass  nur  zwei  Allele  und  nicht  Tausende  von  Zielstrukturen  (mRNAs)  pro  Zelle  erreicht 
werden müssen und ist mit der Verfügbarkeit der Genomsequenzen eine viel versprechende 
Strategie eines neuen molekularbiologischen „Drug Design“. Die dazu eingesetzten TFOs 
besitzen die Fähigkeit, nach bestimmten Regeln an die doppelsträngige DNA zu binden und 
stabile  Dreifachketten  zu  bilden.  Die  Kriterien  für  die  Bindung  eines  TFOs  and  die 
doppelsträngige (ds)DNA sind genau definiert. Eine geeignete Zielsequenz muss in einem 
der  beiden  DNA-Stränge  aus  mindestens  12-15  ununterbrochenen  Purinen  bestehen.  Es 
existieren  zwei  verschiedene  Bindungsmotive,  mit  denen  das  TFO  an  den  Doppelstrang 
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dsDNA, die Sequenzspezifität wird über die spezifische Bindung von Guanin (G) an Guanin 
(G):Cytosin (C)- und Adenin (A) (oder auch Thymin) an Adenin (A):Thymin (T)-Basenpaare 
vermittelt.  Beim  Pyrimidin-Bindungsmotiv  dagegen  binden  die  Oligonukleotide  antiparallel 
zum Purinstrang der dsDNA (Cytosin an Guanin:Cytosin- und Thymin an Adenin:Thymin-
Basenpaare) (Chan and Glazer 1997). 
TFOs  können  im  Prinzip  Änderungen  in  der  Genaktivität  (Inhibition  der  Transkriptions-
Initiation oder der Transkriptions-Elongation; oder Aktivierung der Transkription) induzieren 
(Faria et al. 2000; Intody et al. 2000), oder aber sie werden für strukturelle Änderung in der 
DNA-Sequenz eingesetzt (Sequenzspezifische DNA-Schädigung und Reparatur oder TFO-
vermittelte homologe Rekombination) (Vasquez et al. 2001b). In einem Teil der Publikationen 
werden  sequenzspezifische  Effekte  von  TFOs  auf  die  Genexpression  in  einem  intakten 
zellulären System beschrieben, viele Untersuchungen zu prinzipiellen Bindungseigenschaf-
ten  sind  allerdings  auch  in  zellfreien  Systemen  durchgeführt  worden.  In  intakten  Zellen 
wurden  erfolgreiche  Versuche  beschrieben,  wenn  die  TFO  Zielsequenzen  im  Promoter-
bereich der Gene lagen (Carbone et al. 2004; Cogoi et al. 2000). Hier konkurrierten TFOs mit 
Transkriptionsfaktoren  um  die  entsprechenden  Bindungsstellen.  Andererseits  werden  zur 
Optimierung der TFO-Technik Reportersysteme beschrieben, in denen die Zielsequenzen in 
ein Plasmid kloniert und in Zellen transfiziert wurden. Als Kontrollen können Oligonukleotide 
unterschiedlicher  Länge  und  unterschiedlicher  Basenzusammensetzung  oder  unterschied-
licher  Orientierung  (parallel  statt  antiparallel  zum  purinhaltigen  DNA-Strang)  verwendet 
werden. Bei Plasmiden besteht die Möglichkeit, die Targetsequenz zu mutieren und über ein 
„Nicht-Binden“ der TFOs die Sequenzspezifität zu gewährleisten. Um die Stabilität der TFOs 
in der Zelle zu erhöhen werden verschiedene chemische Modifikationen der Oligonukleotide 
angewendet.  So  können  z.B.  Phosphorothioat-TFOs,  3’Amino-modifizierte  TFOs  oder 
Oligonukleotid-Analoga  mit  N3’-P5’  Verbindungen  gegen  endogene  Targets  eingesetzt 
werden (Praseuth et al. 1999). 
 
In der vorliegenden Arbeit wurden die beiden Gene der Chemokine MCP-1 und RANTES als 
TFO-Targets  untersucht.  In  der  Promoterregion  des  humanen  MCP-1  Gens  befindet  sich 
eine geeignete TFO Zielsequenz in einer Länge von 19 bp. Diese Zielsequenz umfasst die 
Bindungsstellen  für  die  Transkriptionsfaktoren  SP-1  und  AP-1,  welche  sowohl  bei  der 
basalen  als  auch  der  induzierten  Genexpression  von  MCP-1  eine  entscheidende  Rolle 
spielen. Nach den beschriebenen Regeln zur sequenzspezifischen Triplex-Bildung wurde ein 
19  nt  TFO  mit  einem  purinen  Bindungsmotiv  (GT)  synthetisiert  und  es  konnte  im  EMSA 
(electrophoretic mobility shift assay) gezeigt werden, dass dieses sequenzspezifisch an die 
MCP-1 dsDNA (39 bp) bindet. Sequenzspezifität wurde durch ein Kontroll-Oligonukleotid mit 
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Triplex-Formation  führte.  Weiterhin  fand  keine  Triplex-Bildung  mit  einer  RANTES 
Promotersequenz als Kontroll-Target statt. Wie in einer früheren Arbeit gezeigt (Marchand et 
al. 2000), konnte in einem Protein-Bindungstest das TFO das Binden von rekombinantem 
SP-1 und auch von nukleärem Proteinextrakt an den MCP-1 Promoter verhindern; dieses 
bestätigte  zusätzlich  die  Sequenzspezifität.  In  der  vorliegenden  Arbeit  konnte  die  TNF-a 
induzierte  MCP-1  Proteinsekretion  in  HEK  293  Zellen  bei  einer  Konzentration  von  2  µM 
Phosphorothioat-TFO um 25% im Vergleich zu dem Kontroll-Oligonukleotid inhibiert werden.  
 
Die Suche nach geeigneten Zielsequenzen konnte durch die Entwicklung eines Algorithmus 
(in  Kooperation  mit  Bill  Bruno,  Bioinformatiker,  New  Mexico)  optimiert  werden.  Für  ein 
Genbank  Screening  wurden  folgende  Parameter  festgelegt:  Mindestens  14  Basen 
Guanin/Adenin  mussten  in  ununterbrochener  Reihenfolge  vorliegen,  und  in  einer 
Sequenzlänge  von  18  Nukleotiden  war  nur  ein  Mismatch  (Pyrimidin)  erlaubt.  Weiterhin 
musste der Guaningehalt der Zielsequenz mindestens 60 % betragen. Von bisher 2613 mit 
diesem  Algorithmus  geprüften  Sequenzen  konnten  673  als  geeignete  Zielsequenzen 
gefunden werden, die als mögliche Zielsequenzen für die in vitro Testung zur Verfügung 
stehen. Ein weiteres Target war das murine RANTES, welches eine wichtige Rolle in der 
Chemoattraktion  von  Leukozyten  während  des  Entzündungsprozesses  spielt.  Im 
Promoterbereich  von  -262  bis  -235  vom  Transkriptionsstart  aus  befindet  sich  eine  28  bp 
TFO-Zielsequenz. +1 entspricht dem Transkriptionsstart wie beschrieben bei Danoff (Danoff 
et al. 1994). Ein 28 nt TFO mit Purin-Bindungsmotiv (GT) wurde synthetisiert, und Triplex-
Bildung mit der RANTES Promoterzielsequenz konnte im EMSA gezeigt werden. Für eine 
sequenzspezifische Triplex-Formation konnte ein Kd-Wert von 2.5 x 10
-7 M bestimmt werden. 
Die  Wirkung  des  TFO  mit  Phosphorothioat-Modifikation  wurde  in  zwei  verschiedenen 
Zelllinien (T-Lymphozyten und mikrovaskuläre Endothelzellen des Gehirns, b-end3 Zellen) 
getestet.  Hier  konnte  allerdings  kein  inhibitorischer  Effekt  auf  die  endogene  RANTES-
Expression festgestellt werden. 
 
Generelle  Schwierigkeiten  der  Oligonukleotid-Technologien  wie  der  Einsatz  hoher 
Konzentrationen,  Notwendigkeit  chemischer  Modifikationen  und  die  Transfektionseffizienz 
konnten durch die Etablierung von Vektoren zur intrazellulären Generierung von TFOs auf 
RNA-Basis  maßgeblich  verbessert  werden  (Kautz  et  al.  2005).  Dazu  wurde  der 
eukaryotische  Expressionsvektor  pcDNA3.1/Hygro  so  modifiziert,  dass  die  MCP-1  TFO-
Sequenz zusammen mit einem Hygromycin Resistenzgen als Fusionstranskript transkribiert 
werden  konnte.  In  mit  diesem  Vektor  transfizierten  HEK  293  Zellen  werden  TFO-RNA 
Moleküle produziert, die als dritter Strang an die MCP-1 Promoter Targetsequenz binden 
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das  Pyrimidin-Bindungsmotiv  (Cytosin-Uracil,  CU)  gewählt,  da  die  Triplex-Bildung  mit 
Oligoribonukleotiden  (RNA*DNA:DNA)  im  Purin-Bindungsmotiv  als  sehr  unwahrscheinlich 
beschrieben wird (Lacroix et al. 1996). Der Vektor pcDNA3.1/Hygro (ca. 5,6 kb) wurde mit 
den Restriktionsenzymen ApaI und SmaI geschnitten, sodass der Bereich zwischen 1002 bp 
und 2079 bp entfernt wurde. Der ApaI Überhang wurde aufgefüllt und der Vektor religiert. Die 
multiple  Klonierungsstelle  lag  nun  im  5’  UTR  des  Hygromycin  Resistenzgens  unter  der 
Kontrolle des CMV Promoters. Eine Sequenz, die in die multiple Klonierungsstelle kloniert 
wurde,  wurde  zusammen  mit  dem  Hygromycin  Resistenzgen  als  Fusionstranskript 
abgeschrieben. Als Insert wurde ein 49 bp Doppelstrang mit Schnittstellen für die Enzyme 
HindIII,  XhoI  und  BamHI  synthetisiert.  Dieser  Doppelstrang  enthielt  die  19  bp  TFO-RNA 
generierende  Sequenz,  die  als  dritter  Strang  an  den  MCP-1  Promoter  binden  sollte.  Als 
Kontrolle  wurde  ein  Vektor  mit  einer  RNA-Sequenz  konstruiert,  die  nicht  an  die 
Targetsequenz binden konnte. HEK 293 Zellen wurden stabil mit diesem Vektor und den 
verschiedenen  Kontrollvektoren  transfiziert  und  unter  ständigem  Selektionsdruck 
(Hygromycin 250 µg/ml) kultiviert. In Zelllinien, die konstitutiv TFOs generieren, konnte die 
endogene  TNF-a  induzierte  MCP-1  Protein-Sekretion  um  76  ±  10,2%  im  Vergleich  zu 
Kontrollzelllinien inhibiert werden. 
Um eine sequenzspezifische Wirkung der intrazellulär gebildeten TFOs aufzuzeigen, wurde 
in  denselben  Zellüberständen  sowohl  die  MCP-1  als  auch  die  Interleukin-8  (IL-8) 
Proteinkonzentration  bestimmt.  Hierbei  zeigte  sich,  dass  die  TNF-a  induzierte  IL-8 
Expression durch das TFO vollkommen unbeeinflusst blieb. Auch in IFN-g stimulierten Zellen 
konnte eine Inhibition bis zu 83% erreicht werden, in TNF-a und IFN-g kostimulierten Zellen 
bis zu 88%. Die Präsenz der TFOs und der Kontrollen in den verschiedenen Zelllinien konnte 
über RT-PCR und Northern-Blots bestätigt werden. 
Verschiedene  Kontrollen  wurden  in  vitro  durchgeführt,  so  auch  der  Nachweis  der 
spezifischen Triplex-Formation mit synthetischen 19 nt Oligoribonukleotiden und dem 39 bp 
MCP-1  Promoterfragment.  Dazu  wurden  die  Oligoribonukleotide  (TFO  und  verschiedene 
Kontrollen) elektrophoretisch aufgetrennt, auf eine Membran geblottet und anschließend mit 
der  MCP-1  Duplex-DNA  inkubiert.  Hierbei  zeigte  sich,  dass  nur  das  CU-TFO  an  die 
Zielsequenz  band.  Verschiedene  Kontrollen  wurden  parallel  getestet,  so  z.B.  ein 
Oligoribonukleotid  mit  gleicher  Basensequenz  des  TFOs,  aber  mit  nur  einem 
Nukleotidaustausch, mit dem Resultat, dass die Kontrollen nicht an die Duplex-DNA banden. 
Weiterhin wurde ein MCP-1 Promoterfragment mit zwei Nukleotidaustäuschen verwendet, 
und hier konnte keins der verwendeten Oligoribonukleotide binden. Diese Ergebnisse lassen 
eindeutig auf eine sequenzspezifische Triplex-Formation schließen.  
Schließlich konnte auch gezeigt werden, dass das TFO/Hygromycin-Fusionstranskript an die 
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magnetisches  Abfangen  der  Triplex-Komplexe  etabliert.  Die  relative  Menge  der  MCP-1-
Duplex-DNA,  die  hierbei  an  TFO-  oder  Kontroll-Sequenzen  band,  wurde  über  eine  semi-
quantitative PCR bestimmt. Es zeigte sich, dass das in einem Plasmid eingebettete MCP-1 
Promoterfragment  dreimal  stärker  and  das  TFO-Transkript  band  als  an  die  Kontrollen. 
Dieses  Ergebnis  bestätigt,  dass  die  TFO-Sequenz,  eingebettet  in  ein  längeres  RNA-
Transkript,  mit  dem  MCP-1  Promoterfragment  bei  einem  pH-Wert  von  7.0  in  einer 
sequenzspezifischen Art und Weise interagiert.  
 
Neben  der  TFO-Strategie  wurde  in  dieser  Arbeit  auch  die  Möglichkeit  von  siRNAs 
untersucht, um die Expression der Chemokine RANTES und MCP-1 zu inhibieren. Für den 
siRNA  Einsatz  wurden  zwei  verschiedene  Methoden  verwendet,  sowohl  der  Gebrauch 
synthetisch  hergestellter  als  auch  Vektor  generierter  siRNA.  Der  Vektor  pSUPER  besitzt 
einen Polymerase-III H1-RNA Promoter und kann für die intrazellulare Synthese von siRNA 
eingesetzt werden (Brummelkamp et al. 2002). Der Einsatz einer intrazellulär generierten 
siRNA gegen das humane MCP-1 führte zu einer Inhibition der MCP-1 Protein-Sekretion um 
35  ±  11%  in  HEK  293  Zellen.  Allerdings  zeigte  sich  auch  eine  leicht  reduzierte  Protein 
Sekretion nach Transfektion mit dem Leervektor ohne codierende siRNA Sequenz um 18 ± 
7%; ein geringer inhibitorische Effekt durch die transiente Transfektion des Vektors selbst 
war also nicht auszuschließen. Weiterhin wurde auch der Effekt von zwei verschiedenen 
synthetischen siRNA Sequenzen getestet. Eine Sequenz entsprach genau der, die auch in 
dem Vektor pSUPER verwendet wurde. Hier wurde die MCP-1 Expression um 23% in TNF-a 
stimulierten und um 30% in unstimulierten Zellen inhibiert. Eine weitere siRNA-Sequenz war 
eine vom Hersteller validierte Sequenz gegen MCP-1 und erzielte in HEK 293 Zellen eine 
Inhibition der MCP-1 Protein-Sekretion von 62.3 ± 10.3%. Für weitergehende Versuche wäre 
es lohnenswert, genau diese erfolgreiche Sequenz in den Vektor pSUPER zu klonieren, um 
die Effizienz von Vektor generierter und synthetischer siRNA in Bezug auf das Chemokin 
MCP-1 vergleichen zu können.  
Ebenso wurde die siRNA Technik eingesetzt, um murines RANTES in T-Lymphozyten und 
Endothelzellen (Th1 und b-end3 Zellen) zu inhibieren. Wie beim MCP-1 wurde auch hier eine 
Vektor-generierte  und  eine  synthetische  siRNA  untersucht,  es  zeigte  sich  allerdings  kein 
inhibitorischer  Effekt  auf  die  endogene  RANTES  Expression  in  beiden  Zelllinien. 
Zusammenfassend lässt sich sagen, dass für MCP-1 die siRNA-Strategie ein erfolgreicher 
Ansatz ist, die Expression signifikant zu verringern. Für das Chemokin RANTES scheint es 
erforderlich, weitere siRNA Sequenzen zu testen, um eine Inhibition erreichen zu können.  
 
Ein weiteres Ziel dieser Arbeit war es, den potentiellen Einsatz von TFO oder siRNA als 
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humanen Gentherapie wird eine Vielzahl unterschiedlicher Viren als Gentransfer-Vektoren 
angewendet,  darunter  auch  die  retroviralen  Vektoren.  Die  Verwendung  viraler  Systeme 
beruht auf der natürlichen Fähigkeit von Viren, Zellen zu infizieren. Diese Vektoren weisen 
einige Vorzüge auf, wie etwa die spezifische Bindung an und die Aufnahme in die Zielzellen, 
den Transport der DNA zum Zellkern und den Schutz der Nukleinsäuren vor Abbau. Die auf 
Lentiviren basierenden Vektoren weisen zusätzlich einige Vorteile auf, da sie aufgrund eines 
aktiven  Transportes  dieser  Viren  in  den  Zellkern  auch  nicht  proliferierende  Zellen 
transduzieren  können  (Naldini  et  al.  1996).  Bei  der  Herstellung  dieser  Vektoren  werden 
essentielle  Teile  des  viralen  Genoms  entfernt  und  die  therapeutisch  wirksamen 
Gensequenzen  eingesetzt.  Die  fehlenden  viralen  Proteine  werden  in  trans  von 
entsprechenden  Verpackungsvektoren  produziert.  Enthält  das  modifizierte  Genom  die 
notwendigen Verpackungssignale, so wird es in den Zellen in virale Hüllen verpackt.  
In  dieser  Arbeit  wurden  lentivirale  Partikel  durch  eine  transiente  Transfektion  von  239T 
Zellen mit dem Transfervektor SEW und den notwendigen Verpackungsvektoren hergestellt. 
Der  SEW  Vektor  enthält  als  Marker  das  grüne  Fluoreszenzprotein  (GFP).  Im  Anschluss 
wurden  Th1  Zellen  mit  den  infektiösen  lentiviralen  Vektoren  transduziert.  Die  relative 
Frequenz an GFP-produzierenden Zellen konnte mittels FACS-Analyse bestimmt werden. 
Die  Transduktionseffizienz  lag  bei  über  82%.  Durch  diese  hohe  Transduktionseffizienz 
ergeben  sich  auch  optimale  Bedingungen  für  den  Einsatz  von  TFO  und  siRNA.  Die 
erfolgreichen  TFO-  und  siRNA-Sequenzen  gegen  das  humane  MCP-1  könnten  weiterhin 
auch  lentiviral  exprimiert  werden,  um  den  Gentransfer  zu  verbessern.  Die  Effizienz  der 
beiden  Strategien  könnte  in  verschiedenen  Zelllinien  und  letztendlich  auch  im  Tiermodell 
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